<SEC-DOCUMENT>0001104659-25-057746.txt : 20250609
<SEC-HEADER>0001104659-25-057746.hdr.sgml : 20250609
<ACCEPTANCE-DATETIME>20250609141552
ACCESSION NUMBER:		0001104659-25-057746
CONFORMED SUBMISSION TYPE:	N-CSRS
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250609
DATE AS OF CHANGE:		20250609
EFFECTIVENESS DATE:		20250609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			abrdn Life Sciences Investors
		CENTRAL INDEX KEY:			0000884121
		ORGANIZATION NAME:           	
		EIN:				043147016
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		N-CSRS
		SEC ACT:		1940 Act
		SEC FILE NUMBER:	811-06565
		FILM NUMBER:		251033574

	BUSINESS ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		6177728515

	MAIL ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKLA LIFE SCIENCES INVESTORS
		DATE OF NAME CHANGE:	20141015

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	H&Q LIFE SCIENCES INVESTORS
		DATE OF NAME CHANGE:	19920929
</SEC-HEADER>
<DOCUMENT>
<TYPE>N-CSRS
<SEQUENCE>1
<FILENAME>tm2516624d12_ncsrs.htm
<DESCRIPTION>N-CSRS
<TEXT>
<!-- Assembled by CompSci Transform  (tm) - http://www.compsciresources.com - version 1.2 -->
<!-- Created: Thu Jun 05 09:07:18 UTC 2025 -->
<html>
<head>
     <title></title>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2516624d12_ncsr-cover.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-12/tm2516624-12_ncsrsseq1" -->

<p style="margin: 0">&#xa0;</p>


<p style="margin: 0"></p>


<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#xa0;</div></div><!-- Field: /Rule-Page -->


<p style="margin: 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#xa0;N-CSR</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT
INVESTMENT COMPANIES</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><font style="font-size: 10pt">Investment
    Company Act file number:</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="width: 49%; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">811-06565</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td><td><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Exact name of registrant as
    specified in charter:</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 14pt">abrdn Life Sciences Investors</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td><td><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><font style="font-size: 10pt">Address
    of principal executive offices:</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">1900 Market Street, Suite&#xa0;200</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; padding-left: 3in"><font style="font-size: 10pt">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Philadelphia, PA 19103</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td><td><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Name and address of agent for
    service:</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Sharon Ferrari</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 3.5in"><font style="font-size: 10pt">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">abrdn Inc.</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 3.5in"><font style="font-size: 10pt">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">1900 Market Street Suite&#xa0;200</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 3.5in"><font style="font-size: 10pt">&#xa0;</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Philadelphia, PA 19103</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td><td><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><font style="font-size: 10pt">Registrant&#x2019;s
    telephone number, including area code:</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">1-800-522-5465</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td><td><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.5in; padding-left: 0.5in"><font style="font-size: 10pt">Date
    of fiscal year end:</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">September&#xa0;30</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td><td><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.5in; padding-left: 0.5in"><font style="font-size: 10pt">Date
    of reporting period:</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">March&#xa0;31, 2025</font></td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="margin: 0"></p>


<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#xa0;</div></div><!-- Field: /Rule-Page -->


<p style="margin: 0">&#xa0;</p>


<p style="margin: 0"></p>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->


<p style="margin: 0">&#xa0;</p>


</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2516624d12_item1.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-12/tm2516624-12_ncsrsseq1" -->

<p style="margin: 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1. Reports to Stockholders.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&#xa0;A copy of the report transmitted
to shareholders pursuant to Rule&#xa0;30e-1 under the Investment Company Act of 1940 (the &#x201c;1940 Act&#x201d;) is filed herewith.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="margin: 0"></p>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->


<p style="margin: 0">&#xa0;</p>


</div><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2516624d12_hqlreport.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-12/tm2516624-12_ncsrsseq1" --><div style="width:100%">
<div style="overflow:hidden; width:100%">
<div style="margin-top: 0pt; position: relative; text-align: left; width: 100%">
<img src="tm2516624d12hqlreporti001.gif" alt=" ">
<div style="left:43pt; position:absolute; top:44pt"><img src="tm2516624d12hqlreporti002.gif" alt=" ">
</div><div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; left:43pt; line-height:10pt; position:absolute; text-decoration:none; text-transform:none; top:44pt">&#x2009;</div></div>


</div>
<div style="margin-top:29pt; width:93.96%">
<div style="color:#000000; font-family:Arial; font-size:20pt; font-style:Normal; font-weight:bold; line-height:23pt; text-align:left; text-decoration:none; text-transform:none">abrdn Life Sciences Investors (HQL)</div>
<div style="color:#000000; font-family:Arial; font-size:14pt; font-style:Normal; font-weight:bold; line-height:17pt; margin-top:14pt; text-align:left; text-decoration:none; text-transform:none">Semi-Annual Report</div>
<div style="color:#000000; font-family:Arial; font-size:14pt; font-style:Normal; font-weight:Normal; line-height:17pt; margin-top:2pt; text-align:left; text-decoration:none; text-transform:none">March 31, 2025</div>
</div>
<div style="margin-top:67pt; width:93.96%">
<div style="color:#000000; font-family:Arial; font-size:21.5pt; font-style:Normal; font-weight:bold; line-height:24.5pt; margin-top:2pt; text-align:right; text-decoration:none; text-transform:none">aberdeeninvestments.com</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Managed Distribution Policy
 &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)<br>
</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:22.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Board of Trustees&#xa0; (the "Board") of
the abrdn Life Sciences Investors(the &#x201c;Fund&#x201d;) has authorized a managed distribution policy (&#x201c;MDP&#x201d;) of paying quarterly distributions at an annual rate, set once a year, that is a percentage of
the rolling average of the Fund&#x2019;s net asset values over the preceding three month period ending on the last day of the month immediately preceding the distribution&#x2019;s declaration date (the "Distribution
Policy"). The Distribution Policy is subject to regular review by the Board. The Distribution Policy seeks to provide investors with a distribution out of current income, supplemented by realized capital gains and, to
the extent necessary, paid-in capital.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">With each distribution, the Fund will issue
a notice to shareholders and an accompanying press release which will provide detailed information regarding the estimated amount and composition of the distribution and other information required by the Fund&#x2019;s
MDP exemptive order. The Board may amend or terminate the MDP at any time without prior notice to shareholders; however, at this time,there are no reasonably foreseeable circumstances that might cause the termination
of the MDP. You should not draw any conclusions about the Fund&#x2019;s investment performance from the amount of distributions or from the terms of the Fund&#x2019;s MDP.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:34.5pt; width:92.99%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Distribution Disclosure
Classification &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)<br>
</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
</div>
<div style="padding-top:22.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s policy is to provide
investors with a stable distribution rate. Each quarterly distribution will be paid out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is subject to U.S.
corporate tax and securities laws. Under U.S. tax rules, the amount applicable to the Fund and character of distributable income for each fiscal period depends on the actual exchange rates during the entire year
between the U.S. Dollar and the currencies in which the Fund's assets are denominated and on the aggregate gains and losses realized by the Fund during the entire year.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">Therefore, the exact amount
of distributable income for each fiscal year can only be determined as of the end of the Fund&#x2019;s fiscal year, September 30. Under Section 19 of the Investment Company Act of 1940, as amended (the &#x201c;1940
Act&#x201d;), the Fund is required to indicate</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">the sources of certain distributions to
shareholders. The estimated distribution composition may vary from quarter to quarter because it may be materially impacted by future income, expenses and realized gains and losses on securities and fluctuations in
the value of the currencies in which the Fund's assets are denominated.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">Based on generally accepted
accounting principles, the Fund estimates the distributions for the fiscal year commenced October 1, 2024 through the distributions declared on May 9, 2025 consisted of 35% net realized short-term capital gains, 28%
net realized long-term capital gains and 37% tax return of capital.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">In January 2026, a Form
1099-DIV will be sent to shareholders, which will state the final amount and composition of distributions and provide information with respect to their appropriate tax treatment for the 2025 calendar year.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:209.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">abrdn Life Sciences Investors</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Letter to Shareholders &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt">
<div style="float:left; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Dear Shareholder,</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">We present the Semi-Annual
Report, which covers the activities of abrdn Life Sciences Investors&#xa0;(the &#x201c;Fund&#x201d;), for the six-month period ended March 31, 2025. The Fund&#x2019;s investment objective is to seek long-term capital
appreciation by investing primarily in securities of Life Sciences companies.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Total Investment Return<sup style="font-size:85%; font-style:Normal; text-transform:none">1</sup></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">For the six-month period
ended March 31, 2025, the total return to shareholders of the Fund based on the net asset value (&#x201c;NAV&#x201d;) and market price of the Fund, respectively, compared to the Fund&#x2019;s benchmark, &#xa0;is as
follows:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; border-top:0.5pt solid #000000; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:4pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:81.29%; background-color: #F0F0F0;">NAV<sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">3</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6.14pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:22.20%; background-color: #F0F0F0;">-10.15%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:81.29%; background-color: #F0F0F0;">Market Price<sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:7.84pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:22.20%; background-color: #F0F0F0;">-9.66%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:81.29%; background-color: #F0F0F0;">Nasdaq Biotechnology Index<sup style="font-size:85%; font-style:Normal; text-transform:none">4</sup>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:4pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:22.20%; background-color: #F0F0F0;">-10.62%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">For more information about
Fund performance, please visit the Fund on the web at https://www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds. Here, you can view quarterly commentary on the Fund's performance,
monthly fact sheets, distribution and performance information, and other Fund literature.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">NAV, Market Price and
Premium(+)/Discount(-)</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The below table represents a
comparison between the current six-month period end and the prior fiscal year end of the&#xa0;Fund's market price to&#xa0;NAV and associated Premium(+) and Discount(-).</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:97.67%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="padding-bottom:1.75pt; padding-right:4pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:42.96%; background-color: #D9D9D9;">&#xa0;
</td><td style="padding-bottom:1.75pt; padding-right:6pt; padding-top:3pt; text-align:center; vertical-align:bottom; width:14.36%; background-color: #D9D9D9;">&#xa0;
</td><td style="padding-bottom:1.75pt; padding-right:6pt; padding-top:3pt; text-align:right; vertical-align:bottom; width:16.02%; background-color: #D9D9D9;">&#xa0;
</td><td style="padding-bottom:1.75pt; padding-right:12pt; padding-top:3pt; text-align:right; vertical-align:bottom; width:24.28%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:2.5pt; padding-right:4pt; padding-top:1.75pt; text-align:left; vertical-align:bottom; width:42.96%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2.5pt; padding-left:4pt; padding-right:6pt; padding-top:1.75pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.36%; background-color: #D9D9D9;">NAV
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.02%; background-color: #D9D9D9;">Closing<br>
Market<br>
Price
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:24.28%; background-color: #D9D9D9;">Premium(+)/<br>
Discount(-)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:4pt; padding-top:3.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:42.96%; background-color: #F0F0F0;">3/31/2025
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:6pt; padding-top:3.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:14.36%; background-color: #F0F0F0;">$<font style="padding-left:1.94pt"></font>13.71
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:3.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:16.02%; background-color: #F0F0F0;">$<font style="padding-left:0.38pt"></font>12.69
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:12pt; padding-top:3.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:24.28%; background-color: #F0F0F0;">-7.44%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:42.96%; background-color: #F0F0F0;">9/30/2024
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:4pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:14.36%; background-color: #F0F0F0;">$16.38
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.02%; background-color: #F0F0F0;">$15.08
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:6.18pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:24.28%; background-color: #F0F0F0;">-7.94%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">During the six-month period
ended March 31, 2025, the Fund&#x2019;s NAV was within a range of $13.71 to $16.94 and the Fund&#x2019;s market price traded within a range of $12.69 to $15.25. During the six-month period ended March 31, 2025, the
Fund&#x2019;s shares traded within a range of a premium(+)/discount(-) of -12.56% to -7.44%.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">Aberdeen Name Change</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">On March 4, 2025, abrdn plc,
the parent company of the Fund's adviser, announced that it would change its name, and from that date, will use `Aberdeen' as the principal trading identity for its Investments business. On March 12, 2025, abrdn plc
completed the steps to legally change its name to Aberdeen Group plc. Aberdeen has retained `abrdn' as an operational abbreviation across its subsidiary legal entities (including the Fund's adviser, fund names and
descriptors).</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Managed Distribution Policy</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund has a managed
distribution policy of paying quarterly distributions at an annual rate, set by the Board of Trustees (the "Board") once a year, as a percentage of the rolling average of the Fund&#x2019;s NAV over the preceding three
month period ending on the last day of the month immediately preceding the distribution&#x2019;s declaration date. On March 11, 2025, the Board determined the rolling distribution rate to be 12% for the 12-month period
commencing with the distribution payable in June 2025. This policy will be subject to regular review by the Board. The distributions will be made from current income, supplemented by realized capital gains and, to the
extent necessary, paid-in capital, which is a nontaxable return of capital.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">On May 9, 2025, the Fund
announced that it will pay on June 30, 2025, a stock distribution of US $0.43 per share to all shareholders of record as of May 22, 2025. This stock distribution will automatically be paid in newly issued shares of
the Fund unless otherwise instructed by the shareholder. Shares of common stock will be issued at the lower of the NAV per share or the market price per share with a floor for the NAV of not less than 95% of the
market price. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts at Computershare Investor Services who will have whole and fractional shares added to
their account.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Shareholders may request to
be paid their quarterly distributions in cash instead of shares of common stock by providing advance notice to the bank, brokerage or nominee who holds their shares if the shares are in &#x201c;street name&#x201d; or by
filling out in advance an election card received from Computershare Investor Services if the shares are in registered form.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:24.5pt; width:94%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">1</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">Past performance is no guarantee of future results. Investment returns and principal value will fluctuate and shares, when sold, may be worth more or less than original cost. Current performance may be
lower or higher than the performance quoted. NAV return data include investment management fees, custodial charges and administrative fees (such as Trustee and legal fees) and assumes the reinvestment of all
distributions.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:46pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">Assuming the reinvestment of dividends and distributions.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:57pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">3</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">The Fund&#x2019;s total return is based on the reported NAV for each financial reporting period end and may differ from what is reported on the Financial Highlights due to financial statement rounding or adjustments.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:80pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">4</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">The Nasdaq Biotechnology Index contains securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals industry. The Index
is unmanaged and has been provided for comparison purpose only. No fees or expenses are reflected. You cannot invest directly in an index.
</td></tr></table>
</div>
</div>
</div>
<div style="padding-top:9.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">1
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Letter to Shareholders &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt">
<div style="float:left; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is covered under exemptive relief
received by the Fund&#x2019;s investment adviser from the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) that allows the Fund to distribute long-term capital gains as frequently as quarterly in any one
taxable year.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Unclaimed Share Accounts</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Please be advised that
abandoned or unclaimed property laws for certain states require financial organizations to transfer (escheat) unclaimed property (including Fund shares) to the state. Each state has its own definition of unclaimed
property, and Fund shares could be considered &#x201c;unclaimed property&#x201d; due to account inactivity (e.g., no owner-generated activity for a certain period), returned mail (e.g., when mail sent to
a&#xa0;shareholder&#xa0; is returned to the Fund's transfer agent as undeliverable), or a combination of both. If your Fund shares are categorized as unclaimed, your financial advisor or the Fund's transfer agent will
follow the applicable state&#x2019;s statutory requirements to contact you, but if unsuccessful, laws may require that the shares be escheated to the appropriate state. If this happens, you will have to contact the
state to recover your property, which may involve time and expense. For more information on unclaimed property and how to maintain an active account, please contact your financial adviser or the Fund's transfer
agent.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Options Writing</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">In order to further support
the increase in distribution rate for the Fund, the Fund employs a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) put options on a portion of
the common stocks in its portfolio and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and sectors of securities generally within the healthcare industry.
This option strategy is intended to generate current income from option premiums as a means to enhance distributions payable to the Fund's shareholders. The Fund's investment team does not anticipate any adverse
implications to the Fund's existing total return potential or risk profile as a result of the strategy; however, the investment adviser may choose to decrease or modify its use of the option writing strategy to the
extent that it may negatively impact the Fund's ability to benefit from capital appreciation. The Fund currently expects that it will not write options on more than 10% of its assets.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Open Market Repurchase Program</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Board has&#xa0;approved
an open market repurchase and discount management policy (the &#x201c;Program&#x201d;). The Program allows the Fund to purchase, in the open market, its outstanding common shares, with the amount and timing of any
repurchase determined at the discretion of the Fund's investment adviser. Such purchases may be made opportunistically at certain discounts to NAV per share in the reasonable judgment of management based on historical
discount levels and current market conditions. If shares are repurchased, the Fund reports repurchase activity on its website on a monthly basis.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">For the six-month period ended March 31, 2025,
the Fund did not repurchase any shares through the Program.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">On a quarterly basis, the
Board will receive information on any transactions made pursuant to this policy during the prior quarter and management will post the number of shares repurchased on the Fund's website on a monthly basis.&#xa0; Under
the terms of the Program, the Fund is permitted to repurchase up to 12% of its outstanding shares of common stock in the open market during any 12-month period.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Portfolio Holdings Disclosure</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund's complete schedule
of portfolio holdings for the second and fourth quarters of each fiscal year are included in the Fund's semi-annual and annual reports to shareholders. The Fund files its complete schedule of portfolio holdings with
the SEC for the first and third quarters of each fiscal year as an exhibit to its reports on Form N-PORT. These reports are available on the SEC&#x2019;s website at http://www.sec.gov. The Fund makes the information
available to shareholders upon request and without charge by calling Investor Relations toll-free at 1-800-522-5465.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Proxy Voting</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">A description of the policies
and procedures that the Fund uses to determine how to vote proxies relating to portfolio securities and information regarding how the Fund voted proxies relating to portfolio securities during the most recent 12-month
period ended June 30 is available by August 31 of the relevant year: (1) upon request without charge by calling Investor Relations toll-free at 1-800-522-5465; and (2) on the SEC&#x2019;s website at
http://www.sec.gov.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Investor Relations Information</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">As part of Aberdeen's
commitment to shareholders, we invite you to visit the Fund on the web at https://www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds. Here, you can view monthly fact sheets, quarterly
commentary, distribution and performance information, as well as other Fund literature. Enroll in Aberdeen's email services to receive content related to your fund. In addition, you will receive monthly factsheets
based on your preferences. Sign up today at https://www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:17.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">2
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Letter to Shareholders &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Contact Us:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:5pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:5.81%">&#x2022;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.19%">Visit: https://www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:1pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:5.81%">&#x2022;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.19%">Email: Investor.Relations@aberdeenplc.com; or
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:2pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:5.81%">&#x2022;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.19%">Call: 1-800-522-5465 (toll free in the U.S.).
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Yours sincerely,</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">/s/ Alan Goodson<br>
<font style="font-weight:bold">Alan Goodson<br>
</font>President&#xa0;</div>
</div>
<div style="margin-top:501pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:17pt; text-align:center; text-decoration:none; text-transform:none">All amounts are U.S. Dollars
unless otherwise stated.</div>
</div>
<div style="margin-top:21.79pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">3
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Total Investment Return &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:6pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:33.5pt; width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The following table summarizes
the average annual Fund performance compared to the Fund&#x2019;s primary benchmark&#xa0;for the six-month (not annualized), 1-year, 3-year, 5-year and 10-year periods ended March 31, 2025.</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:10pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3.5pt; padding-right:12pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:48.72%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.53%; background-color: #D9D9D9;">6 Months
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.68%; background-color: #D9D9D9;">1 Year
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.77%; background-color: #D9D9D9;">3 Years
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.72%; background-color: #D9D9D9;">5 Years
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:6pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.58%; background-color: #D9D9D9;">10 Years
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:6pt; padding-right:12pt; padding-top:2.12pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:48.72%; background-color: #F0F0F0;">Net Asset Value (NAV)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.53%; background-color: #F0F0F0;">-10.15%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12.21pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.68%; background-color: #F0F0F0;">-2.54%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.77%; background-color: #F0F0F0;">3.21%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12.26pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">5.68%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:6pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">2.98%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:6pt; padding-right:12pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:48.72%; background-color: #F0F0F0;">Market Price
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:16.12pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.53%; background-color: #F0F0F0;">-9.66%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:15.30pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.68%; background-color: #F0F0F0;">6.76%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12.21pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.77%; background-color: #F0F0F0;">2.14%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">6.84%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:6pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">2.04%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:12pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:48.72%; background-color: #F0F0F0;">Nasdaq Biotechnology Index
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:12pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.53%; background-color: #F0F0F0;">-10.62%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:12pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.68%; background-color: #F0F0F0;">-3.39%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:13.10pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.77%; background-color: #F0F0F0;">1.46%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:12.26pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">5.39%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:12pt; padding-right:6pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">2.30%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:13pt; text-align:left; text-decoration:none; text-transform:none">Performance of a $10,000
Investment<font style="font-weight:Normal"> (as of March 31, 2025)</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:7pt; text-align:left; text-decoration:none; text-transform:none">This graph shows the change in
value of a hypothetical investment of $10,000 in the Fund for the periods indicated. For comparison, the same investment is shown in the indicated&#xa0;index.</div>
<div style="margin-left:26.48%; margin-top:5pt; text-align:Center; width:47.22%">
<img src="tm2516624d12hqlreporti003.jpg" alt=" ">
</div>


<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:justify; text-decoration:none; text-transform:none">Returns represent past
performance. Total investment return at NAV is based on changes in the NAV of Fund shares and assumes reinvestment of dividends and distributions, if any, at market prices pursuant to the dividend reinvestment program
sponsored by the Fund&#x2019;s transfer agent. All return data at NAV includes fees charged to the Fund, which are listed in the Fund&#x2019;s Statement of Operations under &#x201c;Expenses.&#x201d; Total investment
return at market value is based on changes in the market price at which the Fund&#x2019;s shares traded on the NYSE during the period and assumes reinvestment of dividends and distributions, if any, at market prices
pursuant to the dividend reinvestment program sponsored by the Fund&#x2019;s transfer agent. The Fund&#x2019;s total investment return is based on the reported NAV as of the financial reporting period end date of March
31, 2025. Because the Fund&#x2019;s shares trade in the stock market based on investor demand, the Fund may trade at a price higher or lower than its NAV. Therefore, returns are calculated based on both market price
and NAV. <font style="font-weight:bold">Past performance is no guarantee of future results</font>. The performance information provided does not reflect the deduction of taxes that a shareholder would pay on distributions received
from the Fund or the sale of Fund shares. The current performance of the Fund may be lower or higher than the figures shown. The Fund&#x2019;s yield, return, market price and NAV will fluctuate. Performance information
current to the most recent month-end is available at https://www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds or by calling 800-522-5465.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The annualized gross operating
expense ratio based on the six-month period ended March 31, 2025 was 1.25%.&#xa0;</div>
</div>
<div style="margin-top:147pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">4
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio Summary &#xa0;<font style="font-size:11pt; line-height:14pt"> (as a percentage of net assets) (unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of March 31, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">The following table summarizes
the composition of the Fund&#x2019;s portfolio by asset allocation.</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.81%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #D9D9D9;">Asset Allocation
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:9pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:6.96%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Common Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:9.81pt; padding-right:9pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">87.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:15.20pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">7.9%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Milestone Interests
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.55pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">3.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Convertible Notes
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.38pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">0.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:91.18%; background-color: #F0F0F0;">Warrants
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.13pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Short-Term Investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:15.72pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">3.1%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Call Options Written
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:30.14pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">-
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Liabilities in Excess of Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:7.89pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">(2.3%)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">100.0%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:18pt; text-align:left; text-decoration:none; text-transform:none">The following table summarizes
the industry composition of the Fund&#x2019;s portfolio, in S&amp;P Global Inc.&#x2019;s Global Industry Classification Standard (&#x201c;GICS&#x201d;) Industries.&#xa0;</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:6pt; width:99.81%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:91.18%; background-color: #D9D9D9;">Industries
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:9pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:6.96%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:91.18%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:8.55pt; padding-right:9pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">82.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:91.18%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:9.41pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">10.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Life Sciences Tools &amp; Services
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.61pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">5.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Health Care Providers &amp; Services
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.30pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">0.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Health Care Equipment &amp; Supplies
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.13pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Short-Term Investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:15.72pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">3.1%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Liabilities in Excess of Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:7.89pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">(2.3%)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">100.0%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:18pt; text-align:left; text-decoration:none; text-transform:none">The following were the
Fund&#x2019;s top ten holdings as of March 31, 2025:</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:6pt; width:99.81%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #D9D9D9;">Top Ten Holdings
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:9pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:5.21%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Regeneron Pharmaceuticals, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:5.59pt; padding-right:9pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">7.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Amgen, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.67pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">6.7%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Gilead Sciences, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.33pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">6.2%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Vertex Pharmaceuticals, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.19pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">4.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Alnylam Pharmaceuticals, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.39pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">3.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">BioMarin Pharmaceutical, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">3.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Insmed, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.21pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">2.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Argenx SE, ADR
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.21pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">2.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">BioNTech SE, ADR
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.41pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">2.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.93%; background-color: #F0F0F0;">Sarepta Therapeutics, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.62pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.21%; background-color: #F0F0F0;">2.2%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;</div>
</div>
<div style="margin-top:204pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">5
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio of Investments&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of March 31, 2025</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:13.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:57.01%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.78%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Convertible Preferred Stocks<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>&#x2014;7.9%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Biotechnology&#x2014;4.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Abcuro, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.32pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;232,252
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">$&#x2002;&#x2007;&#x2007;1,274,994
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Abcuro, Inc. Series C1
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.30pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;51,403
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.17pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;310,407
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Arbor Biotechnologies, Inc. Series B, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.49pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;38,624
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.09pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;640,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Arbor Biotechnologies, Inc. Series C, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.09pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;389,294
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.82pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;1,599,998
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Arkuda Therapeutics, Inc. Series A, 6.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.43pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2007;1,008,829
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.90pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;461,741
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Arkuda Therapeutics, Inc. Series B, 6.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.31pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;447,566
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.92pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;188,067
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Atalanta Therapeutics Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:3.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;777,778
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.70pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;1,400,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Aviceda Therapeutics Series C
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;38,906
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.29pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;224,091
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Flamingo Therapeutics, Inc. Series A3
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:3.87pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;107,120
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.12pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;202,724
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Glycomine, Inc. Series C, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.06pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2007;2,655,105
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.78pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;1,593,063
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc. Series B, 6.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.82pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2007;1,291,668
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.52pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;2,672,074
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc. Series C, 6.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.60pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;284,119
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.12pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;827,894
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Incendia Therapeutics, Inc. Series A
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.34pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;832,650
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.15pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;1,599,995
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Priothera Co. Ltd. Series A, 6.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.54pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;152,534
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;17
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Quell Therapeutics Ltd. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.12pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;846,561
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.71pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;1,760,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Recode Therapeutics, Inc. Series B, 5.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.66pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;155,959
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.87pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;1,440,001
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Seismic Therapeutics, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.88pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">282,340
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.94pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,274,991
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Third Arc Bio, Inc. Series A, 8.00%
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.68pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">403,954
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:23.12pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">850,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.01%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:13.05pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">18,320,057
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Health Care Equipment &amp; Supplies&#x2014;0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">IO Light Holdinigs, Inc. Series A2
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.78pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">421,634
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:42.53pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">42
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Pharmaceuticals&#x2014;3.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Biotheryx, Inc. Series E, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.21pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">609,524
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.99pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">295,131
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Curasen Therapeutics, Inc. Series A
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.30pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">9,049,182
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.47pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">4,339,083
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Curasen Therapeutics, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.58pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">1,379,821
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.20pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">661,624
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc. Series B, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.31pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">296,855
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.44pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,936,860
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc. Series C, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.18pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">54,815
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.17pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">357,646
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Engrail Therapeutics, Inc. Series B, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.86pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">2,124,646
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.72pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,250,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">HiberCell, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.53pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">1,305,163
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:23.91pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">538,902
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">HiberCell, Inc. Series C
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.72pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">719,652
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.05pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">333,631
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Nuvig Therapeutics, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.04pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">739,010
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:24.44pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">775,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Qlaris Bio, Inc. Series B
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.63pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">1,974,522
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.45pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,550,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.01%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:14.41pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">13,037,877
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.79%; background-color: #F0F0F0;" colspan="3">Total Convertible Preferred Stocks
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:14.92pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">31,357,976
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Convertible Notes<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>&#x2014;0.3%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:57.01%; background-color: #F0F0F0;">Biotechnology&#x2014;0.3%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc., 6.00%, 04/10/26
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:2.99%; background-color: #F0F0F0;">$&#x2002;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.53pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">323,870
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:24.42pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">323,870
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Incendia Therapeutics, Inc., 8.00%, 04/18/25
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.93pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">738,460
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:23.82pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">738,460
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.01%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:16.72pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,062,330
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:57.01%; background-color: #F0F0F0;">Pharmaceuticals&#x2014;0.0%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.5pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">HiberCell, Inc., 10.00%, 12/31/25
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.95pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">206,589
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:23.84pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">206,589
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Total Convertible Notes
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:17.67pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,268,919
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Common Stocks&#x2014;87.4%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Biotechnology&#x2014;77.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Abeona Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.61pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">224,356
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.17pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,067,935
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Affimed NV<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.19pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">20,862
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:29.35pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">15,087
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Akero Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.47pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">164,668
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.80pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">6,665,761
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Alkermes PLC<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.83pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">67,632
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.34pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,233,209
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Allogene Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.29pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">867,250
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.57pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,266,185
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Alnylam Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.76pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">50,600
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.53pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">13,663,012
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">ALX Oncology Holdings, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.19pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">66,211
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:29.18pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">41,249
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Amgen, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.20pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">84,612
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.42pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">26,360,869
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Arbutus Biopharma Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.00pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">467,383
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.01pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,631,167
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Arcutis Biotherapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.26pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">192,536
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.80pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">3,011,263
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Ardelyx, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.83pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">441,923
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.53pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,169,842
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Argenx SE, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:2.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:18.57pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">16,111
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:19.09pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">9,535,537
</td></tr></table>
</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:57.01%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.78%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:4pt; padding-top:1.5pt; text-align:left; vertical-align:top; width:57.01%; background-color: #F0F0F0;">
</td><td style="padding-top:1.5pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">
</td><td style="padding-right:4pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">
</td><td style="padding-right:6pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:6pt; text-align:left; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Arrowhead Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.71pt; padding-right:4pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;347,935
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">$&#x2002;&#x2007;&#x2007;4,432,692
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">ARS Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.99pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;186,125
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.61pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;2,341,453
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Ascendis Pharma AS, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.92pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;47,233
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.72pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;7,361,735
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Avidity Biosciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.24pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;138,274
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.69pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;4,081,849
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">BioMarin Pharmaceutical, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.44pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;192,503
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.37pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;13,608,037
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">BioNTech SE, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.86pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;101,845
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.26pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;9,274,006
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Caribou Biosciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:3.32pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;411,144
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.30pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;375,416
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Centessa Pharmaceuticals PLC, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;90,883
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.97pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;1,306,898
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Chinook Therapeutics, Inc. CVR<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.45pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;59,063
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.62pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;133,482
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Cidara Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.33pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;36,762
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.21pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;791,853
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Corbus Pharmaceuticals Holdings, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.33pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;26,894
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.87pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;142,807
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Crinetics Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.41pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;91,281
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.81pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;3,061,565
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Cytokinetics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.90pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;138,707
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.67pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;5,574,634
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Denali Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.97pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;337,505
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.07pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;4,588,381
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Dyne Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.29pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;314,586
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.07pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;3,290,570
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Galera Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.60pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;125,773
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.14pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;3,773
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Geron Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.20pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">1,360,622
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.23pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,163,389
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Gilead Sciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.67pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">218,860
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">24,523,263
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">GRAIL, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.61pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">86,408
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.37pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,206,860
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Halozyme Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.16pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">39,580
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.93pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,525,600
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Ideaya Biosciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.78pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">154,726
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.84pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,534,412
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">I-Mab, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.85pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">26,109
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:33.13pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">21,511
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Immatics NV<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.19pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">309,867
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.88pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,397,500
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Immunic, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4.61pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">1,059,484
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.88pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,154,838
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Immunovant, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.70pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">262,867
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.17pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">4,492,397
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Incyte Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.95pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">15,287
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.93pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">925,628
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Inozyme Pharma, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.92pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">326,758
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:27.27pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">297,350
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Insmed, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.54pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">125,361
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.20pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">9,563,791
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Ionis Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.04pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">128,658
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.58pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">3,881,612
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Iovance Biotherapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.66pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">131,800
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:24.97pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">438,894
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Janux Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.56pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">71,237
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.80pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,923,399
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Korro Bio, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.88pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">84,428
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.15pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,469,891
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Krystal Biotech, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.28pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">12,557
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.29pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,264,027
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Mereo Biopharma Group PLC, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.58pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">843,891
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.08pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,898,755
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Merus NV<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.88pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">41,013
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.11pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,726,237
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Mural Oncology PLC<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.47pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">14,952
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:30.08pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">18,840
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Neurocrine Biosciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.41pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">56,639
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.26pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">6,264,273
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Newamsterdam Pharma Co. NV<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.01pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">59,888
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.42pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,225,907
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Nkarta, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.03pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">28,988
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:29.87pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">53,338
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Novavax, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.77pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">26,612
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.87pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">170,583
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Nuvalent, Inc., Class A<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.33pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">33,821
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.86pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,398,585
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Oruka Therapeutics, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.22pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">2,705
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:32.01pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">27,753
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Praxis Precision Medicines, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.72pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">27,485
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.53pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,040,857
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Pyxis Oncology, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.57pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">286,408
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.62pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">280,651
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Rallybio Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.87pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">377,375
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.01pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">246,992
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Regeneron Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.30pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">45,913
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.97pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">29,119,402
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Rhythm Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.77pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">36,897
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.31pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,954,434
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Sarepta Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.59pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">135,231
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.13pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">8,630,442
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Scholar Rock Holding Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.18pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">32,760
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.63pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,053,234
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Sionna Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.79pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">225,248
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.62pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,356,094
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Summit Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.29pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">412,254
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.00pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">7,952,380
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Syndax Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.30pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">132,433
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.68pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,626,939
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Tenaya Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.78pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">600,700
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.66pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">342,459
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Travere Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.99pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">150,369
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.93pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,694,612
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">TScan Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.63pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">393,440
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.12pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">542,947
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Ultragenyx Pharmaceutical, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.99pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">154,610
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.69pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">5,598,428
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">uniQure NV<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.60pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">542,249
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.94pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">5,747,839
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Vaxcyte, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.49pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">87,633
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.66pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">3,309,022
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Vertex Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.51pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">37,016
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.94pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">17,946,097
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Vigil Neuroscience, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:2.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:6.13pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">1,724,520
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:19.16pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">3,069,646
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:14pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">6
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio of Investments&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of March 31, 2025</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:22.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:57.01%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.78%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Common Stocks (continued)
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.5pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Biotechnology (continued)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Vir Biotechnology, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.94pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;216,154
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">$&#x2002;&#x2007;&#x2007;1,400,678
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Xencor, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.19pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;185,509
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.24pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;1,973,816
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Xenon Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.34pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;158,248
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.09pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;5,309,220
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.01%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:8.59pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">305,795,089
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Health Care Equipment &amp; Supplies&#x2014;0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Willow Laboratories, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.44pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;130,000
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.82pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;13
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Health Care Providers &amp; Services&#x2014;0.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Guardant Health, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.32pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;57,952
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.56pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;2,468,755
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Life Sciences Tools &amp; Services<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>&#x2014;5.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Adaptive Biotechnologies Corp.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.58pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;432,737
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.39pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;3,215,236
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Codexis, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;606,294
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.79pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;1,630,931
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Illumina, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.20pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;72,264
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.59pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;5,733,426
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Medpace Holdings, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.36pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;6,077
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.64pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;1,851,601
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Personalis, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.11pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;894,205
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.49pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;3,138,659
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Quanterix Corp.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.14pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;268,717
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.49pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;1,749,348
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Tempus AI, Inc.
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.70pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;85,772
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.57pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;4,137,641
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.01%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:13.28pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">21,456,842
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Pharmaceuticals<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>&#x2014;4.1%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Amylyx Pharmaceuticals, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.64pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">743,089
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.30pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,630,535
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Arvinas, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.47pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">2,491
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:31.59pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">17,487
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Axsome Therapeutics, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.29pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">29,802
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.61pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">3,475,807
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Edgewise Therapeutics, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.71pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">116,450
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.06pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,561,900
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">EyePoint Pharmaceuticals, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.55pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">70,281
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:24.79pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">380,923
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Fusion Pharmaceuticals, Inc. CVR<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(e)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.82pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">3,256
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:33.07pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">4,493
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Oculis Holding AG<sup style="font-size:85%; font-style:Normal; text-transform:none">(e)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.68pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">170,667
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.12pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">3,247,793
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Spectrum Pharmaceuticals, Inc. CVR<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.61pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">34,880
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:47.56pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Structure Therapeutics, Inc., ADR
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.54pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">78,960
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.15pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,366,798
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Tarsus Pharmaceuticals, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.30pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">51,869
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.10pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2,664,511
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Tetraphase Pharmaceuticals, Inc. CVR<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.03pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">14,218
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:39.19pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">284
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.01%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:14.83pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">16,350,531
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.79%; background-color: #F0F0F0;" colspan="3">Total Common Stocks
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:9.07pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">346,071,230
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Warrants<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>&#x2014;0.0%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:57.01%; background-color: #F0F0F0;">Pharmaceuticals&#x2014;0.0%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">HiberCell, Inc.(expiration date 09/15/28, exercise price $0.46)
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.78pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">719,652
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:48.70pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">HiberCell, Inc.(expiration date 09/13/34, exercise price $0.08)
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4.65pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">2,582,362
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:47.95pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">2
</td></tr>
<tr style="page-break-inside:avoid"><td style="line-height:8pt; padding-bottom:2.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.01%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:8pt; padding-bottom:2.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:2.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.5pt; padding-left:47.53pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">3
</td></tr></table>
</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:57.01%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.78%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Short-Term Investment&#x2014;3.1%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">State Street Institutional U.S. Government Money Market Fund, Premier Class, 4.29%<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.86pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #F0F0F0;">12,161,215
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">$<font style="padding-left:4.85pt"></font>&#x2002;&#x2007;12,161,215
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.79%; background-color: #F0F0F0;" colspan="3">Total Short-Term Investment
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:18.19pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">12,161,215
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:75.79%; background-color: #F0F0F0;" colspan="3">Total Investments Before Milestone Interests&#x2014;98.7%<br>
(Cost $402,142,937)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:8.57pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">390,859,343
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.01%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.79%; background-color: #CCCCCC;">Interests
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Milestone Interests<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>&#x2014;3.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Biotechnology&#x2014;0.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Amphivena Milestone Interest
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">$<font style="padding-left:0.85pt"></font>&#x2002;&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;0
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Invetx, Inc. Milestone Interest
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.96pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;&#x2007;1,387,824
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.01%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:19.79pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">1,387,824
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Pharmaceuticals&#x2014;3.2%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Afferent Milestone Interest
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.63pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Amolyt Milestone Interest
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.36pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;702,412
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Ethismos Research Milestone Interest
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.63pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;0
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.01%; background-color: #F0F0F0;">Neurovance Milestone Interest
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.11pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">&#x2007;11,970,670
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:57.01%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:15.79%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:14.68pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">12,673,082
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.79%; background-color: #F0F0F0;" colspan="3">Total Milestone Interests
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:13.46pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">14,060,906
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.79%; background-color: #F0F0F0;" colspan="3">Total Investments (Cost $405,663,364)<sup style="font-size:85%; font-style:Normal; text-transform:none">(g)</sup>&#x2014;102.3%
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:8.36pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">404,920,249
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.79%; background-color: #F0F0F0;" colspan="3">Liabilities in Excess of Other Assets (2.3%)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.46pt; padding-right:6pt; padding-top:1.5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.13%; background-color: #F0F0F0;">(8,978,348)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:0.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.79%; background-color: #F0F0F0;" colspan="3">Net Assets&#x2014;100.0%
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:0.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.13%; background-color: #F0F0F0;">$<font style="padding-left:2.10pt"></font>395,941,901
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:10pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(a)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:10pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">Level 3 security. See Note 2(a) of the accompanying Notes to&#xa0;Financial Statements.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(b)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">Non-income producing security.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(c)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">Restricted security.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(d)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">A portion of security is pledged as collateral for call options written.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(e)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">Foreign security.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(f)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">Registered investment company advised by State Street Global Advisors. The rate shown is the 7 day yield as of March 31, 2025.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(g)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">See accompanying Notes to Financial Statements for tax unrealized appreciation/(depreciation) of securities.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:6pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">ADR
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:6pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">American Depositary Receipt
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">ARS
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">Auction Rate Security
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">CVR
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">Contingent Value Right
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">PLC
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">Public Limited Company
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; width:100%">
</div>
</div>
<div style="padding-top:196pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">7
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio of Investments&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(concluded)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of March 31, 2025</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:13.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.91%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:34.20%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:25.85%; background-color: #CCCCCC;">Number of Contracts<br>
(100 shares each)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:25.73%; background-color: #CCCCCC;">Notional Amount ($)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.38%; background-color: #CCCCCC;">Value ($)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%; background-color: #E6E6E6;" colspan="4">Option Contracts Written&#x2014;0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%; background-color: #E6E6E6;" colspan="4">Call Options Written&#x2014;0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">Akero Therapeutics, Inc. Apr25 50 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">167
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(835,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(4,843)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">Alnylam Pharmaceuticals, Inc. Apr25 270 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">16
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(432,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(12,640)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">Amgen, Inc. Apr25 330 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">32
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(1,056,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(3,840)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">BioMarin Pharmaceutical, Inc. Apr25 75 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">112
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(840,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(4,480)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">BioNTech SE Apr25 105 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">60
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(630,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(2,400)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">Cytokinetics, Inc. Apr25 50 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">84
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(420,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(4,620)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">Gilead Sciences, Inc. Apr25 115 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">55
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(632,500)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(8,250)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">Illumina, Inc. Apr25 90 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">70
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(630,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(2,450)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">Regeneron Pharmaceuticals, Inc. Apr25 680 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">6
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(408,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(2,400)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">Regeneron Pharmaceuticals, Inc. Apr25 680 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">9
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(612,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(1,170)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">Sarepta Therapeutics, Inc. Apr25 85 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">198
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(1,683,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(2,970)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">Summit Therapeutics, Inc. Apr25 25 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">251
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(627,500)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(4,016)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">uniQure NV Apr25 15 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">280
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(420,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(2,800)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #E6E6E6;">Vertex Pharmaceuticals, Inc. Apr25 530 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.85%; background-color: #E6E6E6;">12
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">(636,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(1,296)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3.5pt; padding-left:14pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:bottom; width:85.78%; background-color: #E6E6E6;" colspan="3">Total Call Options Written<br>
(Premiums received $(217,394))
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.38%; background-color: #E6E6E6;">(58,175)
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; margin-top:9pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to Financial
Statements.</div>
</div>
<div style="margin-top:415pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">8
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statement of Assets and Liabilities&#xa0;<font style="font-size:11pt; line-height:14pt"> (unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of March 31, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:85.70%">Assets
</td><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:13.49%">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Investments, at value (cost $389,981,722)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.49%; background-color: #F0F0F0;">$<font style="padding-left:0.11pt"></font>&#x2003;378,698,128
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Short-term investment, at value (cost $12,161,215)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:21.25pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.49%; background-color: #F0F0F0;">&#x2003;12,161,215
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Milestone interests, at value(cost $3,520,427)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:15.28pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.49%; background-color: #F0F0F0;">&#x2003;14,060,906
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Foreign currency, at value (cost $1)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:63.06pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">1
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Receivable for investments sold
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:28.61pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">6,274,644
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Interest and dividends receivable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:37.04pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">104,148
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Tax reclaim receivable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:45.21pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">8,970
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Prepaid expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:40.45pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">33,570
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Other assets (Note 2j)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:52.84pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">189
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Total assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:19.61pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">411,341,771
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:85.70%">Liabilities
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.49%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Due to custodian
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:30.17pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">8,103,941
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Payable for investments purchased
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:27.95pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">6,540,292
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Investment advisory fees payable (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:34.68pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">389,835
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Written options, at value (premiums received$217,394)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:42.50pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">58,175
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Trustee fees payable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:41.67pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">31,523
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Administration fees payable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:45.68pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">6,019
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Investor relations fees payable (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:44.88pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">3,895
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Other accrued expenses
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:36.58pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">266,190
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Total liabilities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:21.76pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.49%; background-color: #F0F0F0;">15,399,870
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Commitments and Contingencies (Notes 7 &amp; 9)
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.49%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:2.38pt; text-align:left; vertical-align:bottom; white-space:nowrap; width:99.18%" colspan="2">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Net Assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.49%; background-color: #F0F0F0;">$<font style="padding-left:4.06pt"></font>395,941,901
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Composition of Net Assets
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.49%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Common stock (par value $0.010 per share) (Note 5)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.49%; background-color: #F0F0F0;">$<font style="padding-left:15.63pt"></font>&#x2003;288,724
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Paid-in capital in excess of par
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:12.68pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.49%; background-color: #F0F0F0;">&#x2003;426,168,819
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Accumulated loss
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:13.63pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.49%; background-color: #F0F0F0;">&#x2003;(30,515,642)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Net Assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.49%; background-color: #F0F0F0;">$<font style="padding-left:4.06pt"></font>395,941,901
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.70%">Net asset value per share based on 28,872,416 shares issued and outstanding
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.49%; background-color: #F0F0F0;">$<font style="padding-left:35.21pt"></font>13.71
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:225pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">9
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statement of Operations&#xa0;<font style="font-size:11pt; line-height:14pt"> (unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">For the Six-Month Period Ended March 31, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Net Investment Income
</td><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:12.57%">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Investment Income:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:86.62%">Dividends
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">$<font style="padding-left:7.74pt"></font>&#x2003;1,116,372
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Interest and other income
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.66pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#x2003;245,462
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Total investment income
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.77pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.57%; background-color: #F0F0F0;">1,361,834
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:86.62%">Expenses:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Investment advisory fee (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:15.09pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#x2003;2,305,899
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Independent auditors&#x2019; fees and tax expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:28.66pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#x2003;78,874
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Legal fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:28.10pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#x2003;76,244
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Trustees' fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:27.09pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#x2003;70,089
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Reports to shareholders and proxy solicitation
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:28.58pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#x2003;66,215
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Transfer agent&#x2019;s fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:29.68pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#x2003;28,311
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Investor relations fees and expenses (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:27.36pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#x2003;28,263
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Custodian&#x2019;s fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:29.38pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#x2003;16,778
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Insurance expense
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:30.20pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#x2003;14,123
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Administration fee
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:29.78pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#x2003;11,262
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:86.62%">Miscellaneous
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:27.66pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#x2003;41,049
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Total expenses
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:27.43pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.57%; background-color: #F0F0F0;">2,737,107
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:2.5pt; text-align:left; vertical-align:bottom; white-space:nowrap; width:99.18%" colspan="2">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Net Investment Loss
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.57pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.57%; background-color: #F0F0F0;">(1,375,273)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Net Realized/Unrealized Gain/(Loss):
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Net realized gain/(loss) from:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:1.5pt; text-align:right; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Investments in unaffiliated issuers
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:20.41pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.57%; background-color: #F0F0F0;">16,556,361
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Written options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:30.82pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.57%; background-color: #F0F0F0;">280,518
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; vertical-align:bottom; width:86.62%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:18.86pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.57%; background-color: #F0F0F0;">16,836,879
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Net change in unrealized appreciation/depreciation on:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:12.57%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Investments in unaffiliated issuers
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:16.98pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.57%; background-color: #F0F0F0;">(63,219,576)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Investments in affiliated issuers
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:37.23pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.57%; background-color: #F0F0F0;">14,261
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Milestone interests
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:31.66pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.57%; background-color: #F0F0F0;">393,185
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Written options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:31.85pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.57%; background-color: #F0F0F0;">116,260
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; vertical-align:bottom; width:86.62%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:15.17pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.57%; background-color: #F0F0F0;">(62,695,870)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Net realized and unrealized gain from investments, milestone interests and written options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:15.64pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.57%; background-color: #F0F0F0;">(45,858,991)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.62%">Change in Net Assets Resulting from Operations
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.57%; background-color: #F0F0F0;">$(47,234,264)
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:168pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">10
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statements of Changes in Net Assets<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:7.5pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:67.71%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:7.5pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.85%">For the<br>
Six-Month<br>
Period Ended<br>
March 31, 2025<br>
(unaudited)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%">For the<br>
Year Ended<br>
September 30, 2024
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Increase/(Decrease) in Net Assets:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:13.85%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:67.71%">Operations:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:13.85%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Net investment loss
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.85%; background-color: #F0F0F0;">$<font style="padding-left:11.14pt"></font>(1,375,273)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">$<font style="padding-left:12.42pt"></font>(1,920,347)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Net realized gain from investments and written options
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:19.89pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">16,836,879
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:26.97pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">31,957,173
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:10pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:67.71%">Net change in unrealized appreciation/depreciation investments, milestone interests
and written options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.21pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">(62,695,870)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.15pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">55,259,633
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Net increase/(decrease) in net assets resulting from operations
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.17pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">(47,234,264)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:21.53pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">85,296,459
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Distributions to Shareholders From:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:13.85%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Distributable earnings
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.87pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">(27,409,869)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:18.47pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">(39,686,734)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Return of capital
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:58.62pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.35pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">(5,606,991)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Net decrease in net assets from distributions
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.87pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">(27,409,869)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.74pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">(45,293,725)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:10pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:67.71%">Reinvestment of dividends resulting in the issuance of 811,017 and 1,270,202 shares of
common stock, respectively
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:20.36pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">10,891,428
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.05pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">17,758,355
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Change in net assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.25pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">(63,752,705)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.88pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">57,761,089
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Net Assets:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:13.85%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Beginning of period
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:13.11pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">459,694,606
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.11pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">401,933,517
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">End of period
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">$395,941,901
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">$459,694,606
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:296pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">11
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statement of Cash Flows&#xa0;<font style="font-size:11pt; line-height:14pt"> (unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">For the Six-Month Period Ended&#xa0;&#xa0;March
31, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Cash flows from operating activities:
</td><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Net increase/(decrease) in net assets resulting from operations
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">$<font style="padding-left:3.63pt"></font>&#x2003;(47,234,264)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:10pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:85.25%">Adjustments to reconcile net increase in net assets resulting<br>
from operations to net cash provided by operating activities:
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Investments purchased
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:12.68pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">&#x2003;(157,455,663)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Investments sold and principal repayments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:15.47pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">&#x2003;161,844,976
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Proceeds from option contracts written
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:31.01pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">&#x2003;404,142
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Net change in short-term investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:25.99pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">&#x2003;5,070,113
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Decrease in interest, dividends and other receivables
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:36.53pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">&#x2003;56,791
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Decrease in prepaid expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:42.63pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">&#x2003;7,961
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Decrease in accrued investment advisory fee payable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:34.41pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">&#x2003;(15,277)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Decrease in other accrued expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:28.67pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">&#x2003;(123,270)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Net change in unrealized depreciation of investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:18.10pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">&#x2003;62,695,870
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Net realized gain on investments transactions and options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:15.84pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">&#x2003;(16,836,879)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Net cash provided by operating activities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:28.16pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.93%; background-color: #F0F0F0;">8,414,500
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Cash flows from financing activities:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Increase in payable to custodian
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">$<font style="padding-left:12.57pt"></font>&#x2003;8,103,941
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Distributions paid to shareholders
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.34pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.93%; background-color: #F0F0F0;">(16,518,441)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Net cash used in financing activities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:24.86pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.93%; background-color: #F0F0F0;">(8,414,500)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Unrestricted and restricted cash and foreign currency, beginning of period
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:65.52pt; padding-right:12pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.93%; background-color: #F0F0F0;">1
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.25%">Unrestricted and restricted cash and foreign currency, end of period
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.93%; background-color: #F0F0F0;">$<font style="padding-left:52.51pt"></font>1
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:335pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">12
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Financial Highlights<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:9.5pt; padding-bottom:3pt; padding-right:6.5pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:39.98%; background-color: #D9D9D9;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.23%; background-color: #D9D9D9;">For the<br>
Six-Month<br>
Period Ended<br>
March 31,
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:12pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:46.58%; background-color: #D9D9D9;" colspan="5">For the Fiscal Years Ended September 30,
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:6.5pt; padding-top:1.75pt; text-align:left; vertical-align:bottom; width:39.98%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.23%; background-color: #D9D9D9;">2025<br>
(unaudited)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #D9D9D9;">2024<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #D9D9D9;">2023<br>


</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #D9D9D9;">2022<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #D9D9D9;">2021<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #D9D9D9;">2020<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">PER SHARE OPERATING PERFORMANCE:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:12.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.33%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.26%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.27%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.39%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.32%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Net asset value per common share, beginning of period
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.15pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">$16.38
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.23pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">$15.00
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.12pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">$15.49
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.81pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">$21.22
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.10pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">$20.25
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.78pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">$16.55
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Net investment loss<sup style="font-size:85%; font-style:Normal; text-transform:none">(c)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.02pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(0.05)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.47pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">(0.07)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:22.34pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">(0.08)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:25.12pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(0.12)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:26.12pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">(0.17)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:22.86pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">(0.09)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Net realized and unrealized gains/(losses) on investments, written
options and foreign currency transactions
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.54pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(1.65)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:29.58pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">3.11
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.11pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">0.87
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.76pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(4.14)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.70pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">2.83
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.93pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">5.25
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Total from investment operations applicable to common shareholders
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.76pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(1.70)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.94pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">3.04
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.30pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">0.79
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.01pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(4.26)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.76pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">2.66
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:28.54pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">5.16
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Distributions to common shareholders from:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:12.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.33%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.26%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.27%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.39%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.32%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Net investment income
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.79pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(0.97)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.08pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">(0.69)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:22.76pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">(0.02)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:22.58pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(0.03)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.49pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">(0.42)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:39.11pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Net realized gains
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:39.06pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.93pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">(0.76)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:24.28pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">(1.26)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.78pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(1.44)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:25.59pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">(1.27)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:24.82pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">(1.47)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Return of capital
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:39.06pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.48pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">(0.21)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:38.78pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:38.81pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:39.47pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:39.11pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Total distributions
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.79pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(0.97)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.37pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">(1.66)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.14pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">(1.28)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.53pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(1.47)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.74pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">(1.69)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.82pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">(1.47)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Effect of Fund shares repurchased
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:39.06pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:39.15pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:38.78pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:38.81pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:39.47pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.95pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">0.01
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Net asset value per common share, end of period
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.09pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">$13.71
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.25pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">$16.38
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.85pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">$15.00
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.16pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">$15.49
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:18.47pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">$21.22
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.74pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">$20.25
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Market price, end of period
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.55pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">$12.69
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.26pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">$15.08
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.71pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">$12.47
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.04pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">$13.66
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.25pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">$20.80
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.05pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">$17.58
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Total Investment Return Based on<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:12.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.33%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.26%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.27%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.39%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.32%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Market price
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.30pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(9.66%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:13.51pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">35.94%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:18.12pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">0.23%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:12.74pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(27.97%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:14.26pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">28.32%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.23pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">27.50%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Net asset value
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:13.61pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(10.15%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:14.69pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">22.75%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:18.49pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">6.32%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:10.89pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(19.88%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.07pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">13.65%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:12.80pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">34.00%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Ratio to Average Net Assets Applicable to Common Shareholders/Supplementary Data:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:12.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.33%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.26%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.27%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.39%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.32%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Net assets applicable to common shareholders, end of period (000 omitted)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">$395,942
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">$459,695
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">$401,934
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:7.78pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">$397,902
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">$523,440
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">$483,570
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Average net assets applicable to common shareholders (000 omitted)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:8.32pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">$439,717
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:8.11pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">$433,142
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:7.15pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">$421,289
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">$436,937
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:7.72pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">$519,380
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.99pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">$449,677
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Gross operating expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:14.51pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">1.25%<sup style="font-size:85%; font-style:Normal; text-transform:none">(e)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.56pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">1.36%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.45pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">1.35%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.09pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">1.38%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:20.26pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">1.24%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:20.01pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">1.22%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Net Investment loss
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.14pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(0.63%)<sup style="font-size:85%; font-style:Normal; text-transform:none">(e)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:14.91pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">(0.44%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.34pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">(0.52%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:14.69pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(0.68%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.17pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">(0.80%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.62pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">(0.47%)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:39.98%; background-color: #F0F0F0;">Portfolio turnover
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:20.97pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">38%<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.30pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">46%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.39pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">35%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.24pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">42%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.03pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">62%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.97pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.32%; background-color: #F0F0F0;">51%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(a)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Effective October 27, 2023, abrdn Inc. became the investment adviser of the Fund. Prior to October 27, 2023, the Fund was managed by Tekla Capital Management, LLC. Members of the portfolio management
team from Tekla joined abrdn Inc., and continue to manage the Fund.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(b)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Beginning with the year ended September 30, 2023, the Fund&#x2019;s financial statements were audited by KPMG LLP.<br>
Previous years were audited by a different independent registered public accounting firm.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(c)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Based on average shares outstanding.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(d)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Total investment return based on market value is calculated assuming that shares of the Fund&#x2019;s common stock were purchased at the closing market price as of the beginning of the period, dividends,
capital gains and other distributions were reinvested as provided for in the Fund&#x2019;s dividend reinvestment plan and then sold at the closing market price per share on the last day of the period. The computation
does not reflect any sales commission investors may incur in purchasing or selling shares of the Fund. The total investment return based on the net asset value is similarly computed except that the Fund&#x2019;s net
asset value is substituted for the closing market value.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(e)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Annualized.<div style="margin-top:19pt"></div><font style="font-size:9.5pt; line-height:12.5pt">See accompanying Notes to Financial Statements.</font>
</td></tr></table>
</div>
</div>
<div style="margin-top:24pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">13
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Financial Highlights<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:22.5pt; width:100%">
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(f)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Not annualized.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:620pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">14
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:17.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">1.&#xa0;&#xa0;Organization</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">abrdn Life Sciences
Investors (the "Fund") is a Massachusetts business trust formed on February 20, 1992, and registered under the Investment Company Act of 1940 as a non-diversified closed-end management investment company. The Fund
commenced operations on May 8, 1992. The Fund&#x2019;s investment objective is to seek long-term capital appreciation by investing primarily in securities of life sciences companies. The Fund invests primarily in
securities of public and private companies that are believed by the Fund&#x2019;s investment adviser, abrdn Inc.&#xa0;to have significant potential for above-average growth. The Fund may invest up to 20% of its net
assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of U.S. issuers that are traded primarily in foreign markets.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">2.&#xa0;&#xa0;Summary of Significant
Accounting Policies</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is an investment
company and accordingly follows the investment company accounting and reporting guidance of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic 946 Financial Services-Investment
Companies. The following is a summary of significant accounting policies followed by the Fund in the preparation of its financial statements. The policies conform to generally accepted accounting principles in the
United States of America ("U.S.&#xa0;GAAP"). The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of
contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expenses for the period. Actual results could differ from those estimates. The accounting records of
the Fund are maintained in U.S. Dollars and the U.S. Dollar is used as both the functional and reporting currency.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">a.&#xa0;&#xa0;Security Valuation:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund values its
securities at fair value, consistent with regulatory requirements. "Fair value" is defined in the Fund's Valuation and Liquidity Procedures as the price that could be received to sell an asset or paid to transfer a
liability in an orderly transaction between willing market participants without a compulsion to transact at the measurement date, also referred to as market value. Pursuant to Rule 2a-5 under the 1940 Act, the Board
designated Aberdeen as the valuation designee ("Valuation Designee") for the Fund to perform the fair value determinations relating to Fund investments for which market quotations are not readily available or
deemed&#xa0;unreliable and the Fund's investments in securities of early and/or later stage financing of a privately held companies ("Venture Capital Securities").</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In accordance with the
authoritative guidance on fair value measurements and disclosures under U.S. GAAP, the Fund discloses the fair value of its investments using a three-level hierarchy that classifies the inputs to valuation techniques
used to measure the fair</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">value. The hierarchy assigns Level 1, the
highest level, measurements to valuations based upon unadjusted quoted prices in active markets for identical assets, Level 2 measurements to valuations based upon other significant observable inputs, including
adjusted quoted prices in active markets for similar assets, and Level 3, the lowest level, measurements to valuations based upon unobservable inputs that are significant to the valuation. Inputs refer broadly to the
assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, for example, the risk inherent in a particular valuation technique used to measure fair value
including a pricing model and/or the risk inherent in the inputs to the valuation technique. Inputs may be observable or unobservable. Observable inputs are inputs that reflect the assumptions market participants
would use in pricing the asset or liability, which are based on market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity&#x2019;s own
assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. A financial instrument&#x2019;s level within the
fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Long-term debt and other
fixed-income securities are valued at the last quoted or evaluated bid price on the valuation date provided by an independent pricing service provider. If there are no current day bids, the security is valued at the
previously applied bid. Pricing services generally price debt securities assuming orderly transactions of an institutional &#x201c;round lot&#x201d; size and the strategies employed by the Valuation Designee generally
trade in round lot sizes. In certain circumstances, some trades may occur in smaller &#x201c;odd lot&#x201d; sizes which may be effected at lower, or higher, prices than institutional round lot trades. Short-term debt
securities (such as commercial paper and U.S. treasury bills) having a remaining maturity of 60 days or less are valued at the last quoted or evaluated bid price on the valuation date provided by an independent
pricing service, or on the basis of amortized cost, if it represents the best approximation of fair value. Debt and other fixed-income securities are generally determined to be Level 2 investments.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Equity securities that are
traded on an exchange are valued at the last quoted sale price or the official close price on the principal exchange on which the security is traded at the &#x201c;Valuation Time&#x201d; subject to application, when
appropriate, of the valuation factors described in the paragraph below. Under normal circumstances, the Valuation Time is as of the close of regular trading on the New York Stock Exchange ("NYSE") (usually 4:00 p.m.
Eastern Time). In the absence of a sale price, the security is valued at the mean of the bid/ask price quoted at the close on the principal exchange on which the security is traded. Securities traded on NASDAQ are
valued at the NASDAQ official closing price.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:23.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">15
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Convertible preferred shares, warrants or
convertible note interests in Venture Capital Securities, milestone interests, and other restricted securities are typically valued in good faith, based upon the recommendations made by&#xa0;the Valuation Designee
pursuant to fair valuation policies and procedures approved by the Board.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Derivative instruments are
valued at fair value. Exchange-traded futures are generally Level 1 investments and centrally cleared swaps and forwards are generally Level 2 investments. Forward foreign currency contracts are generally valued based
on the bid price of the forward rates and the current spot rate. Forward exchange rate quotations are available for scheduled settlement dates, such as 1-, 3-, 6-, 9- and 12-month periods. An interpolated valuation is
derived based on the actual settlement dates of the forward contracts held. Futures contracts are valued at the settlement price or at the last bid price if no settlement price is available. Swap agreements are
generally valued by an approved pricing agent based on the terms of the swap agreement (including future cash flows). Exchange-traded options are valued at the last quoted sales price. In the absence of a sales price,
options are valued at the mean of the bid/ask price quoted at the close on the exchange on which the options trade. When market quotations or exchange rates are not readily available, or if the Adviser concludes that
such market quotations do not accurately reflect fair value, the fair value of the Fund&#x2019;s assets are determined in good faith in accordance with the Valuation Procedures.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Foreign equity securities
that are traded on foreign exchanges that close prior to the Valuation Time are valued by applying valuation factors to the last sale price or the mean price as noted above. Valuation factors are provided by an
independent pricing service provider. These valuation factors are used when pricing the Fund's portfolio holdings to estimate market movements between the time foreign markets close and the time the Fund values such
foreign securities. These valuation factors are based on inputs such as depositary receipts, indices, futures, sector indices/exchange-traded funds ("ETFs"), exchange rates, and local exchange opening and closing
prices of each security. When prices with the application of valuation factors are utilized, the value assigned to the foreign securities may not be the same as quoted or published prices of the securities on their
primary markets. A security that applies a valuation factor is generally determined to be a Level 2 investment because the exchange-traded price has been adjusted. Valuation factors are not utilized if the independent
pricing service provider is unable to provide a valuation factor or if the valuation factor falls below a predetermined threshold; in such case, the security is determined to be a Level 1 investment.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Short-term investments are
comprised of cash and cash equivalents invested in short-term investment funds which are redeemable daily. The Fund sweeps available cash into the State Street Institutional&#xa0;U.S. Government Money Market Fund,
which has elected to qualify as a &#x201c;government money market fund&#x201d; pursuant to</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Rule 2a-7 under the 1940 Act, and has an
objective, which is not guaranteed, to maintain a&#xa0;$1.00 per share NAV. Generally, these investment types are&#xa0;categorized as Level 1 investments.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In the event that a
security&#x2019;s, other than a Venture Capital Security, market quotations are not readily available or are deemed unreliable (for reasons other than because the foreign exchange on which it trades closes before the
Valuation Time), the security is valued at fair value as determined by the Valuation Designee, taking into account the relevant factors and surrounding circumstances using valuation policies and procedures approved by
the Board. A security that has been fair valued by the Adviser may be classified as Level 2 or Level 3 depending on the nature of the inputs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Venture Capital Securities
are valued based on a consideration of relevant factors, including both observable and&#xa0;unobservable inputs. Observable and unobservable inputs considered may include (i) the existence of any contractual
restrictions on the disposition of securities; (ii) information obtained from the company, which may include an analysis of the company's financial statements, products, intended markets or technologies; (iii) the
price of the same or similar security negotiated at arm's length in an issuer's completed subsequent round of financing; (iv) the price and extent of public trading in similar securities of the issuer or of comparable
companies; or (v) a probability and time value adjusted analysis of contractual terms. Where available and appropriate, multiple valuation methodologies are applied to confirm fair value.&#xa0;Significant unobservable
inputs are often used in the fair value determination. A significant change in any of these inputs may result in a significant change in the fair value measurement. Additionally, changes in the market environment and
other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different from the valuations used at the date of these
financial&#xa0;statements.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The three-level hierarchy of
inputs is summarized below:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Level 1 - quoted prices
(unadjusted) in active markets for identical investments;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Level 2 - other significant observable
inputs (including valuation factors, quoted prices for similar securities, interest rates, prepayment speeds, and credit risk, etc.); or</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Level 3 - significant unobservable inputs
(including the Fund&#x2019;s own assumptions in determining the fair value of investments).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Level 3 investments are
valued using significant unobservable inputs. The Fund may also use a discounted cash flow based valuation approach in which the anticipated future cash flows of the investment are used to estimate the current fair
value. The derived value of a Level 3 investment may not represent the value which is received upon disposition and this could impact the results of&#xa0;operations.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:21.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">16
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">A summary of standard inputs is
listed below:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:4.5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.05%">Security Type
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3.5pt; padding-left:4.5pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:66.11%">Standard Inputs
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:4.5pt; padding-top:2.88pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:33.05%; background-color: #F0F0F0;">Foreign equities utilizing a fair value factor
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.5pt; padding-right:6pt; padding-top:2.88pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:66.11%; background-color: #F0F0F0;">Depositary receipts, indices, futures, sector indices/ETFs, exchange rates, and local
exchange opening and closing prices of each security.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The following is a summary of
the inputs used as of March 31, 2025 in valuing the Fund's investments and other financial instruments at fair value. The inputs or methodology used for valuing securities are not necessarily an indication of the risk
associated with investing in those securities. Please refer to the Portfolio of Investments for a detailed breakout of the security types:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.90%">Investments, at Value
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%">Level 1 &#x2013; Quoted<br>
Prices
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%">Level 2 &#x2013; Other Significant<br>
Observable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%">Level 3 &#x2013; Significant<br>
Unobservable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.19%">Total
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:69.78%; background-color: #F0F0F0;" colspan="3">Assets
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:13.19%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:48.91%; background-color: #F0F0F0;" colspan="2">Investments in Securities
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:13.19%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.90%; background-color: #F0F0F0;">Common Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:1.57pt"></font>345,932,958
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:17.04pt"></font>138,272
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.19%; background-color: #F0F0F0;">$<font style="padding-left:5.51pt"></font>346,071,230
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.90%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:56.99pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.18pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:18.03pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">31,357,976
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:24.42pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.19%; background-color: #F0F0F0;">31,357,976
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.90%; background-color: #F0F0F0;">Milestone Interests
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:56.99pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.18pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.99pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">14,060,906
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:20.38pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.19%; background-color: #F0F0F0;">14,060,906
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.90%; background-color: #F0F0F0;">Convertible Notes
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:56.99pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.18pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:21.08pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">1,268,919
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:27.47pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.19%; background-color: #F0F0F0;">1,268,919
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:34.90%; background-color: #F0F0F0;">Warrants
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:56.99pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:11.18pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:53.06pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">3
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:59.45pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.19%; background-color: #F0F0F0;">3
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.90%; background-color: #F0F0F0;">Short-Term Investment
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:23.16pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">12,161,215
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:11.18pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:53.78pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:26.35pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.19%; background-color: #F0F0F0;">12,161,215
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.90%; background-color: #F0F0F0;">Total Investments
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">$358,094,173
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:0.24pt"></font>46,826,076
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.19%; background-color: #F0F0F0;">$<font style="padding-left:0.55pt"></font>404,920,249
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.90%; background-color: #F0F0F0;">Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:46.02pt"></font><font style="font-weight:bold">&#x2013;</font>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font><font style="font-weight:bold">&#x2013;</font>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:32.10pt"></font><font style="font-weight:bold">189</font>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.19%; background-color: #F0F0F0;">$<font style="padding-left:38.49pt"></font><font style="font-weight:bold">189</font>
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.90%; background-color: #F0F0F0;">Total Investment Assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">$358,094,173
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">$46,826,265
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.19%; background-color: #F0F0F0;">$404,920,438
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:69.78%; background-color: #F0F0F0;" colspan="3">Liabilities
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:13.19%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:48.91%; background-color: #F0F0F0;" colspan="2">Other Financial Instruments
</td><td style="line-height:9.5pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:13.19%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.90%; background-color: #F0F0F0;">Written Options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:22.87pt"></font>(58,175)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:42.82pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.19%; background-color: #F0F0F0;">$<font style="padding-left:26.06pt"></font>(58,175)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.90%; background-color: #F0F0F0;">Total Investment Liabilities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:20.81pt"></font>(58,175)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:42.61pt"></font>&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.19%; background-color: #F0F0F0;">$<font style="padding-left:24.00pt"></font>(58,175)
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
</div>
<div style="margin-top:321pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">17
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:10.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.26%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:100.00%" colspan="7">Rollforward of Level 3 Fair Value Measurements<br>
For the Six Months Ended March 31, 2025
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%">Investments<br>
in Securities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Balance<br>
as of<br>
September 30,<br>
2024
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.23%">Net Realized<br>
Gain (Loss)<br>
and Change<br>
in Unrealized<br>
Appreciation/<br>
Depreciation
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.91%">Net<br>
Purchases<br>
and<br>
conversions
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.91%">Net<br>
Sales<br>
and<br>
conversions
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.21%">Balance<br>
as of<br>
March 31,<br>
2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.58%">Net Change in<br>
Unrealized<br>
Appreciation/<br>
Depreciation<br>
from<br>
Investments<br>
Held at<br>
March 31,<br>
2025
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #F0F0F0;">Common Stocks
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.21%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:34.20%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:19.39pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$133,482
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:33.34pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">$0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:38.28pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">$0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:35.76pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">$0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:19.97pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.21%; background-color: #F0F0F0;">$133,482
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:33.34pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">$0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #F0F0F0;">Health Care Equipment &amp; Supplies
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:46.59pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">13
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:38.31pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.25pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:40.72pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:47.17pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.21%; background-color: #F0F0F0;">13
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:38.31pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:34.20%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:33.35pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">5,346
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:25.70pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">(269)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.25pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:40.72pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:35.47pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.21%; background-color: #F0F0F0;">4,777
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:25.70pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">(269)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #F0F0F0;">Convertible Notes
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.21%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:34.20%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:17.15pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">1,062,330
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:38.31pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.25pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:40.72pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:17.73pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.21%; background-color: #F0F0F0;">1,062,330
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:38.31pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:34.20%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:23.30pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">206,589
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:38.31pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.25pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:40.72pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:23.88pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.21%; background-color: #F0F0F0;">206,589
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:38.31pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.21%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:34.20%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.46pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">15,621,446
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:10.92pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">396,900
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:8.82pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">3,080,407
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.92pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">(778,696)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.54pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.21%; background-color: #F0F0F0;">18,320,057
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:10.92pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">396,900
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #F0F0F0;">Health Care Equipment &amp; Supplies
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.49pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">42
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:38.31pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.25pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:40.72pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:46.07pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.21%; background-color: #F0F0F0;">42
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:38.31pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:34.20%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.66pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">12,030,060
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:14.59pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">(97,008)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:12.12pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">1,104,825
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:40.72pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:15.47pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.21%; background-color: #F0F0F0;">13,037,877
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:14.59pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">(97,008)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #F0F0F0;">Milestone Interests
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.21%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:34.20%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:17.18pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">1,399,863
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">82,583
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.25pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:15.80pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">(94,662)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:19.56pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.21%; background-color: #F0F0F0;">1,387,824
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">82,583
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:34.20%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:12.20pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">12,362,480
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:12.51pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">310,602
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.25pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:40.72pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.21%; background-color: #F0F0F0;">12,673,082
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:12.51pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">310,602
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:34.20%; background-color: #F0F0F0;">Warrants
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.21%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:34.20%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:50.48pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">3
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:38.31pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:43.25pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:40.72pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:51.06pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.21%; background-color: #F0F0F0;">3
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:38.31pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.20%; background-color: #F0F0F0;">Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:41.36pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">189
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:38.31pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">0
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:43.25pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:40.72pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">0
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:41.95pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.21%; background-color: #F0F0F0;">189
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:38.31pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:34.20%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$42,821,843
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">$692,808
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">$4,185,232
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">$(873,358)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.21%; background-color: #F0F0F0;">$46,826,265
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">$692,808
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.63%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.65%">Description
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.54%">Fair Value at<br>
03/31/25
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.44%">Valuation Technique (s)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.05%">Unobservable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.09%">Range
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.09%">Weighted<br>
Average
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:4pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Relationship<br>
Between<br>
Fair Value<br>
and Input;<br>
if input value<br>
increases then<br>
Fair Value:
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:14.65%; background-color: #F0F0F0;">Common Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.54%; background-color: #F0F0F0;">$13
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:15.09%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.09%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">Increase
</td></tr>
<tr style="page-break-inside:avoid"><td style="line-height:0pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:14.65%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.54%; background-color: #F0F0F0;">$138,259
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Probability of events<br>
Timing of events
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:15.09%; background-color: #F0F0F0;">0.00% - 90.00%<br>
0.00 - 4.75 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.09%; background-color: #F0F0F0;">75.00%<br>
1.65 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Increase<br>
Decrease
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:14.65%; background-color: #F0F0F0;">Convertible Notes
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.54%; background-color: #F0F0F0;">$1,268,919
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:15.09%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.09%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">Increase
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:14pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:14.65%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.54%; background-color: #F0F0F0;">$26,335,667
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:15.09%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.09%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">Increase
</td></tr>
<tr style="page-break-inside:avoid"><td style="line-height:0pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:14.65%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.54%; background-color: #F0F0F0;">$4,372,501
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Timing of events<br>
Implied market volatility<br>
Risk free rate<br>
Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:15.09%; background-color: #F0F0F0;">3 years<br>
113.26% - 137.91%<br>
3.48% - 4.31%<br>
N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.09%; background-color: #F0F0F0;">3 years<br>
118.00%<br>
3.65%<br>
N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Decrease<br>
Decrease<br>
Decrease<br>
Increase
</td></tr>
<tr style="page-break-inside:avoid"><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:14.65%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.54%; background-color: #F0F0F0;">$649,808
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Discount rate<br>
Probability of events<br>
Timing of events
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:15.09%; background-color: #F0F0F0;">4.23% - 4.47%<br>
1.00% - 90.00%<br>
1.50 - 12.00 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.09%; background-color: #F0F0F0;">4.35%<br>
27.16%<br>
5.59 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Decrease<br>
Increase<br>
Decrease
</td></tr></table>
</div>
</div>
<div style="margin-top:40.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">18
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:85.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.63%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.65%">Description
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.54%">Fair Value at<br>
03/31/25
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.44%">Valuation Technique (s)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.05%">Unobservable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.09%">Range
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.09%">Weighted<br>
Average
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:4pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Relationship<br>
Between<br>
Fair Value<br>
and Input;<br>
if input value<br>
increases then<br>
Fair Value:
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:14.65%; background-color: #F0F0F0;">Milestone Interests
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.54%; background-color: #F0F0F0;">$14,060,906
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Discount rate<br>
Probability of events<br>
Timing of events
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:15.09%; background-color: #F0F0F0;">4.23% - 10.00%<br>
0.00% - 90.00%<br>
0.00 - 9.25 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.09%; background-color: #F0F0F0;">4.86%<br>
50.66%<br>
3.66 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Decrease<br>
Increase<br>
Decrease
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:14.65%; background-color: #F0F0F0;">Warrants
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.54%; background-color: #F0F0F0;">$3
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:15.09%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.09%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">Increase
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:14.65%; background-color: #F0F0F0;">Other Assets
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.54%; background-color: #F0F0F0;">$189
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Discount rate<br>
Probability of events<br>
Timing of events
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.09%; background-color: #F0F0F0;">4.41%<br>
5.00%<br>
6.75 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.09%; background-color: #F0F0F0;">4.41%<br>
5.00%<br>
6.75 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">Decrease<br>
Increase<br>
Decrease
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:14.65%; background-color: #F0F0F0;">Total
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.54%; background-color: #F0F0F0;">$46,826,265
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:18.44%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:19.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:15.09%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.09%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.47%">(a)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.09%">The valuation technique used as a basis to approximate fair value of these investments is based on a transaction price or&#xa0;subsequent financing rounds.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">b.&#xa0;&#xa0;Restricted
Securities:</div>
</div>
<div style="margin-top:8.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Restricted securities are privately-placed
securities whose resale is restricted under U.S. securities laws. The Fund may invest in restricted securities, including unregistered securities eligible for resale without registration pursuant to Rule 144A and
privately-placed securities of U.S. and non-U.S. issuers offered outside the U.S. without registration pursuant to Regulation S under the Securities Act of 1933, as amended (the "1933 Act"). Rule 144A securities may
be freely traded among certain qualified institutional investors, such as the Fund, but resale of such securities in the U.S. is permitted only in limited circumstances.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">c.&#xa0;&#xa0;Foreign Currency
Translation:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Foreign securities,
currencies, and other assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate of said currencies against the U.S. Dollar, as of the Valuation Time, as provided by
an independent pricing service approved by the Board.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Foreign currency amounts are
translated into U.S. Dollars on the following basis:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">(i) fair value of investment
securities, other assets and liabilities &#x2013; at the current daily rates of exchange at the Valuation Time; and</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">(ii) purchases and sales of
investment securities, income and expenses &#x2013; at the relevant rates of exchange prevailing on the respective dates of such transactions.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund does not isolate
that portion of gains and losses on investments in equity securities due to changes in the foreign exchange rates from the portion due to changes in market prices of</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">equity securities. Accordingly, realized and
unrealized foreign currency gains and losses with respect to such securities are included in the reported net realized and unrealized gains and losses on investment transactions balances.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Net unrealized currency gains
or losses from valuing foreign currency denominated assets and liabilities at period end exchange rates are reflected as a component of net unrealized appreciation/depreciation in value of investments, and translation
of other assets and liabilities denominated in foreign currencies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Net realized foreign exchange
gains or losses represent foreign exchange gains and losses from transactions in foreign currencies and forward foreign currency contracts, exchange gains or losses realized between the trade date and settlement date
on security transactions, and the difference between the amounts of interest and dividends recorded on the Fund&#x2019;s books and the U.S. Dollar equivalent of the amounts actually received.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Foreign security and currency
transactions may involve certain considerations and risks not typically associated with those of domestic origin, including unanticipated movements in the value of the foreign currency relative to the U.S. Dollar.
Generally, when the U.S. Dollar rises in value against foreign currency, the Fund's investments denominated in that foreign currency will lose value because the foreign currency is worth fewer U.S. Dollars; the
opposite effect occurs if the U.S. Dollar falls in relative value.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:24.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">19
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">d.&#xa0;&#xa0;Rights Issues and Warrants:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Rights issues give the
right, normally to existing shareholders, to buy a proportional number of additional securities at a given price (generally at a discount) within a fixed period (generally a short-term period) and are offered at the
company&#x2019;s discretion. Warrants are securities that give the holder the right to buy common stock at a specified price for a specified period of time. Rights issues and warrants are speculative and have no value
if they are not exercised before the expiration date. Rights issues and warrants are valued at the last sale price on the exchange on which they are traded.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">e.&#xa0;&#xa0;Options:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">An option contract is a
contract in which the writer (seller) of the option grants the buyer of the option, upon payment of a premium, the right to purchase from (call option) or sell to (put option) the writer a designated instrument at a
specified price within a specified period of time. Certain options, including options on indices, will require cash settlement by the Fund if the option is exercised.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s obligation
under an exchange traded written option or investment in an exchange traded purchased option is valued at the last sale price, or in the absence of a sale, the mean between the closing bid and asked prices. Gain or
loss is recognized when the option contract expires, is exercised or is closed.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">If the Fund writes a covered
call option, the Fund foregoes, in exchange for the premium, the opportunity to profit during the option period</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">from an increase in the market value of the
underlying security above the exercise price. If the Fund writes a put option it accepts the risk of a decline in the market value of the underlying security below the exercise price. Over-the-counter options have the
risk of the potential inability of counterparties to meet the terms of their contracts. The Fund&#x2019;s maximum exposure to purchased options is limited to the premium initially paid. In addition, certain risks may
arise upon entering into option contracts including the risk that an illiquid secondary market will limit the Fund&#x2019;s ability to close out an option contract prior to the expiration date and that a change in the
value of the option contract may not correlate exactly with changes in the value of the securities or currencies hedged.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">All options on securities and
securities indices written by the Fund are required to be covered. When the Fund writes a call option, this means that during the life of the option the Fund may own or have the contractual right to acquire the
securities subject to the option or may maintain with the Fund&#x2019;s custodian in a segregated account appropriate liquid securities in an amount at least equal to the market value of the securities underlying the
option. When the Fund writes a put option, this means that the Fund will maintain with the Fund&#x2019;s custodian in a segregated account appropriate liquid securities in an amount at least equal to the exercise price
of the option.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:8.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Summary of Derivative
Instruments:</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The&#xa0;Fund may
use derivatives for various purposes as noted above. The following is a summary of the fair value of derivative instruments, not accounted for as hedging instruments, as of March 31, 2025:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:9pt; padding-bottom:3pt; padding-right:6pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:37.50%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:62.51%" colspan="7">Risk Exposure Category
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:6pt; padding-top:2.62pt; text-align:left; vertical-align:bottom; width:37.50%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Interest<br>
Rate<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Foreign<br>
Currency<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Credit<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Equity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%">Commodity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.55%">Other
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:8.08%">Total
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:6pt; padding-top:2.75pt; text-align:left; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="8">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:100.00%; background-color: #F0F0F0;" colspan="8">Liabilities:
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="8">Unrealized depreciation on:
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:37.50%; background-color: #F0F0F0;">Written Options, market value
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:1.73pt"></font>58,175
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:6.55%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:8.08%; background-color: #F0F0F0;">$<font style="padding-left:1.73pt"></font>58,175
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:37.50%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$58,175
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.55%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:8.08%; background-color: #F0F0F0;">$58,175
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
</div>
</div>
<div style="padding-top:128.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">20
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The effect of derivative
instruments on the Statement of Operations for the six-month period ended March 31, 2025:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:9pt; padding-bottom:3pt; padding-right:6pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:42.66%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:57.35%" colspan="6">Risk Exposure Category
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:6pt; padding-top:2.62pt; text-align:left; vertical-align:bottom; width:42.66%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Interest<br>
Rate<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Foreign<br>
Currency<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Credit<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.38%">Equity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%">Commodity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.38%">Total
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:6pt; padding-top:2.75pt; text-align:left; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="7">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:16pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="7">Realized Gain/(Loss) on Derivatives Recognized<br>
as a Result of Operations:
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:42.66%; background-color: #F0F0F0;">Written Options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.38%; background-color: #F0F0F0;">$<font style="padding-left:2.07pt"></font>280,518
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.38%; background-color: #F0F0F0;">$<font style="padding-left:2.07pt"></font>280,518
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:42.66%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.38%; background-color: #F0F0F0;">$280,518
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.38%; background-color: #F0F0F0;">$280,518
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:16pt; padding-right:6pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="7">Net Change in Unrealized Appreciation/Depreciation on<br>
Derivatives Recognized as a Result of Operations:
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:42.66%; background-color: #F0F0F0;">Written Options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.38%; background-color: #F0F0F0;">$<font style="padding-left:3.10pt"></font>116,260
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.38%; background-color: #F0F0F0;">$<font style="padding-left:3.10pt"></font>116,260
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:42.66%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.38%; background-color: #F0F0F0;">$<font style="padding-left:0.91pt"></font>116,260
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.38%; background-color: #F0F0F0;">$<font style="padding-left:0.91pt"></font>116,260
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
</div>
<div style="margin-top:8.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Information about derivatives reflected as
of the date of this report is generally indicative of the type of activity for the six-month period ended March 31, 2025. The table below summarizes the weighted average values of derivatives holdings for the Fund
during the six-month period ended March 31, 2025.</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100.00%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:71.24%">Derivative
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:26.46%">Average<br>
Notional Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:71.24%; background-color: #F0F0F0;">Written Options Contracts
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.46%; background-color: #F0F0F0;">$84,441
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">f.&#xa0;&#xa0;Security Transactions,
Investment Income and Expenses:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Security transactions are
recorded on the trade date. Realized and unrealized gains/(losses) from security and currency transactions are calculated on the identified cost basis. Dividend income and corporate actions are recorded generally on
the ex-date, except for certain dividends and corporate actions which may be recorded after the ex-date, as soon as the Fund acquires information regarding such dividends or corporate actions. Interest income and
expenses are recorded on an accrual basis.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">g.&#xa0;&#xa0;Distributions:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund has a managed
distribution policy to pay distributions from net investment income supplemented by net realized capital gains and return of capital distributions, if necessary, on a quarterly basis. The managed distribution policy
is subject to regular review by the Board. The Fund will also declare and pay distributions at least annually from net realized gains on investment transactions and net realized foreign exchange gains, if any.
Dividends and distributions to shareholders are recorded on the ex-dividend date. Dividends and distributions to shareholders are determined in accordance with federal income tax regulations, which may differ from
U.S.&#xa0;GAAP.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">h.&#xa0;&#xa0;Federal Income Taxes:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund intends to
continue to qualify as a &#x201c;regulated investment company&#x201d; ("RIC") by complying with the provisions available to certain investment companies, as defined in Subchapter M of the Internal Revenue Code of 1986,
as amended (the "Code"), and to make distributions of net investment income and net realized capital gains sufficient to relieve the Fund from all federal income taxes. Therefore, no federal income tax provision is
required.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund recognizes the tax
benefits of uncertain tax positions only where the position is &#x201c;more likely than not&#x201d; to be sustained assuming examination by tax authorities. Management of the Fund has concluded that there are no
significant uncertain tax positions that would require recognition in the financial statements. Since tax authorities can examine previously filed tax returns, the Fund's U.S. federal and state tax returns for each of
the most recent four fiscal years up to the most recent fiscal year ended September 30, 2024 are subject to such review.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">i.&#xa0;&#xa0;Milestone Interests</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund holds financial
instruments which reflect the current value of future milestone payments the Fund may receive as a result of contractual obligations from other parties. The value of such payments are adjusted to reflect the estimated
risk based on the relative uncertainty of both the timing and the achievement of individual milestones. A risk to the Fund is that the milestones will not be achieved and no payment will be received by the Fund. The
milestone interests were received as part of the proceeds from the sale of six private companies. Any payments&#xa0;received are treated as a reduction of the cost basis of the milestone interests with payments
received in excess of the cost basis treated as a realized gain. The contractual obligations with respect to the milestone interests provide for</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:28.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">21
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">payments at various stages of the
development of Afferent, Amolyt, Amphivena, Ethismos Research, Invetx and Neurovance principal product candidate as of the date of the sale.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The following is a summary of
the impact of the milestone interests on the financial statements as of and for the six-month period ended March 31, 2025:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100.00%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:74.31%; background-color: #F0F0F0;">Statement of Assets and Liabilities, Milestone interests, at value
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:23.39%; background-color: #F0F0F0;">$14,060,906
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:74.31%; background-color: #F0F0F0;">Statement of Assets and Liabilities, Total distributable earnings
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:23.39%; background-color: #F0F0F0;">$<font style="padding-left:0.93pt"></font>10,540,479
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:16pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:74.31%; background-color: #F0F0F0;">Statement of Operations, Change in unrealized appreciation/depreciation
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:23.39%; background-color: #F0F0F0;">$<font style="padding-left:13.87pt"></font>393,185
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">j.&#xa0;&#xa0;Other Assets</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Other assets in the
Statement of Assets and Liabilities consists of amounts due to the Fund at various times in the future in connection with the sale of investments in one private company.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">3.&#xa0;&#xa0;Agreements and Transactions
with Affiliates</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">a.&#xa0;&#xa0;Investment Advisory and
Other Affiliated Fees</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Effective as of the close
of business October 27, 2023, abrdn Inc. serves as the Fund&#x2019;s Investment Adviser pursuant to an investment advisory agreement (the &#x201c;Advisory Agreement&#x201d;) with the Fund. The Adviser is a wholly-owned
indirect subsidiary of Aberdeen Group plc. In rendering management services, the Adviser may use the resources of investment advisor subsidiaries of Aberdeen Group plc. These affiliates have entered into procedures
pursuant to which investment professionals from affiliates may render portfolio management and research services as associated persons of the Adviser. As compensation for its services to the Fund, the Adviser receives
an annual investment advisory fee at an annual rate of (i) 2.50% of the average net assets for the month of its venture capital and other restricted securities up to 25% of net assets and (ii) for all other net
assets, 0.98% of the average net assets up to $250 million, 0.88% of the average net assets for the next $250 million, 0.80% of the average net assets for the next $500 million and 0.70% of the average net assets
thereafter. The aggregate fee would not exceed a rate when annualized of 1.36%. For the six-month period ended March 31, 2025, the Fund paid the Adviser $2,305,899.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund entered into a
Services Agreement (the "Agreement") with the prior adviser to the Fund (the "Prior Adviser"). Pursuant to the terms of the Agreement, the Fund reimbursed the Prior Adviser for certain services related to a portion of
the payment of salary and provision of benefits to the Fund&#x2019;s Chief Compliance&#xa0;Officer. Expenses incurred pursuant to the Agreement as well as certain expenses paid for by the Prior Adviser are allocated to
the Fund in an equitable fashion as approved by the Trustees or officers of the Fund who were</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">also officers of the Prior Adviser. The
Agreement terminated on October 27, 2023.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Effective upon the close of
business on October 27, 2023, the Adviser as Adviser of the Fund, entered into a written contract with the Fund to limit the total ordinary operating expenses of the Fund (excluding leverage costs, interest, taxes,
brokerage commissions, acquired fund fees and expenses and any non-routine expenses) from exceeding 1.36% of the average daily net assets of the Fund on an annualized basis for twelve months (the &#x201c;Expense
Limitation Agreement&#x201d;). The Expense Limitation Agreement may not be terminated before October 27, 2025, without the approval of the Fund&#x2019;s trustees who are not &#x201c;interested persons&#x201d; of the Fund
(as defined in the 1940 Act). For the fiscal year ended September 30, 2024 the Adviser did not waive any Fund's expenses pursuant to the Expense Limitation Agreement.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">b.&#xa0;&#xa0;Investor Relations:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Effective March 1, 2024,
under the terms of the Investor Relations Services Agreement, abrdn Inc. is compensated to provide and may pay third parties to provide investor relations services to the Fund and certain other funds advised by
Aberdeen or its affiliates as part of an Investor Relations Program. Under the Investor Relations Services Agreement, the Fund owes a portion of the fees related to the Investor Relations Program (the "Fund's
Portion"). However, investor relations services fees are limited by Aberdeen so that the Fund will only pay up to an annual rate of 0.05% of the Fund's average weekly net assets. Any difference between the capped rate
of 0.05% of the Fund's average weekly net assets and the Fund's Portion is paid for by Aberdeen.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Pursuant to the terms of the
Investor Relations Services Agreement, abrdn Inc. (or third parties engaged by Aberdeen), among other things, provides objective and timely information to shareholders based on publicly-available information; provides
information efficiently through the use of technology while offering shareholders immediate access to knowledgeable investor relations representatives; develops and maintains effective communications with investment
professionals from a wide variety of firms; creates and maintains investor relations communication materials such as fund manager interviews, films and webcasts, publishes white papers, magazine articles and other
relevant materials discussing the Fund's investment results, portfolio positioning and outlook; develops and maintains effective communications with large institutional shareholders; responds to specific shareholder
questions; and reports activities and results to the Board and management detailing insight into general shareholder sentiment.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">During the six-month period
ended March 31, 2025, the Fund incurred investor relations fees of approximately $28,263. For the six-month period ended March 31, 2025, Aberdeen did not contribute to the</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:32.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">22
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">investor relations fees for the Fund because
the Fund&#x2019;s contribution was below 0.05% of the Fund&#x2019;s average weekly net assets on an annual basis.</div>
</div>
<div style="margin-top:9.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">4.&#xa0;&#xa0;Investment Transactions</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">Purchases and sales of
investment securities (excluding short-term securities) for the six-month period ended March 31, 2025, were $163,994,164 and $167,200,605, respectively.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">5.&#xa0;&#xa0;Capital</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The Fund is authorized to
issue an unlimited number of common shares of beneficial interest at par value $0.01 per common share. As of March 31, 2025, there were 28,872,416 shares of common stock issued and outstanding.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The following table shows the
shares issued by the Fund as a part of a quarterly distribution to shareholders during the fiscal year ended March 31, 2025.</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:88.10%">Payment Date
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.90%">Shares Issued
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:88.10%; background-color: #F0F0F0;">January 10, 2025
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.90%; background-color: #F0F0F0;">404,917
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:88.10%; background-color: #F0F0F0;">March 31, 2025
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.90%; background-color: #F0F0F0;">406,100
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">6.&#xa0;&#xa0;Open Market Repurchase
Program</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">In March 2024, the Board
approved the renewal of the repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares in the open market for a one-year period ending July 14, 2025.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">For the six-month period ended
March 31, 2025, the Fund did not repurchase any shares through this program.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">7.&#xa0;&#xa0;Private Companies and Other
Restricted Securities</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The Fund may invest in private
companies and other restricted securities if these securities currently comprise 40% or less of net assets. The value of these securities represented 11.83% of the Fund&#x2019;s net assets at March 31, 2025.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">At March 31, 2025, the Fund had
a commitment of $2,979,043 relating to additional investments in three private companies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The following table details the
acquisition date, cost, carrying value per unit, and value of the Fund&#x2019;s private companies and other restricted securities at March 31, 2025. The Fund on its own does not have the right to demand that such
securities be registered.</div>
</div>
<div style="margin-top:280pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">23
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:10.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:4.5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:49.49%">Security
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%">Acquisition<br>
Date
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%">Cost
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.08%">Carrying Value<br>
per Unit
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Abcuro, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">12/19/23, 8/10/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.97pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.03%; background-color: #F0F0F0;">$1,276,911
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:9.38pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.08%; background-color: #F0F0F0;">$5.49
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.08pt; padding-right:6pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.26%; background-color: #F0F0F0;">$1,274,994
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Abcuro, Inc., Series C1 &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">2/7/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.93pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">310,407
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.85pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">6.04
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.15pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">310,407
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Afferent Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">7/27/16
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:28.33pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">24,556
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.73pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Amolyt Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">7/12/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:21.94pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">684,946
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:5.82pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">102.55
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.60pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">702,412
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Amphivena Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/18/22
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:49.51pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.73pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Arbor Biotechnologies, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/29/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.42pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">643,721
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:11.14pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">16.57
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:22.69pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">640,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Arbor Biotechnologies, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/27/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.41pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,604,052
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.36pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">4.11
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.91pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">1,599,998
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Arkuda Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">1/24/22, 1/23/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:22.80pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">599,336
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.13pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.42
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.86pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">188,067
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Arkuda Therapeutics, Inc., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">05/16/19, 4/2/20,<br>
7/15/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.72pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,819,240
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.85pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.46
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:27.21pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">461,741
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Atalanta Therapeutics, Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/11/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.74pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,400,664
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.02pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.80
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.57pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">1,400,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Aviceda Therapeutics, Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">12/17/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.96pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">229,091
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.32pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">5.76
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.31pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">224,091
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Biotheryx, Inc., Series E &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">5/19/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.50pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">3,206,642
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.72pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.48
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:26.60pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">295,132
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Chinook Therapeutics, Inc. CVR &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">8/14/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:27.87pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">23,035
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.71pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">2.26
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.85pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">133,482
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Curasen Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">8/20/24, 1/7/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:22.76pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">662,358
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.72pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.48
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.40pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">661,624
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Curasen Therapeutics, Inc., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">8/20/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.88pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">4,357,668
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.72pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.48
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.23pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">4,339,083
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">1/21/22
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.30pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,402,998
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.49pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">6.53
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.38pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">1,936,860
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">4/19/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.81pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">357,879
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.49pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">6.53
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.36pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">357,646
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Engrail Therapeutics, Inc., Series B
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">3/14/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.57pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">2,250,758
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.15pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.06
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.52pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">2,250,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Ethismos Research Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/31/17
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:49.51pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.73pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Flamingo Therapeutics, Inc., Series A3 &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">4/21/20, 10/28/20
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.39pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">2,469,343
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.25pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.89
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.09pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">202,724
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Fusion Pharmaceuticals, Inc. CVR &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">7/10/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:35.45pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,791
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.27pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.38
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:33.52pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">4,493
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Glycomine, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">7/22/24, 3/26/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.25pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,593,655
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.80pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.60
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.86pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">1,593,063
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">HiberCell, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/15/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:22.09pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">334,898
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.85pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.46
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.22pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">333,631
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">HiberCell, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">5/5/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.82pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,607,454
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.03pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.41
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.87pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">538,902
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">HiberCell, Inc. &#x2014; Warrant
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/15/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:33.81pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,294
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:52.08pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">1
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">HiberCell, Inc. &#x2014; Convertible Note
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/13/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:22.57pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">206,589
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">100.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.80pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">206,589
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">HiberCell, Inc. &#x2014; Warrant
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/13/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:49.51pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.98pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">3
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">11/15/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.65pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">923,279
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">2.91
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.09pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">827,894
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">4/22/20, 6/17/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:19.67pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">3,111,268
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.88pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">2.07
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.73pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">2,672,074
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc. &#x2014; Convertible Note
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">4/12/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.26pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">323,870
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">100.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.48pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">323,870
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Incendia Therapeutics, Inc., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">8/12/21, 5/24/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.86pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,606,097
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.92
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.31pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">1,599,995
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Incendia Therapeutics, Inc. &#x2014; Convertible Note
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">4/18/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:22.54pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">738,460
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">100.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.77pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">738,460
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Invetx, Inc. Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/4/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.14pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,305,241
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:11.23pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">99.14
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:19.47pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">1,387,824
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">IO Light Holdinigs, Inc., Series A2 &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">4/30/20, 5/17/21,<br>
9/15/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.09pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,395,847
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:45.99pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">42
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Neurovance Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">3/20/17
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.43pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,505,684
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:7.27pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">351.51
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.87pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">11,970,670
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Nuvig Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/18/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:26.48pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">777,913
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.42pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.05
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.50pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">775,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Priothera Co. Ltd., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">10/07/20, 10/19/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.84pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,782,961
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:47.01pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">16
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Qlaris Bio, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">4/11/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:19.39pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,551,724
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.79
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.40pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">1,550,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Quell Therapeutics Ltd., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">11/29/21, 3/23/22,<br>
2/18/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.99pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,609,803
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.12pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">2.08
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.78pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">1,760,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Recode Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">1/26/24, 10/21/21,<br>
2/16/22, 9/15/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.18pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,446,891
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.56pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">9.23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.97pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">1,440,001
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Seismic Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">8/30/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:20.73pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">1,277,774
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.57pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">4.52
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:20.35pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">1,274,991
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Spectrum Pharmaceuticals, Inc. CVR &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">8/2/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:33.21pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">2,790
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.73pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Tetraphase Pharmaceuticals, Inc. CVR &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">6/8/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:32.31pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">2,844
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.09pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.02
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:40.78pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">284
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Third Arc Bio, Inc., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">7/15/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.22pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">853,027
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.42pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">2.10
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:22.94pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">850,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.49%; background-color: #F0F0F0;">Willow Laboratories, Inc. &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">3/31/98
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:49.51pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:47.09pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">13
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:49.49%; background-color: #F0F0F0;">Total
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.03%; background-color: #F0F0F0;">$47,284,759
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; vertical-align:bottom; width:12.08%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.5pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.26%; background-color: #F0F0F0;">$46,826,077
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:1.39%">*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:99.17%">Carrying value is less than $0.01.
</td></tr></table>
</div>
</div>
<div style="margin-top:12.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">24
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:17.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">8.&#xa0;&#xa0;Portfolio Investment
Risks</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">a.&#xa0;&#xa0;Concentration Risk:</div>
</div>
<div style="margin-top:8.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s portfolio may be more
sensitive to, and possibly more adversely affected by, regulatory, economic or political factors or trends relating to the healthcare industries than a portfolio of companies representing a larger number of
industries. This risk is in addition to the risks normally associated with any strategy seeking capital appreciation by investing in a portfolio of equity securities. As a result of its concentration policy, the
Fund&#x2019;s investments may be subject to greater risk than a fund that has securities representing a broader range of investments and may cause the value of the Fund&#x2019;s shares to fluctuate significantly over
relatively short periods of time.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">b.&#xa0;&#xa0;Derivatives Risk
(including Options):</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Derivatives are speculative
and may hurt the Fund&#x2019;s performance. The potential benefits to be derived from the Fund&#x2019;s options strategy are dependent upon the portfolio managers&#x2019; ability to discern pricing inefficiencies and
predict trends in these markets, which decisions could prove to be inaccurate.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">c.&#xa0;&#xa0;Equity Securities
Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The stock or other security
of a company may not perform as well as expected, and may decrease in value, because of factors related to the company (such as poorer than expected earnings or certain management decisions), to the industry in which
the company is engaged (such as a reduction in the demand for products or services in a particular industry) or to the market as a whole (such as periods of market volatility or instability, or general and prolonged
periods of economic decline). Holders of common stock generally are subject to more risks than holders of preferred stock or debt securities because the right to repayment of common shareholders' claims is
subordinated to that of preferred stock and debt securities upon the bankruptcy of the issuer.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">d.&#xa0;&#xa0;Key Personnel Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">There may be only a limited
number of securities professionals who have comparable experience to that of the Fund&#x2019;s existing portfolio management team in the area of healthcare companies. If one or more of the team members dies, resigns,
retires or is otherwise unable to act on behalf of the Investment Adviser, there can be no assurance that a suitable replacement could be found immediately.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">e.&#xa0;&#xa0;Restricted Securities
and Valuation Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Some of the Fund&#x2019;s
investments are subject to restrictions on resale and generally have no established trading market or are otherwise illiquid with little or no trading activity. The valuation process requires an analysis of various
factors. The Fund&#x2019;s fair value methodology includes the examination of, among other things, (i) the existence of any contractual restrictions on the disposition of the securities; (ii)</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">information obtained from the issuer which
may include an analysis of the company&#x2019;s financial statements, the company&#x2019;s products or intended markets, or the company&#x2019;s technologies; and (iii) the price of a security sold at arm&#x2019;s length
in an issuer&#x2019;s subsequent completed round of financing. As there is typically no readily available market&#xa0;value for some of the Restricted Securities in the Fund&#x2019;s portfolio, such Restricted
Securities in the Fund&#x2019;s portfolio are valued at fair value as determined in good faith by or under the direction of the Board pursuant to the Fund&#x2019;s valuation policy and a consistently applied valuation
process. Because of the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Fund&#x2019;s investments determined in good faith by
the Board may differ significantly from the values that would have been used had a ready market existed for the investments, and the differences could be material.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">f.&#xa0;&#xa0;Risks Associated with
the Fund&#x2019;s Option Strategy:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The ability of the Fund to
achieve its investment objective is partially dependent on the successful implementation of its option strategy. There are several risks associated with transactions in options on securities used in connection with
the Fund's option strategy. For example, there are significant differences between the securities and options markets that could result in an imperfect correlation between these markets, causing a given transaction
not to achieve its objectives. A decision as to whether, when and how to use options involves the exercise of skill and judgment, and even a well-conceived transaction may be unsuccessful to some degree because of
market behavior or unexpected events.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">As the writer of a call
option covered with a security held by the Fund, the Fund forgoes, during the option's life, the opportunities to profit from increases in the market value of the security covering the call option above the sum of the
premium and the strike price of the call but retains the risk of loss should the price of the underlying security decline. As the Fund writes such covered calls over more of its portfolio, its ability to benefit from
capital appreciation becomes more limited. To the extent the Fund writes call options that are not fully covered by securities in its portfolio (such as calls on an index or sector), it will lose money if the portion
of the security or securities underlying the option that is not covered by securities in the Fund's portfolio appreciate in value above the exercise price of the option by an amount that exceeds the premium received
on the option plus the exercise price of the option. The amount of this loss theoretically could be unlimited. The writer of an option has no control over the time when it may be required to fulfill its obligations as
a writer of the option.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:16.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">25
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">When the Fund writes put options, it bears
the risk of loss if the value of the underlying stock declines below the exercise price minus the put premium. If the option is exercised, the Fund could incur a loss if it is required to purchase the stock underlying
the put option at a price greater than the market price of the stock at the time of exercise plus the put premium the Fund received when it wrote the option. While the Fund's potential gain as the writer of a covered
put option is limited to the premium received from the purchaser of the put option, the Fund risks a loss equal to the entire exercise price of the option minus the put premium.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">g.&#xa0;&#xa0;Sector Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">To the extent that the Fund
has a significant portion of its assets invested in securities conducting business in a broadly related group of industries within an economic sector, the Fund may be more vulnerable to unfavorable developments in
that economic sector than funds that invest more broadly.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Pharmaceutical Sector
Risk<font style="font-style:Normal">. The success of companies in the pharmaceutical sector is highly dependent on the development, procurement and marketing of drugs. The values of pharmaceutical companies are also dependent
on the development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability of pharmaceutical companies may be significantly affected by such things as the
expiration of patents or the loss of, or the inability to enforce, intellectual property rights. The research and other costs associated with developing or procuring new drugs and the related intellectual property
rights can be significant, and the results of such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development of a profitable drug.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The pharmaceutical sector is
also subject to rapid and significant technological change and competitive forces that may make drugs obsolete or make it difficult to raise prices and, in fact, may result in price discounting. Companies in the
pharmaceutical sector may also be subject to expenses and losses from extensive litigation based on intellectual property, product liability and similar claims. Companies in the pharmaceutical sector may be adversely
affected by government regulation and changes in reimbursement rates. The ability of many pharmaceutical companies to commercialize and monetize current and any future products depends in part on the extent to which
reimbursement for the cost of such products and related treatments are available from third-party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Biotechnology Industry
Risk.<font style="font-style:Normal"> The success of biotechnology companies is highly dependent on the development, procurement and/or marketing of drugs. The values of biotechnology companies are also dependent on the
development, protection and exploitation of</font></div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">intellectual property rights and other
proprietary information, and the profitability of biotechnology companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability to enforce, intellectual property
rights. The research and other costs associated with developing or procuring new drugs, products or technologies and the related intellectual property rights can be significant, and the results of such research and
expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development of a profitable drug, product or technology.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The biotechnology sector is
also subject to rapid and significant technological change and competitive forces that may make drugs, products or technologies obsolete or make it difficult to raise prices and, in fact, may result in price
discounting. Companies in the biotechnology sector may also be subject to expenses and losses from extensive litigation based on intellectual property, product liability and similar claims. Companies in the
biotechnology sector may be adversely affected by government regulation and changes in reimbursement rates. Healthcare providers, principally hospitals, that transact with companies in the biotechnology industry,
often rely on third party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations to reimburse all or a portion of the cost of healthcare related products or services.
Biotechnology companies will continue to be affected by the efforts of governments and third-party payors to contain or reduce health care costs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Managed Care Sector
Risk.<font style="font-style:Normal"> Companies in the managed care sector often assume the risk of both medical and administrative costs for their customers in return for monthly premiums. The profitability of these products
depends in large part on the ability of such companies to predict, price for, and effectively manage medical costs. Managed care companies base the premiums they charge and their Medicare bids on estimates of future
medical costs over the fixed contract period; however, many factors may cause actual costs to exceed what was estimated and reflected in premiums or bids.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Managed care companies are
regulated at the federal, state, local and international levels. The evolution of the ACA and other regulatory reforms could materially and adversely affect the manner in which U.S. managed care companies conduct
business and their results of operations, financial position and cash flows. New laws or regulations could drive substantial change to the way healthcare products and services are currently delivered and paid for in
the United States. A transformative overhaul of the U.S. healthcare system could impact the financial viability of managed care companies in which the Fund may invest.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Life Science and Tools
Industry Risk.&#xa0; <font style="font-style:Normal">Life science industries are characterized by limited product focus, rapidly changing technology,</font></div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:19.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">26
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">extensive government regulation, and intense
competition.&#xa0; In particular, technological advances can render an existing product, which may account for a disproportionate share of a company&#x2019;s revenue, obsolete. Extensive regulation can delay cause
delays in product development, which may disadvantage a company in an intensely competitive environment. These various factors may result in abrupt advances and declines in the securities prices of particular
companies, and, in some cases, may have a broad effect on the prices of securities of companies in particular life science industries.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Technology Sector
Risk.<font style="font-style:Normal"> Companies in the healthcare technology sector may incur substantial cost related to product-related liabilities, interruptions at their data centers or client support facilities, claims for
infringement or misappropriation of intellectual property rights of others, or infringement or misappropriation of their intellectual property.&#xa0; Each of these may adversely impact the prices of securities of
companies in the healthcare technology sector.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Additionally, the success of
healthcare technology companies depends upon the recruitment and retention of key personnel. The failure to attract and retain qualified personnel could have a material adverse effect on healthcare technology
companies&#x2019; prospects for long-term growth.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Services Sector
Risk.<font style="font-style:Normal"> The operations of healthcare services companies are subject to extensive federal, state and local government regulations. A violation or departure from any of these legal requirements may
result in government audits, lower reimbursements, significant fines and penalties, the potential loss of certification, recoupment efforts or voluntary repayments. If healthcare services companies fail to adhere to
all of the complex government regulations that apply to their businesses, such companies could suffer severe consequences that would substantially reduce revenues, earnings, cash flows and stock prices.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">A substantial percentage of a
healthcare services company&#x2019;s service revenues may be generated from patients who have state Medicaid or other non-Medicare government-based programs, such as coverage through the Department of Veterans Affairs
(&#x201c;VA&#x201d;), as their primary coverage. As state governments and other governmental organizations face increasing budgetary pressure, healthcare services companies may in turn face reductions in payment rates,
delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Supplies Sector
Risk. <font style="font-style:Normal">If healthcare supplies companies are unable to successfully expand their product lines through internal research and development and acquisitions or are unable to successfully grow their
business through marketing partnerships, their business may be materially and adversely affected.</font></div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Quality is extremely important to healthcare
supplies companies and their customers due to the serious and costly consequences of product failure. Quality certifications are critical to the marketing success of their products and services. If a healthcare
supplies company fails to meet these standards or fails to adapt to evolving standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations could decline.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Facilities Sector
Risk.<font style="font-style:Normal"> A healthcare facility&#x2019;s ability to negotiate favorable contracts significantly affects the revenues and operating results of such healthcare facilities. If a healthcare facility is
unable to enter into and maintain managed care contractual arrangements on acceptable terms, if it experiences material reductions in the contracted rates received from managed care payers, or if it has difficulty
collecting from managed care payers, its results of operations could be adversely affected.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Further changes in the
Medicare and Medicaid programs or other government health care programs could have an adverse effect on a healthcare facility&#x2019;s business. In addition to the changes affected by the ACA, the Medicare and Medicaid
programs are subject to other regulatory changes which could materially increase or decrease payments from government programs in the future, as well as affect the cost of providing services to patients and the timing
of payments to facilities, which could in turn adversely affect a healthcare facility&#x2019;s overall business, financial condition, results of operations or cashflows.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Equipment Sector
Risk. <font style="font-style:Normal">The medical device markets are highly competitive and characterized by rapid change, which may affect a company&#x2019;s ability to be competitive. They are also rigorously regulated and it
is anticipated that governmental authorities will continue to scrutinize this industry closely, and that additional regulation may increase compliance and legal costs, exposure to&#xa0;&#xa0;&#xa0; litigation, and
other adverse effects to operations.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare equipment
companies are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to such rights may negatively impact the ability of healthcare
equipment companies to sell current or future products.&#xa0; Quality problems with the processes, goods and services of a healthcare equipment company could harm the company&#x2019;s reputation for producing
high-quality products and erode its competitive advantage, sales and market share. Quality certifications are critical to the marketing success of goods and services. If a healthcare equipment company fails to meet
these standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations could decline.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Distributors
Sector Risk.<font style="font-style:Normal"> Companies in the healthcare distribution sector operate in markets that are highly competitive and in an industry that is highly regulated and often subject to legal proceedings. Due to the
nature of the business of healthcare</font></div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:18.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">27
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">distribution companies, each of the above
may have an adverse impact on the securities prices of companies in the healthcare distribution sector.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare distribution
companies depend on the availability of various components, compounds, raw materials and energy supplied by others for their operations. Any of these supplier relationships could be interrupted due to events beyond
the control of such companies, including pandemics, epidemics or natural disasters, or could be terminated. A sustained supply interruption could have an adverse effect on business.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">h.&#xa0;&#xa0;Valuation Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The price that the Fund
could receive upon the sale of any particular portfolio investment may differ from the Fund's valuation of the investment, particularly for securities that trade in thin or volatile markets or that are valued using a
fair valuation methodology or a price provided by an independent pricing service. As a result, the price received upon the sale of an investment may be less than the value ascribed by the Fund, and the Fund could
realize a greater than expected loss or lower than expected gain upon the sale of the investment. The Fund's ability to value its investments may also be impacted by technological issues and/or errors by pricing
services or other third-party service providers.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">i.&#xa0;&#xa0;Venture Capital
Investments Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may occasionally
invest in venture capital opportunities. While these securities offer the opportunity for significant capital gains, such investments also involve a degree of risk that can result in substantial losses. Some of the
venture capital opportunities in which the Fund may invest are expected to be companies that are in a &#x201c;start-up&#x201d; stage of development, have little or no operating history, operate at a loss or with
substantial variations in operating results</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">from period to period, have limited
products, markets, financial resources or management depth, or have the need for substantial additional &#x201c;follow-on&#x201d; capital to support expansion or to achieve or maintain a competitive position. Such
additional investments may dilute the interests of prior investors, such as the Fund. Some of these companies may be emerging companies at the research and development stage with no marketable or approved products or
technology. There can be no assurance that securities of start-up or emerging growth companies will, in the future, yield returns commensurate with their associated risks.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">These investments, which are
considered Restricted Securities, will be made primarily in convertible preferred stock. The Fund may also purchase non-convertible debt securities in connection with its venture capital investments, and otherwise
when the Investment Adviser believes that such investments would be consistent with the Fund&#x2019;s investment objective. While these debt investments typically will not be rated, the Investment Adviser believes
that, in light of the risk characteristics associated with investments in emerging growth companies, if such investments were to be compared with investments rated by S&amp;P or Moody&#x2019;s, they may be rated as low
as &#x201c;C&#x201d; in the rating categories established by S&amp;P and Moody&#x2019;s. Such securities are commonly referred to as &#x201c;junk bonds&#x201d; and are considered, on balance, as predominantly
speculative.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">9.&#xa0;&#xa0;Contingencies</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In the normal course of
business, the Fund may provide general indemnifications pursuant to certain contracts and organizational documents. The Fund's maximum exposure under these arrangements is dependent on future claims that may be made
against the Fund, and therefore, cannot be estimated; however, the Fund expects the risk of loss from such claims to be remote.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:9.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">10.&#xa0;&#xa0;Tax
Information</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The U.S. federal
income tax basis of the Fund's investments (including derivatives, if applicable) and the net unrealized depreciation as of March 31, 2025, were as follows:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:6pt; padding-right:10.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.29%">Tax Cost of<br>
Securities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:28.75%">Unrealized<br>
Appreciation
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.64%">Unrealized<br>
Depreciation
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.96%">Net<br>
Unrealized<br>
Appreciation/<br>
(Depreciation)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:0pt; padding-right:10.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.29%; background-color: #F0F0F0;">$422,207,071
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:28.75%; background-color: #F0F0F0;">$93,584,417
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.64%; background-color: #F0F0F0;">$(110,712,020)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:6pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.96%; background-color: #F0F0F0;">$(17,127,603)
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">11.&#xa0;&#xa0;Segment
Reporting</div>
</div>
</div>
<div style="padding-top:7pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">In this reporting period, the Fund adopted
FASB Accounting Standards Update 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;). Adoption of the new standard impacted disclosures only and did not
affect the Fund&#x2019;s financial position nor the results of its operations. Operating segments are components of a public entity that engage in business activities</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">from which it may recognize revenues and
incur expenses, have discrete financial information available, and have their operating results regularly reviewed by the public entity&#x2019;s chief operating&#xa0;decision maker (&#x201c;CODM&#x201d;) when assessing
segment performance and making decisions about segment resources. The Chief Financial Officer of the Fund acts as the Fund&#x2019;s CODM. The</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:21.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">28
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(concluded)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">CODM monitors the operating results of the
Fund as a whole, and the Fund&#x2019;s asset allocation is managed in accordance with its Prospectus. The Fund operates as a single operating and reporting segment pursuant to its investment objective and principal
investment strategy. The Fund&#x2019;s portfolio composition, total returns, expense ratios and changes in net assets used by the CODM to assess segment performance and make resource allocations are consistent with the
information presented within the Fund's financial statements. Segment assets are reflected on the Fund&#x2019;s Statement of Assets and Liabilities as &#x201c;Total Assets&#x201d; and significant segment expenses are
listed on the Statement of Operations.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">12.&#xa0;&#xa0;Subsequent Events</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Based on this evaluation,
no disclosures and/or adjustments were required to the financial statements as of March 31, 2025, other than as noted below.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">On May 9, 2025, the Fund
announced that it will pay on June 30, 2025, a stock distribution of US $0.43 per share to all shareholders of record as of May 22, 2025.&#xa0;</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:516.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">29
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Dividend Reinvestment and Optional Cash Purchase
Plan&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund intends to distribute to
shareholders substantially all of its net investment income and to distribute any net realized capital gains at least annually. Net investment income for this purpose is income other than net realized long-term and
short-term capital gains net of expenses. Pursuant to the Dividend Reinvestment and Optional Cash Purchase Plan (the &#x201c;Plan&#x201d;), shareholders whose shares of common stock are registered in their own names
will be deemed to have elected to have all distributions automatically reinvested by Computershare Trust Company N.A. (the &#x201c;Plan Agent&#x201d;) in the Fund shares pursuant to the Plan, unless such shareholders
elect to receive distributions in cash. Shareholders who elect to receive distributions in cash will receive such distributions paid by check in U.S. Dollars mailed directly to the shareholder by the Plan Agent, as
dividend paying agent. In the case of shareholders such as banks, brokers or nominees that hold shares for others who are beneficial owners, the Plan Agent will administer the Plan on the basis of the number of shares
certified from time to time by the shareholders as representing the total amount registered in such shareholders&#x2019; names and held for the account of beneficial owners that have not elected to receive
distributions in cash. Investors that own shares registered in the name of a bank, broker or other nominee should consult with such nominee as to participation in the Plan through such nominee and may be required to
have their shares registered in their own names in order to participate in the Plan. Please note that the Fund does not issue certificates so all shares will be registered in book entry form. The Plan Agent serves as
agent for the shareholders in administering the Plan. If the Trustees of the Fund declare an income dividend or a capital gains distribution payable either in the Fund&#x2019;s common stock or in cash, nonparticipants
in the Plan will receive cash and participants in the Plan will receive common stock, to be issued by the Fund or purchased by the Plan Agent in the open market, as provided below. If the market price per share (plus
expected per share fees) on the valuation date equals or exceeds NAV per share on that date, the Fund will issue new shares to participants at NAV; provided, however, that if the NAV is less than 95% of the market
price on the valuation date, then such shares will be issued at 95% of the market price. The valuation date will be the payable date for such distribution or dividend or, if that date is not a trading day on the NYSE,
the immediately preceding trading date. If NAV exceeds the market price of Fund shares at such time, or if the Fund should declare an income dividend or capital gains distribution payable only in cash, the Plan Agent
will, as agent for the participants, buy Fund shares in the open market, on the NYSE or elsewhere, for the participants&#x2019; accounts on, or shortly after, the payment date. If, before the Plan Agent has completed
its purchases, the market price exceeds the NAV of the Fund's share, the average per share purchase price paid by the Plan Agent may exceed the NAV of the Fund&#x2019;s shares, resulting in the acquisition of fewer
shares than if the distribution had been paid in shares issued by the Fund on the dividend payment date. Because of</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">the foregoing difficulty with respect to
open-market purchases, the Plan provides that if the Plan Agent is unable to invest the full dividend amount in open-market purchases during the purchase period or if the market discount shifts to a market premium
during the purchase period, the Plan Agent will cease making open-market purchases and will receive the uninvested portion of the dividend amount in newly issued shares at the close of business on the last purchase
date.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Participants have the option
of making additional cash payments of a minimum of $50 per investment (by check, one-time online bank debit or recurring automatic monthly ACH debit) to the Plan Agent for investment in the Fund&#x2019;s common stock,
with an annual maximum contribution of $250,000. The Plan Agent will wait up to three business days after receipt of a check or electronic funds transfer to ensure it receives good funds. Following confirmation of
receipt of good funds, the Plan Agent will use all such funds received from participants to purchase Fund shares in the open market on the 25th day of each month or the next trading day if the 25th is not a trading
day.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">If the participant sets up
recurring automatic monthly ACH debits, funds will be withdrawn from his or her U.S. bank account on the 20th of each month or the next business day if the 20th is not a banking business day and invested on the next
investment date. The Plan Agent maintains all shareholder accounts in the Plan and furnishes written confirmations of all transactions in an account, including information needed by shareholders for personal and tax
records. Shares in the account of each Plan participant will be held by the Plan Agent in the name of the participant, and each shareholder&#x2019;s proxy will include those shares purchased pursuant to the Plan. There
will be no brokerage charges with respect to common shares issued directly by the Fund. However, each participant will pay a per share fee of $0.02 incurred with respect to the Plan Agent&#x2019;s open market purchases
in connection with the reinvestment of dividends, capital gains distributions and voluntary cash payments made by the participant. Per share fees include any applicable brokerage commissions the Plan Agent is required
to pay.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Participants also have the
option of selling their shares through the Plan. The Plan supports two types of sales orders. Batch order sales are submitted on each market day and will be grouped with other sale requests to be sold. The price will
be the average sale price obtained by Computershare&#x2019;s broker, net of fees, for each batch order and will be sold generally within 2 business days of the request during regular open market hours. Please note that
all written sales requests are always processed by Batch Order. ($10 and $0.12 per share). Market Order sales will sell at the next available trade. The shares are sold real time when they hit the market, however an
available trade must be presented to complete this transaction. Market Order sales may only</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:16.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">30
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Dividend Reinvestment and Optional Cash Purchase
Plan&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">be requested by phone at 1-800-647-0584 or
using Investor Center through www.computershare.com/buyaberdeen. ($25 and $0.12 per share).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The receipt of dividends and
distributions under the Plan will not relieve participants of any income tax that may be payable on such dividends or distributions. The Fund or the Plan Agent may terminate the Plan as applied to any voluntary cash
payments made and any dividend or distribution paid subsequent to notice of the termination sent to members of the Plan at least 30 days prior to the record date for such dividend or distribution. The Plan also may be
amended by</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">the Fund or the Plan Agent, but (except when
necessary or appropriate to comply with applicable law or the rules or policies of the Securities and Exchange Commission or any other regulatory authority) only by mailing a written notice at least 30 days prior to
the effective date to the participants in the Plan. All correspondence concerning the Plan should be directed to the Plan Agent by phone at 1-800-647-0584, using Investor Center through <font style="color:#0000FF; text-decoration:underline">www.computershare.com/buyaberdeen</font> or in writing to Computershare Trust Company N.A., P.O. Box 43006, Providence, RI 02940-3078.&#xa0;</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:517.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">31
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:10pt; font-style:Normal; font-weight:Normal; line-height:13pt; text-align:center; text-decoration:none; text-transform:none">[THIS PAGE INTENTIONALLY LEFT BLANK]</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Corporate Information<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
</div>
<div style="margin-top:2pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:26.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48%">
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Trustees</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Todd Reit, <font style="font-style:italic">Chair<br>
</font>Jeffrey Bailey<br>
Rose DiMartino<br>
Kathleen Goetz<br>
C. William Maher<br>
Christian Pittard</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Investment Adviser</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">abrdn Inc.<br>
1900 Market Street, Suite 200<br>
Philadelphia, PA&#xa0;19103</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Custodian</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">State Street Bank and Trust Company<br>
One Congress Street, Suite 1<br>
Boston, MA 02114-2016</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Transfer Agent</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Computershare Trust Company, N.A.<br>
P.O. Box 43006<br>
Providence, RI 02940-3078</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48%">
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Independent Registered Public Accounting Firm</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">KPMG LLP<br>
191 West Nationwide Blvd., Suite 500<br>
Columbus, OH 43215</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Legal Counsel</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Dechert LLP<br>
1900 K Street N.W.<br>
Washington, D.C. 20006</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Investor Relations</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">abrdn Inc.<br>
1900 Market Street, Suite 200<br>
Philadelphia, PA 19103<br>
1-800-522-5465<br>
Investor.Relations@aberdeenplc.com</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:207pt; width:100%">
<div style="margin-left:38.41%; margin-top:5pt; text-align:Center; width:23.19%">
<img src="tm2516624d12hqlreporti004.jpg" alt=" ">
</div>


<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:9pt; text-align:left; text-decoration:none; text-transform:none">The Financial Statements
as of March 31, 2025, included in this report, were not audited and accordingly, no opinion is expressed thereon.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Notice is hereby given in
accordance with Section 23(c) of the Investment Company Act of 1940, as amended, that the Fund may purchase, from time to time, shares of its common stock in the open market.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Shares of abrdn Life
Sciences Investors are traded on the NYSE under the symbol &#x201c;HQL.&#x201d; Information about the Fund&#x2019;s net asset value and market price is available at
https://www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">This report, including
the financial information herein, is transmitted to the shareholders of abrdn Life Sciences Investors for their general information only. It does not have regard to the specific investment objectives, financial
situation and the particular needs of any specific person. Past performance is no guarantee of future results.</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">HQL-SEMI-ANNUAL</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2516624d12_items2-19.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-12/tm2516624-12_ncsrsseq1" -->

<p style="margin: 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&#xa0;Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 2. Code of Ethics.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This item is inapplicable to semi-annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3. Audit Committee Financial Expert.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This item is inapplicable to semi-annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 4. Principal Accountant Fees and Services.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This item is inapplicable to semi-annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 5. Audit Committee of Listed Registrants.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This item is inapplicable to semi-annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 6. Schedule of Investments.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&#xa0;Schedule of Investments in securities
of unaffiliated issuers as of close of the reporting period is included as part of the Report to Shareholders filed under Item 1 of this
Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&#xa0;Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7. Financial Statements and Financial
Highlights for Open-End Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8. Changes in and Disagreements with Accountants
for Open-End Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9. Proxy Disclosures for Open-End Management Investment Companies</b></font>.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 10. Remuneration Paid to Directors, Officers,
and Others of Open-End Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 11. Statement Regarding Basis for Approval
of Investment Advisory Contract.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 12. Disclosure of Proxy Voting Policies and Procedures for
Closed-End Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This item is inapplicable to semi-annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 13. Portfolio Managers of Closed-End Management Investment
Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&#xa0; Not applicable to semi-annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&#xa0;There has been no change, as of the date of this filing, in
any of the portfolio managers identified in response to paragraph (a)(1)&#xa0;of this Item in the registrant&#x2019;s most recently filed
annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 14. Purchases of Equity Securities by Closed-End Management
Investment Company and Affiliated Purchasers.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;  border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period</b></font></td>
    <td style="white-space: nowrap">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)&#xa0;Total&#xa0;No.<br>
of&#xa0;Shares<br>
Purchased&#xa0;</b></font></td>
    <td style="white-space: nowrap">&#xa0;</td>
    <td style="white-space: nowrap">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)&#xa0;Average<br>
Price&#xa0;Paid&#xa0;per<br>
Share</b></font></td>
    <td style="white-space: nowrap">&#xa0;</td>
    <td style="white-space: nowrap">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)&#xa0;Total&#xa0;No.<br>
of&#xa0;Shares<br>
Purchased&#xa0;as<br>
Part&#xa0;of<br>
Publicly<br>
Announced&#xa0;Plans<br>
or&#xa0;Programs(1)</b></font></td>
    <td style="white-space: nowrap">&#xa0;</td>
    <td style="white-space: nowrap">&#xa0;</td>
    <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)&#xa0;Maximum&#xa0;No.<br>
of&#xa0;Shares&#xa0;that<br>
May&#xa0;Yet&#xa0;Be<br>
Purchased&#xa0;Under<br>
the&#xa0;Plans&#xa0;or<br>
Programs(1)</b></font></td>
    <td style="white-space: nowrap">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 42%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Month #1 (Oct.&#xa0;1, 2024 &#x2014; Oct.&#xa0;31, 2024)</font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 10%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 12%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 1%">&#xa0;</td>
    <td style="width: 16%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,326,419</font></td>
    <td style="width: 1%">&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Month #2 (Nov.&#xa0;1, 2024 &#x2014; Nov.&#xa0;30, 2024)</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,326,419</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Month #3 (Dec.&#xa0;1, 2024 &#x2014; Dec.&#xa0;31, 2024)</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,326,419</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Month #4 (Jan.&#xa0;1, 2025 &#x2014; Jan.&#xa0;31, 2025)</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,326,419</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Month #5 (Feb.&#xa0;1, 2025 &#x2014; Feb.&#xa0;28, 2025)</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,326,419</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Month #6 (Mar.&#xa0;1, 2025 &#x2014; Mar.&#xa0;31, 2025)</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,326,419</font></td>
    <td>&#xa0;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid">&#xa0;</td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#x2014;</b></font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>&#x2014;</b></font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid">&#xa0;</td>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td>
    <td style="vertical-align: bottom">&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;  border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#xa0;</td>
    <td style="width: 23px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June&#xa0;30, 2011, the share repurchase program was announced, which has been subsequently reviewed and approved by the Board of Trustees. In March&#xa0;2024, the Board approved the renewal of the repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares in the open market for a one-year period ending July&#xa0;14, 2025. </font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 15. Submission of Matters to a Vote of Security Holders.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the period ended March&#xa0;31, 2025, there were no material
changes to the procedures by which shareholders may recommend nominees to the Registrant&#x2019;s Board of Trustees.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 16. Controls and Procedures.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(a)</td><td style="text-align: justify">The Registrant&#x2019;s principal executive and principal financial officers, or persons performing similar
functions, have concluded that the Registrant&#x2019;s disclosure controls and procedures (as defined in Rule&#xa0;30a-3(c)&#xa0;under
the Investment Company Act of 1940 (the &#x201c;Act&#x201d;) (17 CFR 270.30a-3(c))) are effective, as of a date within 90 days of the filing
date of the report that includes the disclosure required by this paragraph, based on the evaluation of these controls and procedures required
by Rule&#xa0;30a-3(b)&#xa0;under the Act (17 CFR 270.30a3(b)) and Rule&#xa0;13a-15(b)&#xa0;or 15d-15(b)&#xa0;under the Securities Exchange
Act of 1934, as amended (17 CFR 240.13a-15(b)&#xa0;or 240.15d15(b)).</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(b)</td><td style="text-align: justify">There were no changes in the Registrant&#x2019;s internal control over financial reporting (as defined
in Rule&#xa0;30a-3(d)&#xa0;under the Act (17 CFR 270.30a-3(d))) that occurred during the period covered by this report that has materially
affected, or is reasonably likely to materially affect, the Registrant&#x2019;s internal control over financial reporting.</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 17. Disclosure of Securities Lending Activities for Closed-End
Management Investment Companies</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 18. Recovery of Erroneously Awarded Compensation</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not appliable</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 19. Exhibits.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.5in">(a)(1)</td><td style="text-align: justify">Not applicable.</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.5in">(a)(2)</td><td style="text-align: justify">Any policy required by the listing standards adopted pursuant to Rule&#xa0;10D-1 under the Exchange Act
(17 CFR 240.10D-1) by the registered national securities exchange or registered national securities association upon which the registrant&#x2019;s
securities are listed. Not applicable.</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.5in"><a href="tm2516624d12_ex99-cert.htm">(a)(3)</a></td><td style="text-align: justify"><a href="tm2516624d12_ex99-cert.htm">The certifications of the registrant as required by Rule&#xa0;30a-2(a)&#xa0;under the Act are exhibits
to this Form&#xa0;N-CSR.</a></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.5in">(a)(4)</td><td style="text-align: justify">Any written solicitation to purchase securities under Rule&#xa0;23c-1 under the 1940 Act (17 CFR 270.23c-1)
sent or given during the period covered by the report by or on behalf of the registrant to 10 or more persons. Not applicable.</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.5in">(a)(5)</td><td style="text-align: justify">Change in Registrant&#x2019;s independent public accountant. Not applicable.</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.5in"><a href="tm2516624d12_ex99-906cert.htm">(b)</a></td><td style="text-align: justify"><a href="tm2516624d12_ex99-906cert.htm">The certifications of the registrant as required by Rule&#xa0;30a-2(b)&#xa0;under the Act are exhibits
to this Form&#xa0;N-CSR.</a></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.5in">(c)</td><td style="text-align: justify">A copy of the Registrant&#x2019;s notices to stockholders, which accompanied distributions paid, pursuant
to the Registrant&#x2019;s Managed Distribution Policy since the Registrant&#x2019;s last filed N-CSR, are filed herewith as <a href="tm2516624d12_ex99-xcx1.htm">Exhibits (c)(1)</a>&#xa0;and
<a href="tm2516624d12_ex99-xcx2.htm">(c)(2)</a>, as required by the terms of the Registrant&#x2019;s SEC exemptive order.</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="margin: 0"></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->


<p style="margin: 0">&#xa0;</p>


</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2516624d12_sigpg.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-12/tm2516624-12_ncsrsseq1" -->

<p style="margin: 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase"><b><font style="text-decoration:underline">SIGNATURES</font></b></font></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934 and the Investment Company Act of 1940, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">abrdn Life Sciences Investors</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><font style="font-size: 10pt">By:&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><font style="font-size: 10pt"><i>/s/
    Alan Goodson</i></font></td>
    <td style="width: 50%"><font style="font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">Alan Goodson,</font></td>
    <td><font style="font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">Principal Executive Officer of abrdn Life Sciences
    Investors</font></td>
    <td><font style="font-size: 10pt">&#xa0;</font></td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June&#xa0;9, 2025</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><font style="font-size: 10pt">By:&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><font style="font-size: 10pt"><i>/s/
    Alan Goodson</i></font></td>
    <td style="width: 50%"><font style="font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">Alan Goodson,</font></td>
    <td><font style="font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">Principal Executive Officer of abrdn Life Sciences
    Investors</font></td>
    <td><font style="font-size: 10pt">&#xa0;</font></td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June&#xa0;9, 2025</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><font style="font-size: 10pt">By:&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</font></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><font style="font-size: 10pt"><i>/s/
    Sharon Ferrari</i></font></td>
    <td style="width: 50%"><font style="font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">Sharon Ferrari,</font></td>
    <td><font style="font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#xa0;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">Principal Financial Officer of abrdn Life Sciences
    Investors</font></td>
    <td><font style="font-size: 10pt">&#xa0;</font></td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June&#xa0;9, 2025</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="margin: 0"></p>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->


<p style="margin: 0">&#xa0;</p>


</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.CERT
<SEQUENCE>2
<FILENAME>tm2516624d12_ex99-cert.htm
<DESCRIPTION>EXHIBIT 99.CERT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2516624d12_ex99-cert.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-12/tm2516624-12_ncsrsseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.CERT</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>Certification
Pursuant to Rule&nbsp;30</U></B></FONT><B><U>a<FONT STYLE="text-transform: uppercase">-2(</FONT>a<FONT STYLE="text-transform: uppercase">)&nbsp;under
the 1940 Act and Section&nbsp;302 of the Sarbanes-Oxley Act</FONT></U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Sharon Ferrari, certify that:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD>I have reviewed this report on Form&nbsp;N-CSR of abrdn Life Sciences Investors (the &ldquo;Registrant&rdquo;);</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the
financial statements are required to include a statement of cash flows) of the Registrant as of, and for, the periods presented in this
report;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Rule&nbsp;30a-3(c)&nbsp;under the Investment Company Act of 1940) and internal control
over financial reporting (as defined in Rule&nbsp;30a-3(d)&nbsp;under the Investment Company Act of 1940) for the Registrant and have:</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to
the filing date of this report based on such evaluation; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify">Disclosed in this report any change in the Registrant&rsquo;s internal control over financial reporting
that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the
Registrant&rsquo;s internal control over financial reporting; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed to the Registrant&rsquo;s
auditors and the audit committee of the Registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize, and
report financial information; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the Registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date June&nbsp;9, 2025</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Sharon Ferrari</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Sharon Ferrari</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Principal Financial Officer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>Certification
Pursuant to Rule&nbsp;30</U></B></FONT><B><U>a<FONT STYLE="text-transform: uppercase">-2(</FONT>a<FONT STYLE="text-transform: uppercase">)&nbsp;under
the 1940 Act and Section&nbsp;302 of the Sarbanes-Oxley Act</FONT></U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Alan Goodson, certify that:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD>I have reviewed this report on Form&nbsp;N-CSR of abrdn Life Sciences Investors (the &ldquo;Registrant&rdquo;);</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the
financial statements are required to include a statement of cash flows) of the Registrant as of, and for, the periods presented in this
report;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Rule&nbsp;30a-3(c)&nbsp;under the Investment Company Act of 1940) and internal control
over financial reporting (as defined in Rule&nbsp;30a-3(d)&nbsp;under the Investment Company Act of 1940) for the Registrant and have:</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to
the filing date of this report based on such evaluation; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify">Disclosed in this report any change in the Registrant&rsquo;s internal control over financial reporting
that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the
Registrant&rsquo;s internal control over financial reporting; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed to the Registrant&rsquo;s
auditors and the audit committee of the Registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize, and
report financial information; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the Registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June&nbsp;9, 2025</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Alan Goodson</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Alan Goodson</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Principal Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="margin: 0"></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.906CERT
<SEQUENCE>3
<FILENAME>tm2516624d12_ex99-906cert.htm
<DESCRIPTION>EXHIBIT 99.906CERT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2516624d12_ex99-906cert.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-12/tm2516624-12_ncsrsseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.906CERT</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>Certification
Pursuant to Rule&nbsp;30</U></B></FONT><B><U>a<FONT STYLE="text-transform: uppercase">-2(</FONT>b<FONT STYLE="text-transform: uppercase">)&nbsp;under
the 1940 Act and Section&nbsp;906 of the Sarbanes-Oxley Act</FONT></U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alan Goodson, Principal Executive Officer, and
Sharon Ferrari, Principal Financial Officer, of abrdn Life Sciences Investors (the &ldquo;Registrant&rdquo;), each certify that:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s periodic report on Form&nbsp;N-CSR for the period ended March&nbsp;31, 2025 (the
 &ldquo;Form&nbsp;N-CSR&rdquo;) fully complies with the requirements of Section&nbsp;13(a)&nbsp;or Section&nbsp;15(d)&nbsp;of the Securities
Exchange Act of 1934, as amended, as applicable; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The information contained in the Form&nbsp;N-CSR fairly presents, in all material respects, the financial
condition and results of operations of the Registrant.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRINCIPAL EXECUTIVE OFFICER</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">abrdn Life Sciences Investors</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Alan Goodson</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Alan Goodson</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date: June&nbsp;9, 2025</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRINCIPAL FINANCIAL OFFICER</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">abrdn Life Sciences Investors</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Sharon Ferrari</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Sharon Ferrari</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date: June&nbsp;9, 2025</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This certification is being furnished solely pursuant
to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of Form&nbsp;N-CSR or as a separate disclosure document.
A signed original of this written statement, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section&nbsp;906, has been provided to the Registrant
and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="margin: 0"></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(C)(1)
<SEQUENCE>4
<FILENAME>tm2516624d12_ex99-xcx1.htm
<DESCRIPTION>EXHIBIT 99.(C)(1)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2516624d12_ex99-xcx1.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-12/tm2516624-12_ncsrsseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 389pt">Exhibit 99.(c)(1)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2516624d12_ex99-xcx1img001.jpg" ALT=""></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Press Release</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>FOR IMMEDIATE RELEASE</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For More Information Contact: </B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">abrdn U.S. Closed-End Funds</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Investor
Relations</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">1-800-522-5465</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Investor.Relations@abrdn.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ABRDN U.S. CLOSED-END FUNDS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ANNOUNCE DISTRIBUTION PAYMENT DETAILS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Philadelphia, January 10, 2025) - The <U>abrdn U.S. Closed-End
Funds</U> (NYSE: ASGI, HQH, HQL, IFN, JEQ, THQ), (NYSE American: IAF) (the &ldquo;Funds&rdquo; or individually the &ldquo;Fund&rdquo;),
today announced that the Funds paid the distributions noted in the table below on January 10, 2025, on a per share basis to all shareholders
of record as of December 30, 2024 (ex-dividend date December 30, 2024). These dates apply to the Funds listed below with the exception
of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF), the India Fund Inc.
(IFN) and abrdn Japan Equity Fund, Inc. (JEQ) which paid on January 10, 2025, to all shareholders of record as of November 21, 2024 (ex-dividend
date November 21, 2024)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ticker</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exchange</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; padding-bottom: 1pt">ASGI</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left; padding-bottom: 1pt">abrdn Global Infrastructure Income Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.2000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">HQH</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.6200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">HQL</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Life Sciences Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">IAF</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">NYSE American</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Australia Equity Fund, Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">IFN</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">The India Fund, Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.9300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">JEQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Japan Equity Fund, Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">THQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Opportunities Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21pt 0pt 5pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each Fund has adopted a distribution policy to provide investors
with a stable distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the abrdn Healthcare Investors (HQH), abrdn Life Sciences
Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF), the India Fund Inc. (IFN) and abrdn Japan Equity Fund, Inc. (JEQ) the stock
distributions were automatically paid in newly issued shares of the Fund unless otherwise instructed by the shareholder to be paid in
cash. Shares of common stock were issued at the lower of the net asset value (&ldquo;NAV&rdquo;) per share or the market price per share
with a floor for the NAV of not less than 95% of the market price on December 17, 2024. The reinvestment prices per share for these distributions
were as follows: $16.83 for abrdn Healthcare Investors (HQH); $13.87 for abrdn Life Sciences Investors (HQL); $4.35 for abrdn Australia
Equity Fund, Inc. (IAF); $16.8 for the India Fund, Inc. (IFN) and $5.81 for abrdn Japan Equity Fund, Inc. (JEQ). Fractional shares were
generally settled in cash, except for registered shareholders with book entry accounts at Computershare Investor Services who had whole
and fractional shares added to their account.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To have received the abrdn Healthcare Investors (HQH), abrdn Life
Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF), the India Fund Inc. (IFN) and abrdn Japan Equity Fund, Inc. (JEQ)
quarterly distributions payable in January 2025 in cash instead of shares of common stock, for shareholders who hold shares in
 &ldquo;street name,&rdquo; the bank, brokerage or nominee who holds the shares must have advised the Depository Trust Company as to
the full and fractional shares for which they want the distribution paid in cash by December 16, 2024; and for shares that are held
in registered form, written notification for the election of cash by registered shareholders must have been received by
Computershare Investor Services prior to December 16, 2024.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Under applicable U.S. tax rules, the amount and character of distributable
income for each Fund&rsquo;s fiscal year can be finally determined only as of the end of the Fund&rsquo;s fiscal year. However, under
Section 19 of the Investment Company Act of 1940, as amended (the &ldquo;1940 Act&rdquo;) and related rules, the Funds may be required
to indicate to shareholders the estimated source of certain distributions to shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The following tables set forth the estimated amounts of
the sources of the distributions for purposes of Section 19 of the 1940 Act and the rules adopted thereunder. The tables have been computed
based on generally accepted accounting principles. The tables include estimated amounts and percentages for the current distributions
paid this month as well as for the cumulative distributions paid relating to fiscal year to date, from the following sources: net investment
income; net realized short-term capital gains; net realized long-term capital gains; and return of capital. The estimated compositions
of the distributions may vary because the estimated composition may be impacted by future income, expenses and realized gains and losses
on securities and currencies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The Funds&rsquo; estimated sources of the current distribution
paid this month and for its current fiscal year to date are as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="37" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Estimated Amounts of Current Distribution
    per Share</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Distribution<BR>
 Amount</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Investment<BR>
 Income</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Short-<BR>
Term Gains**</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Long-<BR>
Term Gains</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Return of Capital</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">ASGI</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.2000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.0120</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">6</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.1880</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">94</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">HQH</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.6200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.6200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">HQL</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1985</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.3015</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">IAF</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1300</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0117</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0104</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1079</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">83</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">IFN</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.9300</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.9300</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">JEQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">THQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0234</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1566</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">87</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Estimated Amounts of Fiscal Year*
    to Date Cumulative Distributions per Share</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Distribution<BR>
 Amount</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Investment<BR>
 Income</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Short-<BR>
Term Gains**</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Long-<BR>
Term Gains</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Return of Capital</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">ASGI</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.6200</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.0372</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">6</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.5828</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">94</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">HQH</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.6200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.6200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">HQL</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1985</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.3015</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">IAF</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1300</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0117</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0104</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1079</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">83</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">IFN</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.300</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.3000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">JEQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">THQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5400</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0702</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4698</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">87</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">* ASGI, HQH, HQL and THQ have a 9/30 fiscal year end. IAF
and JEQ have a 10/31 fiscal year end. IFN has a 12/31 fiscal year end.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">**includes currency gains</P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where the estimated amounts above show a portion of the distribution
to be a &ldquo;Return of Capital,&rdquo; it means that Fund estimates that it has distributed more than its income and capital gains;
therefore, a portion of your distribution may be a return of capital. A return of capital may occur for example, when some or all the
money that you invested in a Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund&rsquo;s
investment performance and should not be confused with &ldquo;yield&rdquo; or &ldquo;income.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0"><B>The amounts and sources of distributions reported in this
notice are only estimates and are not being provided for tax reporting purposes. The final determination of the source of all distributions
for the current year will only be made after year-end. The actual amounts and sources of the amounts for tax reporting purposes will depend
upon the Fund&rsquo;s investment experience during the remainder of the fiscal year and may be subject to change based on tax regulations.
After the end of each calendar year, a Form 1099-DIV will be sent to shareholders for the prior calendar year that will tell you how to
report these distributions for federal income tax purposes.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27pt 0pt 0">The following tables provide the Funds&rsquo; total return
performance based on net asset value (NAV) over various time periods compared to the Funds&rsquo; annualized and cumulative distribution
rates.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27pt 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Fund Performance and Distribution
    Rate Information</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Average <BR>
Annual Total <BR>
Return on NAV
    <BR>
for the 5 Year <BR>
Period Ending <BR>
11/30/2024<SUP>1</SUP></B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Current Fiscal<BR>
 Period&rsquo;s <BR>
Annualized
    <BR>
Distribution <BR>
Rate on NAV</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Cumulative <BR>
    Total Return on <BR>
    NAV<SUP>1</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Cumulative <BR>
Distribution <BR>
Rate on NAV<SUP>2</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI<SUP>3</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">8.79</TD><TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%<SUP>3</SUP></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">11.79</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">-1.73</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">2.01</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">THQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.82</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.05</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-4.20</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.68</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><SUP>1</SUP>
Return data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under
the Fund&rsquo;s dividend reinvestment plan. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of November 30, 2024. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><SUP>3</SUP>
The Fund launched within the past 5 years; the performance and distribution rate information presented reflects data from inception (July
29, 2020) through November 30, 2024. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund Performance and Distribution Rate Information</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Average <BR>
Annual Total <BR>
Return on NAV
    <BR>
for the 5 Year <BR>
Period Ending <BR>
11/31/2024<SUP>1</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Current Fiscal<BR>
 Period&rsquo;s <BR>
Annualized
    <BR>
Distribution <BR>
Rate on NAV</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Cumulative <BR>
    Total Return on <BR>
    NAV<SUP>1</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Cumulative <BR>
Distribution <BR>
Rate on NAV<SUP>2</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">HQH</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">7.97</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">*</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">-2.31</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">HQL</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.91</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-1.16</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">IAF</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.58</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.36</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32.38</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.36</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">IFN</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.71</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.60</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16.79</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.07</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">JEQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.99</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.47</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24.10</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.47</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><SUP>1</SUP>
Return data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under
the Fund&rsquo;s dividend reinvestment plan. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of October 31, 2024. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">*The Fund&rsquo;s fiscal period to date
is October 1, 202 to O</FONT>ctober 31, 2024, and there were no distributions in this period.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 25pt 0pt 0"><B>Shareholders should not draw any conclusions about a
Fund&rsquo;s investment performance from the amount of the Fund&rsquo;s current distributions or from the terms of the distribution
policy (the &ldquo;Distribution Policy&rdquo;).</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0">While NAV performance may be indicative of the Fund&rsquo;s
investment performance, it does not measure the value of a shareholder&rsquo;s investment in the Fund. The value of a shareholder&rsquo;s
investment in the Fund is determined by the Fund&rsquo;s market price, which is based on the supply and demand for the Fund&rsquo;s shares
in the open market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an exemptive order granted by the Securities and Exchange
Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section 19(b) under the 1940
Act and Rule 19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term capital gains,
long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while generally taxable
at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed at a lower rate
not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in excess of investment
company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed earnings and profits,
and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital distributions exceed
the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the shares have been held
at the date such amount is received.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment of distributions in accordance with the Distribution
Policy may result in a decrease in the Fund&rsquo;s net assets. A decrease in the Fund&rsquo;s net assets may cause an increase in
the Fund&rsquo;s annual operating expense ratio and a decrease in the Fund&rsquo;s market price per share to the extent the market
price correlates closely to the Fund&rsquo;s net asset value per share. The Distribution Policy may also negatively affect the
Fund&rsquo;s investment activities to the extent that the Fund is required to hold larger cash positions than it typically would
hold or to the extent that the Fund must liquidate securities that it would not have sold, for the purpose of paying the
distribution. Each Fund&rsquo;s Board has the right to amend, suspend or terminate the Distribution Policy at any time. The
amendment, suspension or termination of the Distribution Policy may affect the Fund&rsquo;s market price per share. Investors should
consult their tax advisor regarding federal, state, and local tax considerations that may be applicable in their particular
circumstances.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0"><U>Circular 230 disclosure</U>: To ensure compliance with requirements
imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not
intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii)
promoting, marketing or recommending to another party any transaction or matter addressed herein.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 41pt 0pt 0">In the United States, abrdn is the marketing name for the
following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12pt 0pt 0">Closed-end funds are traded on the secondary market
through one of the stock exchanges. A Fund&rsquo;s investment return and principal value will fluctuate so that an investor&rsquo;s
shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a
discount) the net asset value (NAV) of the fund&rsquo;s portfolio. There is no assurance that a Fund will achieve its investment
objective. Past performance does not guarantee future results.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>abrdn.com/en-us/cefinvestorcenter</U></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">###</P>


<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(C)(2)
<SEQUENCE>5
<FILENAME>tm2516624d12_ex99-xcx2.htm
<DESCRIPTION>EXHIBIT 99.(C)(2)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2516624d12_ex99-xcx2.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-12/tm2516624-12_ncsrsseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 381pt">Exhibit 99.(c)(2)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2516624d12_ex99-xcx2img001.jpg" ALT=""></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Press Release</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>FOR IMMEDIATE RELEASE</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>For More Information Contact:</B>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 292pt 0pt 41pt">Aberdeen U.S. Closed-End Funds Investor Relations 1-800-522-5465</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt">Investor.Relations@aberdeenplc.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ABERDEEN U.S. CLOSED-END
FUNDS</B></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ANNOUNCE
DISTRIBUTION PAYMENT DETAILS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">(Philadelphia, March 31, 2025)
- The <U>Aberdeen U.S. Closed-End Funds</U> (NYSE: ASGI, HQH, HQL, IFN, JEQ, THQ), (NYSE American: IAF) (the &ldquo;Funds&rdquo; or individually
the &ldquo;Fund&rdquo;), today announced that the Funds paid the distributions noted in the table below on March 31, 2025, on a per share
basis to all shareholders of record as of March 25, 2025 (ex-dividend date March 25, 2025). These dates apply to the Funds listed below
with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF),
the India Fund Inc. (IFN) and abrdn Japan Equity Fund, Inc. (JEQ) which paid on March 31, 2025, to all shareholders of record as of February
21, 2025 (ex-dividend date February 21, 2025).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Ticker</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Exchange</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; padding-bottom: 1pt">ASGI</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left; padding-bottom: 1pt">abrdn Global Infrastructure Income Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.1900</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">HQH</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">HQL</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Life Sciences Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">IAF</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">NYSE American</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Australia Equity Fund, Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">IFN</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">The India Fund, Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">JEQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Japan Equity Fund, Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">THQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Opportunities Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20pt 0pt 5pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Each Fund has adopted a distribution policy to provide investors
with a stable distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">For the abrdn Healthcare Investors (HQH), abrdn Life Sciences
Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF), the India Fund Inc. (IFN) and abrdn Japan Equity Fund, Inc. (JEQ) the stock
distributions were automatically paid in newly issued shares of the Fund unless otherwise instructed by the shareholder to be paid in
cash. Shares of common stock were issued at the lower of the net asset value (&ldquo;NAV&rdquo;) per share or the market price per share
with a floor for the NAV of not less than 95% of the market price on March 19, 2025. The reinvestment prices per share for these distributions
were as follows: $16.63 for abrdn Healthcare Investors (HQH); $12.99 for abrdn Life Sciences Investors (HQL); $4.045 for abrdn Australia
Equity Fund, Inc. (IAF); $15.45 for the India Fund, Inc. (IFN) and $6.73 for abrdn Japan Equity Fund, Inc. (JEQ). Fractional shares were
generally settled in cash, except for registered shareholders with book entry accounts at Computershare Investor Services who had whole
and fractional shares added to their account.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">To have received the
abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF), the India Fund Inc.
(IFN) and abrdn Japan Equity Fund, Inc. (JEQ) quarterly distributions payable in March 2025 in cash instead of shares of common
stock, for shareholders who hold shares in &ldquo;street name,&rdquo; the bank, brokerage or nominee who holds the shares must have
advised the Depository Trust Company as to the full and fractional shares for which they want the distribution paid in cash by March
18, 2025; and for shares that are held in registered form, written notification for the election of cash by registered shareholders
must have been received by Computershare Investor Services prior to March 18, 2025.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">As announced on March 11, 2025, to avoid potential disruption
to the timing of the proposed tender offer, the Board of Directors of JEQ suspended the Fund&rsquo;s managed distribution policy after
payment of this distribution payable.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Under applicable U.S. tax rules, the amount and character of distributable
income for each Fund&rsquo;s fiscal year can be finally determined only as of the end of the Fund&rsquo;s fiscal year. However, under
Section 19 of the Investment Company Act of 1940, as amended (the &ldquo;1940 Act&rdquo;) and related rules, the Funds may be required
to indicate to shareholders the estimated source of certain distributions to shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The following tables set forth the estimated amounts of
the sources of the distributions for purposes of Section 19 of the 1940 Act and the rules adopted thereunder. The tables have been computed
based on generally accepted accounting principles. The tables include estimated amounts and percentages for the current distributions
paid this month as well as for the cumulative distributions paid relating to fiscal year to date, from the following sources: net investment
income; net realized short-term capital gains; net realized long-term capital gains; and return of capital. The estimated compositions
of the distributions may vary because the estimated composition may be impacted by future income, expenses and realized gains and losses
on securities and currencies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The Funds&rsquo; estimated sources of the current distribution
paid this month and for its current fiscal year to date are as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Estimated Amounts of Current Distribution per Share</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Distribution<BR>
 Amount</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Investment<BR>
 Income</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Short-<BR>
Term Gains**</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Long-<BR>
Term Gains</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Return of Capital</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; width: 10%">ASGI</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.1900</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.0133</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">7</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.1140</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">60</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.0627</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">33</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">HQH</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5700</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0456</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5244</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">92</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">HQL</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4700</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1260</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.3440</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">73</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">IAF</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0180</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0264</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0756</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">63</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">IFN</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4600</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4600</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">JEQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0242</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0858</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">78</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">THQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0198</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1602</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">89</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Estimated Amounts of Fiscal Year* to Date Cumulative Distributions
    per Share</B></TD><TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund</B></TD><TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Distribution<BR>
 Amount</B></TD><TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Investment<BR>
 Income</B></TD><TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Short-<BR>
Term Gains**</B></TD><TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Long-<BR>
Term Gains</B></TD><TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Return of Capital</B></TD><TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%">ASGI</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">1.2000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.0840</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.7200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">0.3960</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right">33</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">HQH</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.1900</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0952</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.0948</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">92</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">HQL</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.9700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.7100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">73</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">IAF</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0375</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0550</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1575</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">63</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">IFN</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">JEQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0506</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1794</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">78</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">THQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.0800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1188</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.9612</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">89</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">* ASGI, HQH, HQL and THQ have a 9/30 fiscal year end. IAF and JEQ
have a 10/31 fiscal year end. IFN has a 12/31 fiscal year end.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">**includes currency gains</P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where the estimated amounts above show a portion of the distribution
to be a &ldquo;Return of Capital,&rdquo; it means that Fund estimates that it has distributed more than its income and capital gains;
therefore, a portion of your distribution may be a return of capital. A return of capital may occur for example, when some or all the
money that you invested in a Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund&rsquo;s
investment performance and should not be confused with &ldquo;yield&rdquo; or &ldquo;income.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0"><B>The amounts and sources of distributions reported in this
notice are only estimates and are not being provided for tax reporting purposes. The final determination of the source of all distributions
for the current year will only be made after year-end. The actual amounts and sources of the amounts for tax reporting purposes will depend
upon the Fund&rsquo;s investment experience during the remainder of the fiscal year and may be subject to change based on tax regulations.
After the end of each calendar year, a Form 1099-DIV will be sent to shareholders for the prior calendar year that will tell you how to
report these distributions for federal income tax purposes.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27pt 0pt 0">The following tables provide the Funds&rsquo; total return
performance based on net asset value (NAV) over various time periods compared to the Funds&rsquo; annualized and cumulative distribution
rates.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27pt 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund Performance and Distribution
    Rate Information</B></TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Average <BR>
Annual Total <BR>
Return on NAV
    <BR>
for the 5 Year <BR>
Period Ending <BR>
02/28/2025<SUP>1</SUP></B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Current Fiscal<BR>
 Period&rsquo;s <BR>
Annualized
    <BR>
Distribution <BR>
Rate on NAV</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Cumulative <BR>
    Total Return on <BR>
    NAV<SUP>1</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Cumulative <BR>
Distribution <BR>
Rate on NAV<SUP>2</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI<SUP>3</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">8.10</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%<SUP>3</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">11.89</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">-2.55</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">5.07</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">THQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.04</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.27</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-3.71</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><SUP>1</SUP>
Return data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under
the Fund&rsquo;s dividend reinvestment plan. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of February 28, 2025. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><SUP>3</SUP>
The Fund launched within the past 5 years; the performance and distribution rate information presented reflects data from inception (July
29, 2020) through February 28, 2025. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="16" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Fund Performance and Distribution
    Rate Information</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Average <BR>
Annual Total <BR>
Return on NAV
    <BR>
for the 5 Year <BR>
Period Ending <BR>
01/31/2025<SUP>1</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Current Fiscal<BR>
 Period&rsquo;s <BR>
Annualized
    <BR>
Distribution <BR>
Rate on NAV</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Cumulative <BR>
    Total Return on <BR>
    NAV<SUP>1</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Cumulative <BR>
Distribution <BR>
Rate on NAV<SUP>2</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center">HQH</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">7.34</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">12.70</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">-0.35</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">3.17</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">HQL</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.83</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.75</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-0.76</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.19</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">IAF</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.09</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.57</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.94</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.67</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">IFN</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.25</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-5.95</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">JEQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.41</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.87</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.51</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.72</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt"><SUP>1</SUP>
Return data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under
the Fund&rsquo;s dividend reinvestment plan. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of January 31, 2025. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>












<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 25pt 0pt 0"><B>Shareholders should not draw any conclusions about a
Fund&rsquo;s investment performance from the amount of the Fund&rsquo;s current distributions or from the terms of the distribution
policy (the &ldquo;Distribution Policy&rdquo;).</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0">While NAV performance may be indicative of the Fund&rsquo;s
investment performance, it does not measure the value of a shareholder&rsquo;s investment in the Fund. The value of a shareholder&rsquo;s
investment in the Fund is determined by the Fund&rsquo;s market price, which is based on the supply and demand for the Fund&rsquo;s shares
in the open market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an exemptive order granted by the Securities and Exchange
Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section 19(b) under the 1940
Act and Rule 19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term capital gains,
long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while generally taxable
at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed at a lower rate
not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in excess of investment
company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed earnings and profits,
and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital distributions exceed
the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the shares have been held
at the date such amount is received.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment of distributions in accordance with the Distribution Policy
may result in a decrease in the Fund&rsquo;s net assets. A decrease in the Fund&rsquo;s net assets may cause an increase in the Fund&rsquo;s
annual operating expense ratio and a decrease in the Fund&rsquo;s market price per share to the extent the market price correlates closely
to the Fund&rsquo;s net asset value per share. The Distribution Policy may also negatively affect the Fund&rsquo;s investment activities
to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must
liquidate securities that it would not have sold, for the purpose of paying the distribution. Each Fund&rsquo;s Board has the right to
amend, suspend or terminate the Distribution Policy at any time. The amendment, suspension or termination of the Distribution Policy
may affect the Fund&rsquo;s market price per share. Investors should consult their tax advisor regarding federal, state, and local tax
considerations that may be applicable in their particular circumstances.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0"><U>Circular 230 disclosure</U>: To ensure compliance with requirements
imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not
intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii)
promoting, marketing or recommending to another party any transaction or matter addressed herein.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0">In the United States, Aberdeen Investments is the marketing
name for the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12pt 0pt 0">Closed-end funds are traded on the secondary market
through one of the stock exchanges. A Fund&rsquo;s investment return and principal value will fluctuate so that an investor&rsquo;s
shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a
discount) the net asset value (NAV) of the fund&rsquo;s portfolio. There is no assurance that a Fund will achieve its investment
objective. Past performance does not guarantee future results.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Closed end funds | Aberdeen</U></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">###</P>


<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0"></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2516624d12_ex99-xcx1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2516624d12_ex99-xcx1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !- ,0# 2(  A$! Q$!_\0
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M\OP^\G@S[/+M\'-X&\&+X0/@3P4 ?UI_V/I_FC_B56.T'[QMU(P/*Q\N-O\
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MO^&[I%9@-&BE:-_!TR>$(U\H>$?!$GA18O W^NA0!_.9_P %QO\ @N[\)?\
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M0=#T?PIHFC>'/#]A;Z-H6@:5I^@Z-IUJ MA8:7H\2:3I&DQ]2(XTV1H!F0;
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M@^+?&G[7?QM_;1U72GM_AE\"OA?JOPD\/ZI=(RM>_&'XJZGX?G;3]&9D&_\
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M/VOZYX>\=>!G>XC,>DZ#XWT/P[XG\-^/- B@EV!_$L/@SQ5;I&(V'BV037
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MBL+@RVU ']DU%?QZ1?\ !0GX[_%O_@O?^VYXCT'XX?%'3/\ @G=_P2:_9?\
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MB@#^7S3/@=_P46_9!_X(ECQU^RK\(OV.?AY_P4 U/PSX;^,WQE\"? ?]A)/
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-Q"V_T;:* "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2516624d12_ex99-xcx2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2516624d12_ex99-xcx2img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ -\# 2(  A$! Q$!_\0
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M '(QFMN+QQJO_#.\V^=S<+>#3A+GYO+(W=?H,5I^*/C+H#)'9^$="@NKV5U
MDFM% '/0+C))Z5V_BOPG?^+_ (5&Q:PM;'56"7(MX  @D';ZX)% 'BOP_P#'
MWA7P?I@%WX7FO]29BTETS(1[!01Q2?$+Q[X7\9::!9>&);#4D<%;D%0".X(
MYKHOA_\ $C0_"FE_\(YXMT81W-F[()OLRNV,]&!&>/6M'Q+\8M'N9+:Q\&:#
M!=7DDH!::S7##^Z%QW]: %B\=:C9?LYQ76]C>O(=/64GE5R1GZ[1C\:M_!OX
M8Z)=^&8?$.L6R7US=DF-)1E8U!QT[DU+\9Q<?\*>TY[RQ@LKI[N)I;> 85&*
MMD5VGP?_ .27:+_UR/\ ,T <%\:/AGH]EX:?Q#HMI'9SVK+YR1<*Z$XSCU!Q
M7H'PEUNXU_X<:9=W;EYU#0LQZML)7)_*H_C'_P DJUS_ *YI_P"AK6=\!_\
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C$1C8N.!6M45M;0V=M%;6\:QPQ*$1%& H'05+0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2516624d12hqlreporti001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2516624d12hqlreporti001.gif
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MT-/3T]C7U]?8U]?8V-O;V]_@W^+BXN?HY^OKZP
M
M                                                 "'Y!
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M?V:RJ0[4/_V.9P<$-2 "ADIJ&F "8.<#0F".1A $.+@G65-BQ0?*GH*@XCQ
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M?.FRE4J5*!<X</!@@<@'$208-=J+XS8*V)IB?(IAPP8-4:-*O7HQZU4,T29
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MJ&8UQ91:9[&UU 14!@HJ+[P&X^0$$  Y[*J%$?J72(0=%I1(*"&*4F2M('
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M((JW,79DMY#DI3$@<X^J9H_Y4YL9Q#_M)'<&DT\^^(\38UWJ%$[7E5T%R4^
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MB4S4"W;PC1-/KVL !0@#@H." H2'B 6$!H>,C(N(AH8#DH23A "6 IL FP(
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MVCNUE/YV+6[:YE86MZL^_MQSD%,GW3C88?<-NPMUU]VH])I7GGG6[*?>OM;
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MDTR"U,(AP3"&[HBH1*<& Q>H  4B:-,$O*$-+A71B&$;UP0B,#;EB,L"&^A
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M!&S+2%"&46]HH85@U1QD(RX9\!&"6!0@< $H$9,!-F!LF).F9X36EGHZV7I
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M^W9:2V<@TN0>A/;^C+"I<P7X6@M2CN@!,(50 "B23L %J/=H3K_Y,0M$3[@
M(KWI(0?4J)E6=LOI,0$I093Z,@89=QT4(=79D+@D>3662HZ1%2!1A UUD>,Y
M4>8Y-31@7B!9 E=S 1&0'5[I%^B2HO1&EBVG6 B%-H9B*#\D 1J@%$/EAPEV
M;0SZAM6&K#YYH%4"E ?*AG*XAM&:H-"*H '*13^U1A/Y-F:DK4JU&2#G5%#5
M6""*;WO1I:."(UKE#9(W7XK1&&,U*WSY&3J61H;3ENO6%!MPF("E+!HG&Y,"
ML*8DL$ZV9'9UL)^4L*YA?B#W5]E2<$M4$5]6>67I',MS4,_S?%=Z2Y'^U1==
M&B]SL6*_-##16![Z\1[=PST]ASE')[+8,Q>FF0BKF9INYF:#)IN:=8[0*)MY
M^IH$2"/K03-B]PF"ZIN$"@NBT)P51*E?IX( B9R"@)R.)D^%RG8!>0L8E(/'
M@(#B<YU:U56)>8H'YQ%OLD*X)GCIQ9%(4P,W(%'F20,8^9$M4"4L!:M!A$<W
MLE5L@6S!J%CU)HP1P&P;5BA7XAE)L29P0GH,NH;-.JW/^KC2:JQNZ*R.JZ!!
M2919)&%,R5\_-8B%J%2,HTH;D;''Z"[GRDO5HP#8(6P)D2I@]:Z^@RRHPW ^
MDE9+41*!LV[O96.CXZ\,^Y<;QW["NWX%&TK^Y:<[1.2CK\%7?O4;CJ&D@K5R
MB4FQXT)CT+&(&GL=G#,Y'&M'>J0ENI0]-0(^!&. _Q)0.E-:Z[.^-K*FV7 P
MW<@,["@-$B.G&:BSZ3NR>MIF'!@>JKF.S$ BBSI<PF5<PQE!C\JT8&=VI."H
MQYFT)$*<6(M!T?E<;]H]EU-JD4=(-2:VB!2("X5K17->XYDT-H"JJ;JJ,#"W
M5M,FL6HY*I9W7N, +1<=P?BWG>$1-<HF-.E2,2FL@A,G5/230SFYUW:'D;N@
MS^JX/^FLT/IZDVN'F2L";,DGGDM4WWH:4":N+C<=_#<YG7*NI))5WP .@X1J
M95E8Z(<[,!JC;'G^N_MI%$RYKS;6++Y;I+L39<,+/+FX&]4BO !K?A[GKV!!
MB[7(I&GA5)?W5;,4'5'%B#ZHI95S9MQ06:()'N=#=)EYO^5#C9_2OJ,)B?^!
MJ?*;CK*%(($V#5.7LYC)<P68OG:'.?]['Z0\D+% =IQ M<'%,<5Y:>Y$=E$+
MM5#+P !)M>8DD)I6"Y8ZG?'X/00X4'_15:][BO&:;D!2JC.0JDACPFL;4>:9
M7NS5PI6"?-G0I9%)'0X N%?I91! PZKF=_G*4IT!>H<[*&KB$U"\Q,L:N0;Z
MN-'*Q/P,N=4ZAP,MN7BRN2& 4X,"E5()KH%Y',Y18EGI+J3RL:2BE97^Z%@B
MM9VQBV.,Q'!O#,3V+#@>L*_=<DC(*XN_RU0<QW[#LQN":3R'E(LR/19*VAOP
M>@&NDM,BU[Q_51&ZV!E:-A$>.D?DP'_G4J[(6)+IVF]515DY1UIAFC,G>S[C
MVQ_:&"K?49D) +_]TTW,4#\URQX^.QZ_E%G^VV;/7#!>.G3K\4WO,T_U2,"-
MAEPB(JE>1PG -< (5,Q2NS&0^M<A IQX_0LLL[06Y*?& ",S,D+7E1 !]ZF
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MJ@?S=F[^ 'V@P2W<V<:4(7&M%&;;A?@HBP,;HEOH:S'1DPF^@*"P(+C0L,#
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M>^@!(! =:1T=F9$Q:5V60[K*<2V^+;#*>*F7V=$A$U1!%4-@U@Q"9Q0/6\J
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MGX8H8A,]]6,1SO,0'6=S,O9)\I(M"1:1)X=1VQ)2+'@_R.,0*N91&0A2(+F
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M\G(5@E.?%:$4U-0/Y.1-5]$0)9$L#:5 Y/- \8D3*X:1*C8O[.A@Z;-Q'\F
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M4;KL<BQVKPP87^S(/OTF%?@GS)9B$2QWS"SGKI=M%04+@_K(3G9!8#LQ&0C
M%)J82+(=UN@@9)ZA-W!9 QT+SD*9&N]QLN6!SJ'*JVD#S_6,.ZH$6T/*F!37
MF-&A2N/V)1KP"<-0"K):)Z3 (85I>S+" 7)VT >-M(!&'W:(E@F]9!$-T39,
MB&JJPSHT>%$'(8M%:8]5.4/,:9?E#VJKWR0]P5,MJ'%+6BH-J9OI'U#^AK4W
M5$E,,R"G^*:KR(H[/;BF6;B56E@W$M1#?<9'C8:,6QX@\ %,[5@9\N%.K2'8
MMU6K0)Q7;8WDYL=5[:-\4F[-^=7O?#NY4WYJ0TVO2WF#9*RQ^RCY!Q4;IRG.
MDQP9@7&7;*0 L7[X<-?=$R[X^Q==@6,[Z"K7FEMR$9\O=TYGC5GLZE["QI%6
MKJW:B[S%;  )P;[R:=B^R8 -UF7MB!#I]1$6@;X744Y%82G*/((8"12Z?.=?
M"#WM T'_)\W86G(+MX#XI3;L\$PMLJ);-61%N$,S0# U, ,>N\"I493F;!TJ
M^S6&+$V;.'YIP]Q?%F:5X E:4DR &KK:,-W^&V#=>OS$5$AG/ W>*QR75B9H
MY%TT9JJ7Z7VF?8EZ>E6(.)18@YE'GBOC?W2G('U-Z*HB)4UNH54RA&I8D#IZ
M?%6(9GJ:AW TN"YZ4N,(/DWA/@V:<&3A<(3A1%W&GA&E2%TRG!&WM!?";@;5
MM^#/G[COEY8*D&6<R-35D]/B7#TFS.F<[_Q,(0*.YT</E*?(! 4IG7)A\*<^
MQV,42(1Q 5$]8[-?"U !/N=?4:Z2[B)"@&UP FC*&"D7F%)Q8J,^!M78A ZO
M!2J"Y8H0*O@J*W:"_WCSZLC(FXU^CA+D<?V\]UK8E)U/#AAA>8I.Z,LM D;*
MR"N@.G_8T $!O4K^7LXWA"7 "$FE&CWDDSU$LK'Q-%LD"0D?Z@%5S_D"6VA;
ME37EQ$MIF/T2C:Q0)UD2Z]TV3'8L(S?31>JA'G(H^.L1^(Z 5N'N:GP)T7IE
MEWRYM:BGWEX;WQI](;:7#:"*).]03="^%&.'2K+DB99&,J.E:@1NMR^$P]R^
M=\%19'S)X"M\6%H\X10.QH.;(XKU>I=*6F<LMVJ<-2*<1X0YIW S]]Q=F/[>
M[_\.-WJL#>*&C=YE;D('6P LQ]Y87H?R')W/?G(=K>S(,9,,?W&]\=D$N_A0
M 6,.GP"44!XWO#'VK0-(41E58M2\#[=94)[MV/G3+F6NK_U:V(!P4'#^8&!
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MLY4[PE,[VJ!0TN<3FT2(Q,5;J<%Y.Y$7S^,.I]=**H$;M+=AMD=_U6$Q#K
M9,$KG:A[<W(^Z8,-ZJ1:)H "\U,_84)/[0 /*U!/,%!/8<A/YI84*\ "MWB+
MAG@J^R50U.<4!75]I_$0('!LC-)!6_$1^K8P#6,/N'(0TN9PWA-2)@12V  7
M[G>-G152V A_)?3^?L=1:966ABA$ 79G:! 3,="V.9O3#]@Q/C9V-MW!<3CD
M(GR58N_15XIU8FHQ,S<'@11X'PKR,PNB( (I9$LE<S4#5<3P<R"(2(Q ,KO
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MG-#A2#MZ/O5WJ?_PIIDJM\UQCHU%=XW5G"QTJLX9)X2)?QE31.^H'9O^.$=
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M6!AH2%_E(UAS(5FF-ZD;1OV)R"_R->V1N'FV4S?4";/0"7B]R587 N[D3O$
MY7."B8-KUQFGO&BM,GD"KW=&@SQ"GZ/@=JDL=WG>4224DAS!,.A3P=G(4:,8
MI"N\0=ST26"1HQ)S9^2SIMDH$O'-$6=[C> E87])0A;TYHFMI-D'$8;NH(NB
MZUDZEY/B$[@8 RQ@P 8,?8^!3=(U*SS_2<Z(W\-"O:/S$>*%P;-DS[;^OFC:
M!GUKDA>T3NNWSL^-:(JP9R[AHNL-1!HB, (M#!%P[Q7,02/ZX#=%R1;B_NV5
MZDC2X;/YS4+Z_2:5"L57. TA+2PB]B8@=OIV1M)T0L5J:^ NK0E]RZ&,F0OB
MM)@LM<:]7[CQ$40Q]NYN]$/R.N]_-!^06]/]D 'Z3C-QS%0!>9$])D6>*]6@
M>_") )2I4)\FZ AIP_!/ R!BM!]K0QXSU<D_9.0_#1\=?^4GAH.BHA<T&@)0
MOA:X]XYOIS0Y[5+;6B47"@@+#@\/$1$."PH*!PD'CHX&!Y$%C@B6"PL,#(0/
M$!,3%!<8&QL<IARD&QBKHZ6FJA<4G[.?%+;^%[BBN:(8IAX>'[_ '+^GI*.X
MMK86L;,2A R8#0^@HAJDJ*BI&QJKNZS@X,FAO-C$Q,+ '\$?(>OO[>WIVJ7
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MH@MNEWT+8+U .K9C"]8NV/H0^' ""$]5KO$?-1:2ACPTOG^\09Z['@,>.54
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MNR.%NG?<+'$OS*!C@-<4C&'*29AI2G/12CPFF=D$2A4G6.!T&A@RYL& @E?
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M';9AZS=3ZB<@<$$R&-89O\,]S@-3K2)_&_)!-Y4A3\%_T70(0],A$7 !_P>
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M6N]A6B6%A\]$%<0 1"D6%54A?U3A$)+PCN*(8YU#CFGD.38X9!=)0CRF,8*
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ME^[<^)OX') (;;!N7THKIFT*M'IY?*68F!0DIJ]H7TZK +,E?ZY# 2N@ T&
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M2:I,Y;U%.02>E]()^()7L27N WKGXXE#L/<1YZ!0?1!KP 2XB E8)$,I*<A
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M1J]3"UK-;<E&R061B:QA"&KD2)0X>Y,FNG%HY6*W&C#B)'>[BSO:@7=0I'Y
MD[6,WD,1U:SK/2M*S(Q/4#4GP/:="<0^4CU.S3/=[J640"\UD?^&3'L?4RB
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M!QU=95;" S6>,E\!IGZ?DCZTF!P+X  9,1RZB!P3HT_OU(N>HD_-PT__U4[
M48LJ(5_'R!']U'X/4&H&XQQ]LSJSUAT7X!@:I0"0\3 V,2J7PA +$$(%4$#A
M6( =5RT@%Q4_M!A[47)\$64R54#1V9QY81;RV$'IXH(R1A@B1!@2%!?G8A'\
MN&Y"X7\,< $GD%?^46B,  $4X17<R8#'&19<\70V.&88Z6T+4IB&PG0-@9$E
M0PHMHH=+LDF#$R/5MI%+4EU54R$_AY) $GG^VA$">.4",%0#-+-K/]=';>-<
MBA,@FJ23W*0DDE4A9"@,A7>&A.=(/W=):AA:E].(Q;!X<8((Q*9:=%B*ID8!
M7CA*>A@CUP0W!%IWGR>4O46(8_E;HW>(9DDYE)-IBH@Y8$(VXA![(R)[)=)<
MNT<(SK2@V34F*HB@P'=MP0>8@_(.D$!>A_D[:DINAN(2X<1>2N1>L6)O/N%.
M3@02 !8QNL$]K%)]C,(\Y^2;N<@]"S42(;$9R\%/J"D1SE@H)"&;BC,+&&*;
M@4$L_J<I^D1.P&D7%$2.Q!F.(U55=C$;/25">D%!J(I3QDDNJII3W2(96Y$N
M4F&=W)F.B5$7 \7^FZQ"<;@1 <!@(7:C"1? $5]!<Q.$& ' D G FX^"D55G
M==!JF*<8/OE@=0':(D&JH$3"DP?JK7[()/9W(3_'""FI"9XP"#;R,E.8H3.)
M>QQ:=XI%.IND>1Q)/[70-5Z#"X*7HH2W(8>7"*_72RR0>':C"H1P(SERKEHD
M#V<F"A#5HYDW.V^C"K@5(5Y9:TDZ>AM+>E_$:\*EB,*%E#&:>& 2;)1((E=:
M(LOFI8DUE]#F)*NW>LTE.ZB0)WNI >8@A']BICQ2"?9@7M3JFL 3M  U3O0B
M=/:4$*924-[C$:A9B_IE'+L!< 1U$YPI3\J17]'C7OQF,9_I3N@39BO^ 58@
MT2C<\Y\24!P1((T1I5L80@%0\2T(\'],![0BUJG#":I[6XY6=9N#470MM:H'
M]"PTMD'<&:M?4:HF%Q4X51?UU1'^U !<X7\/\ $8XJ!N<P'NR4/E@A@?-RP
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MUV9^\V=_@H%O=F%O C YEF,-B;=XT",M^ -_8Q(_CF=PX$!>H$*.$/1P.M1
M$]=J!)@O(C8=9]8A7#>/-CA4)/4=249"+\6&>V,# +E(*1<<C88+0O&$":F0
M034D(N-'4DE4*@:/II(<VD%"+_B"&)F1T %D-EB&1P<+9FA$W1$>OO$C4R:$
MBS8=4P<:Y B=*T8P--E=_=&>42B4'#I76&A"*K*%7V.47(AV96,):/,+7YA$
M2<0V3 F5!!IDK6#^,(^F GICE3*6HY6E A4Z 0A0AX?'&652?\<9<)^F29)G
M3VYY%X]#:I2C&>-46I\7>K\U&>GVF*:(*:L')^U $0U!7.LP*+#2;8R"7.X
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MLB80M40G"@5-^:#^IPMC39R925T2LX;KC9/D+N*F*UEQJ.!#7OK3)MXW4.:
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M:1/) 7+6!KI8B057INR^. K,DF5(%^L;EY:D0IH4=\B-H#71VSAA_8NRA@?
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M[.V;?_'>F;%P:;'^>2)-.N+<?==NW_KS4."<:\]HTK)9+^P27*93P^VFFM?
M.^'H%@[.)\0RQ$Z,;R5EX;R#X8_9#QRP%">P E*=17=8 XW>Z/Q1#%W:K@+?
M5V?.G"@RU0F_\/11 FNV<5IFR3G3Q[KPXQ?O\(.LA$_&CD1893ITV!.\G,R)
M@D58\E"ID;7@K?<!D"W_NS\?K5P$""4?'!@4$Q07&QP>(2$B(B$?'AP;&Q@8
M%YF8EQB5'(L>'XZ/)2:F*2HJ+:LM+BXQ,2XRL["PK[6VKZZQN;RNO\"ZOKW
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M0NH>U&VZ!2FT44>96I6=2R&U%!-+GGYD"*<4D!SJCXH\_[0F3O6DJJH?/;!
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MBMCJN^5X-I:>%R>^= M49GIE_EO/H<JW)E8?FV&QHZ30Y:AQ3F$-4>>*$0"
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M5GPD4+B7*Y35MR6HD^_+7ZCX3X95%_IR+Z[R),V(HGQ6#?C"&HWE)7:W3]Q
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M3U\!&F9\X/'RI@.D"6A!'RT  U$;9%);XQ&/ SML SEP SFN\3FN SG  SS
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ME(U",5@!NZK3G)B1[( =Z17(5A,LB=RJ  0X5K)BPH &.(!9RG+  QS0F*
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MY!C4H 8VR(&2H.0YSBT)=3*EA9:P%2-ZDP@4OY#8"N21.X1V:@4;6("%,1R
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M>9R\ 0&@@$ZKT'-!"70(575)"5%.>6,R)H76(#[CD"@3M0UIF2@_9@Q5*1
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M2??2IRW R80K]5M,6,A2@QJ(IBCEVI$((("S-#EI$NUR%[O@1;E"T*M>!,"
M;$(&L8>)ABA"L0QF!":PRH!F@YP!V$^.X[ 81LR"87'-;RY&F]K8)B8SV9%
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M[N9.+G)'(O8AY',,VP,@*A #-= L0<<T^;,]'K$<?90#.I!%_U(Q*N!'D\5
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M_\B'2YJ*$YV(;5R/C(^WPM:?46*5 %N5Y+FL$MP:FA8LP.D*,2_+QGJM!2Y
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M<C*;IH:]-+)J*K,YRUJ)*0,:QE%KJT"^H<5"+O0-"5 =]7E] **=FPI#TD$
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M"WA# Y=6]W(6^[*2#N<7I;D^QFRC^S<9MB:WI7AI\K9Y)**.KO=IUFP@LSB
MC 5*MU?-*P,:EO6?K^2LQ'3>#$,JS)%5,28=[0QHOV:=T9??\BP-46'/1_&M
MS<@TWXDILF51^('^ON"(OK,,P?#!GNWBO<0#;_;&X&QQ+3Z!9YE428=WNFLS
ML!3.2@9[C^X6)AK>1!Q.XDZG/OT&:2$<"D42PB0>8 R.I6^S((57L 8++RS_
MXO,B 9\TXZ+F-QQPXS[@TSX=!"F0,*)X2Z!@.X 3;P#H. >R&7K="2U@S%&M
M?_1D3R,9I/S$M+= *UL7=@;Q LER4Y;0Y3Y-!$$ !'88$[1B"9YPYORE"&/K
M-<R'A/91  ?UH'7].A+2(1C7T<N,['0;4G#HA2S%U8'"9$WV9&-(96J8Z'O*
MIV>G$BGJ<BXQR8$:J#!AR9A<J*6]"3"P)UC7=;-""S 0RM6"-KG=0^[^?4R2
M(ZHMSR,K#2[AF"[8]MK8!GD#ER]DE9F!)HEG=3F(A@D?GB1P-3"+$<PD38R3
M06G(SLP@'46I*#B\Z7HJ\IN'-1NRB!K4SILS3&!F)%DA6Z&^P2&Z419RU($[
M>HRGG+[L_&?6 =^+)]_3&+_:.:[;>37H<8W+-N^]1?[P^. 4K?J=:IGSXC<#
M^'^ \(%Q,?&0D&! <&# 6'#P:+#X^)CPB'"0H*"YP-G@V<#P$/H ,4&!@;'A
M\2'2ZMH:$AOK6E);*Q+[X<&QZ^'KR\O!J^K[8?S!@3$!H0 923EYB("@P-GY
MR9"MO<  FOT +F%*<4%!43&1/K[!41+3$R3^)!2D4Q+,L<&^@9J\/'YQ 97
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M=+1(3  M&I!P1B.X\DBN&  ZASA$J()C*ZSIKRI4*X7_2N$A"$U@ P])P7?
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MH#2C).%8H 0]Z)5X]R45P2_(!@A3)(Y7IHG6E'F"\$]6VB>)<Y[($9:59"6
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M0N42 BU0!$90!-<H?$%1!#T0 ][! 100 0X #JAH(#BG'\4R3*JX 635: ]
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M#B,Q&Y,"JAD",, #ZRD/11 $.& /(=<=L,6F:"6?YEN^4H$@@F @%=0F_+0
M%% "JS$NY#*/]!AX)I"@"NHQ@71%@,&,+A "$W \'G !AS"IQE,T53(_#V
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M@ F48 8 JXMOBF&,%90C!29H@;1BT +>G. $NT%&2^SW$O?U[P/2RXFX[O&
M-R5B D 14($8$YFC%"!QC!L 5! D,@XA:  +"($+8. OKUSD+ WTP5O^6A4.
M9APL86T9BUS<,K <3&L%*HA8 2[QDU20(EV$H1YB!(&8$\UM $U,D.)$])C,
MJ,QT*_M,[$;C&4[XSC2?^$P$6O.:V%2+9POQV<]*LI#;'*>2M.'9HI13DJ5U
MTEI-@V0DVW&J7U'M'=F!4N^DA!!24O Z8(/=>=;V'EKNB1/N420H6N8VXL -
M?1>@&Q$A4Z0C%:@I3]2C,@$W@ 8A"'!)F1 !(E,AQ2D.B?,J452LXB!Z[<=$
MF&,1BBYGQQ01\0"I4Y?G'F&C'4VB<\G;D2(:,*1Z @F0JCO%GB3@.MN]KG>?
MN1WN"H4H\MG.9J#HV-C89C'A.;0]AOB+Z9#^ISP=N?,2,VJ$G!PQIXJ!XDY@
M:L_V;%)!MSWD.N*9FNT*6@M%;20=+0 '_2"E#9AT(U?V P<W;,H,494#5/WK
M'ZE*)1"'A* &28!"$IC !"3HX /8>44_3,# 5_D@!Q&<C70JB! .=( #Q(&%
M.^[A  5<8 4AL<@,TH@^;;50!26AJOW0PD(4QM!1\GM?.%+@ 5^TPTH7B,";
M$F0 1:1H9$F4S!+WF"![1>5>!J" "K:AJXOXJXI@\4%<",:M&MR 87'9P5O"
MJ$6'M0!B%V@ 1]-%,=>T1A!T.@P0<8F RT6N*$5AW..2TI@^7H)TG4ED:.XA
MFM.,K64U0TQ@<K;^,TU*$H64!$XEB6,<3?HR:<583@E""<FC0:V4IK3.>,S3
M); I$"'H#=3X9+D=]=1I>J41GBWELP%8U"=N^;'M,!\C1$*DS(G*[*8S"0#-
MQP2N;X@]D(809TV]Z:5>"J)7'X5ISC59>$U &D7*X,EA'<D)G^IBQ.@&DT[5
MP0A)?-*:+;#VNBI%"3OAHY)!$16?,BW4,/*=KT,+,8K6! D2[IP$12WJ(R K
MP$>)$$2/KR>*,CU)'R4]*>[J>U*"%I07#4&:2E0P0_K5#U+Q8]\U>&K31XT#
M!C& @9I#Y=-D"/6T D%.#(H A3HC8:E("(((K&2K8[B@!FK!@0UXM5W^J$VG
MJ\(R-$0>H+(0@!!@,4@C53ERVD=F=[*5%0D:=^/F:-GORWP-02M^,PO8,5HO
MD%D,8I?XQ*=@*'$';FQ2$/"!;2RK*S3@"E=NL(/2<G:*SK#!P';0EM&N)2YO
MH4LRTGB!Y\$1 HF @)$R-D?=*8:<D>NFA434'SS^ED@/\$7+?"<!XK*,9ITP
M#,M.P=Q'&N<VN=D-"F>#R4H2S3G'2<XG.\EOD\#-:<#QGCO"2[54;J>\B:HO
MH%XIXX**#3ZUU!)[<*R]T+!G/F^SCS&"J=^Z :A(?AF0@384X,HLJ)D):E"'
M)F3@"UGSY=ET%S=G?F 2H:A%.EJ$CQ;1N5+^Q A-0/HCZM*))N 5#TQX&Y!(
MBRO0E;Z8?+^ <=4&U6(O92FD6F*;TLFT)]U!E! ?'9#Q2#%1Y'4.$Z*KQ(>'
M+@KC]3@5>B(;=X !Y93> @,#A^7KH*P0$>A,&6;6ZTO:1V9P6,-3FGJ4.<:Q
M#/WI+U3*&"H:J:J#)$2ASDPE8!+R; +K*(0C?U9+#F;@@I(8[;L.\=Z?Q$HN
MP1Y@ @P,(:^H>MK3=O(Y+XW6OR)]#!.28W[>6,$P0H"!6=S#)KY;S9LPD]L,
M/=:QKH8^5+JYMVT^( 6YLJ)%JBBP7_,K+:(-XVCCT@-?Q^0NS5YC!\$N[8KU
MY2^I$<0$.M;#Q9C^L[<)=HIE2K0?S>@\,"XS2 'U":91&KZ#7!GS&CKC;L;Q
M7$IC'$<S7?QP>OS 21;('$737:B7=U-3'0;''3/&"U0&'N-!'IYQ'K-D-G7R
M4.E18ZN0:,]1#/@A3$3$7W[Q$_VA?P&F1"W73("C<KP5:U 1 !5230IV./*R
M6Y6A38M#?=WT3>!4(YHA9)E .BC#==239"5F)$7"9$J64&"()$[&"6@#@N(C
M)6B("U 68^/C,M2S"?I4)D:G/>U!)D=")D;G8U9(49" /)GPAT&285Y(/ Z@
M)UTW=^)5-81R$"788E8"5L1@ LA 9O7S99&24S2$B61F#2T!5)X8>:3^(@,^
M  514(J8IP0%A 1"H *TH$ AH (@I!8B06BB]%VVJ&@6X!>:X0$S< ,741>[
M 5,M9 RFMUW&>"LQ)0-FY (R) [20@VYX@(OQ X;X#L-@ ^&D0BU-3(.(GWW
M(GT9@B%5X1A*A"\;X$5=<19GP15I,1=E,44Q\$4Y4&QAD0,-HQ8SD SHIP"9
ML1/0UEJH("#4=AC2UC(/8'_@=!G<J%M]<QE^E#KA-@$U06[$Y1F\8TC)%7(,
ML $EH!NS 4FXX1'0M5WO5AQ$,WS D1R>E%W+<0+)\1S>96@.D5+ADPLG"((S
MUE*S$#5VUW!,XC(05R>(L8(VMC:_ P$*YTO^^B8W]\=_CQ$815(@E.&$!Q9-
M-(=R"#8 %5*.R 1S#385_T%R?$-]D<$?)^).*)-.]@1R/S$F?V$(=XAT#S67
M6J(:Y"5UNF!EAD)0C/@KK*"(O:!+6$B&=%DV-88D<)E08**'K0%B]U1/0T)/
M&99DQ+-+<=@RLD,[@U(H45<0BE@>!M40YR-#+I%3[%-3-:4IA;>:X@ JC,<_
M0^4"/0 %4A %4E";4= $3(5G!M0"K1B8%R "KC(6P&AZ^'8;]D4<Q2$=.:%:
MK]<":54#I.<1+%%I0).!OV0MVB(#(<%"W*(IV4<.&H$!$J NKI$RFR$R("(O
M]_)81_A\L%8BW83^(->G5FJ%1=MG ^4G6MYW%FFA%CL0%CRP%O;8?3$!5Q;P
M)@K &IPP"JP5<JQA;3WT"-C&'WJT;=^$&2<#;IXPD3U1D9\ 'Z!AE-&& 9+H
M;CR#&QTA;_3V;L*P*-!A&]@25_M&0OX62L.PG )'07_I@:GD.JO4'7RW<#1)
M=5<F.V,3<71(/8.0I!>G*,BA<3-H(FOD'_]1 %'I7_JA@UDYE@6F<M-D%&&J
M8 CBE8LS+TK1?(J5%$ST1,ET6T2F,O=48AX%44J&-[M$ESF&-D+)'?VTF8!Z
MAFIX2GY)<(&I2$,Y<62C@K7T)(@:7[=48V8"AY9Y"EPGADR:IUVG'F3^*$C:
MX1T6,%"X0SZ>63LMAF6N$ +%L"\P,2G@>5.K&3^%)ZN>N#]!!1)%D%2W:06U
M"05-  5,Q01)8 1%X )74AX4\6C%29+*F9S4E:*RX@#ZL0 E &CWV1$=(52Z
MD1*X]TN] 5<H%"W*\GNR2D/+TBR>(0$0, I'MA=AN6!D:CCPR5B$%2$*X $@
MH7W^8@-AM##OZ$6?I19BD0-A(19SD8^VUVS]N!H=XZ . ')L29BX)#$?HY 0
MHB']IR(J(Z>NX25*\J$#^#+"-6X)"!N-0I(I*@(B.6_O-AR5Y#37Q9(I0:/,
ML5T %U91<U)%>AV?B@_X("7M0&6 \I=Z^9/^'5H3AHDNDJH]J4%Q2)F<O[1Q
M^F6ED#$D9V(N4\F--,<@5M%$>01-%8(@BW4A27BF^L>$5TF5#H);*C*%= IT
M2O=UV -VE(JI9A,?36N4[H4>!S=C!3=UFVDH>.F7=3<UNN E1_L>Z;&XZ*&N
M(AN B-JHC7JW1EFY1NFXM 0:$F"79H@UGQJJ4M*71)N7ALN9IRJ"D A#,:6)
M,K6:EM@-@0>[K^F:0.5F@!<$25 $18 $N\JKN8EYNXD$1F #XT(N,+8!QI",
MO.*2R.DV]$$;)^$K$[  !'  'N!9-N"+S] HI-(_;)6=RB%O, 17*\"=(B$_
M."4_-7!&(C H$J#^KBE#%=JV8&,;?:^V6T^4&0E2(A.  OAYG]*)%KW6 _[*
M>#!P%C>  P)+?@,Z1G+A,-YK A90()<P1]2C9!4#?WOB$SHA3OP1,A>J?U!H
M(AP+([[PL3XK&A*)#X8D2'-4)!L 0X\4HRHK;Z9'&PIQ21/X;I&H-#Z<79]D
ML[AW'#OJ-87[@56""T(+7B5XI&(CD4(Y/43I'NI!)B\H'%&; AB0D)GA'_P%
M6R*7M5G9C4[8(4U41!:"3?KGE1[BIFG;6$[X35.(9$279&#''G=Z/8-I)HB1
MMV2XM^^!DU@F*%.'.VDXJ 91J*:J'>\; 3W1$R/:$R#8.Q3 )8@K.P'^Y3N>
M<8(W>9-]N\E5-P']A MH*%Z%6J1*K%(RYHA99BTF)%-H5GB5N)I=5#"O6<NS
MNS_*H .VF6=)( 55D 6X^:NZJ9O#JHHB4!U@E4DF06D21!RH0A^;1$DXT4,&
M<(Z!IBS,,%3+9IS&,))4!5=QM1(K(:Z80E/2H@Q[QC+HR2)\-"&(TYZL]HWM
MB:9-I!_W.E>_&(__$D;XF&:QS)VBMQ;)UC!:M(PK80(40,$+^H_2AB0:TP";
M*]&SI7PM C+*9"%0:#(EO GIB@]*DLD7.:(LG&0QW%S\$)*31)*U@<,O"W ]
M3+,SRY(O";,X&[0ZNX;ALQT54%Q:0RN PI/^1+M>L'.32+NHBHM+B\2T;+,Q
MBE*!SY(?'[-&(A,@23=R4E%$<"PA/\A,N85R9@ISW+2>\IE,/,B59^V$)#*%
M@.28Q70F1K>8#KK'2XNWM50VH$RJI)R&E5P++U;*?VNJERS)$/"^ZNJIDDS)
MG,QB6.,Z4'<[LQ)U=W?(>,F7A:H!C.@G&.0.KZ33_G2ZCX@<?M:J[V.)L2N[
ML-N:MBR[M0J;R\ $55 %28"[L6T%55"*I=@$OTJ*FV<$+1 +(L"M+3M5IQ?-
MPJ"J)Q$"'& !JF4!,%!&@O8,HS)4EA;.T!6,2M,;X=PH)K2^8E8--<",)T N
M[^L7[F0)_7$B3F3^+^48CL]7CM]H<FS*6R=B ?R,$?N,%@5;P"^P+P<CL/4H
M1O?(0AV!%\ZY  S:4!K# /'1$PS>P90P3C68T55A,F;9T>'F.R!M$Q,@ 1;I
MLQ$IHH'!D<V%;R$I;Q*$21&82<>923-+LR2D-"?Q;RT;5IM-<#N-#U[2="WE
MO#BM7OZ$R2M,2X9!<38&7WL"I7 3U5;:Q3586$HG<O+2@R?76&.*E5SK@T91
M367J?%]I356:UM3'WLEDUH\1,I2P<_:$3V&""%NX9%NGITS;J+/S.E>6-=XQ
MRGTMV93-7I)LV([\OAT.&J"9UT5M4':>-2K6"U96*(X>V*;,-0^A 5'^YN-B
MQ=F$^S5=(LI);"4*X<HMD2D'G"FOR]ID9F:=& Z+5[N1IP-94 56T 1"@ 11
M< 52X*NXK=M)505-500VD+PL9 *WV#0@(!VO  +,;!(D(&KE>0'//:!JL;ZO
MN6QPM1'+AD)<9GLS.FDJL )_MT(WE<[2B"@2  IZ00EKM!C-9[]ENEB.);;Q
M/2]K5"+4&H_\K"OLPZ\*@P/ON P6(7IC-!9N048(S6P:U= -R^!^ 8<;L\&H
M82,W9UMX%,(DUUL<S;$>31.RU O%I1J%E'SLC#,+R-+.H1 KRX 0R,,MON0O
MWO(U*\36)9,\:K@P%IBGJF*J=VA70E#_E+C^0HDV2YJGG-JD2&D^+*\"^4'5
M3HX9Q21V(R>69$D 9LYR!-:E()(XV%2V9ENE'2*V8]Y89CXX)J,9)W-DF0 )
M:CFGZ92'6(BI=-C'BTK2C^P)?PX?GJH=*JS)?LKGE2P[@O[(<Y^9W %0CFA>
M4L+GHKJ(B5BJF<VCE0X> ^>C_N2Q.T[)/?[IVA*[J<F:J-U%G=B:/Q7ZM:H,
M/?#J61 %NPOKQ)SKPLH$IY^[/B M/G#0&I&<SL+2LH <Y[-=RPY5$7 !+E"P
M<<'O]\-XVGXKH]+MJ\N,_982<*4SW/N,S2 -RG "HG8!\4'!-&*E>*2>&T+/
M\1W^\OQJDL$B^-K^%;I216U!;&0!$-QB PH\C\>VP)JU60=JX&C/L VZ,0]+
M,1)M&(  ,<$ 4:AP@(AH<&#0V#@ *2 P($DYL.BXB+# N= @03$!04$A,4$*
M.A%Q6A@J*,K \+!QLK)2(I*;^Q'2LI("C!L2PCM,/*R;.UQBTNSL?'+27$*-
MFVS\\>&QS=&]\8V!L1%.?B$:BDYQL7XA[K'!W<TQCL&^3HH^H:\?T=__ ,$?
MP <$"PHD.&$#!P^\<I60EN*"(T:-"A084&"!K 8,%B2@)&G214@8+1FP-/(2
M29("+$("$"FDS) @:<Z4">E  9J6(EFJ5*DG28N8$"%(@"B!4@2(%B#^V/34
MZ8(#G!0D6*"@4Z>.L6(]\"I+UM>" PD6*A3A+%JU; .F32N(K;X*%4Y1J+M/
M@H2V</F]TD?*+K[!Z@;?NZ".76)[C->1HT<NLD*%\\9]^R:/\N3+D.O="Z5/
M0EU3@MLI#"$BQ0H7+F+(B!%C!NS7L&?7OHV[-6S=M5NSCL&;M?#A+EJP#I+%
MRA4I1I)8B9*$"10H4J) 21+]2I4D2)!<1Q(DB! ;+DH0>[<AM8IFRE"+H/9>
M! <*'&;T\.'C1X\=.6C/F,':+]2D8)PO*[0@0X(MI# -@R8 PZ **ZB@0@PU
MT*:@<;=@  %!3B4R%2(6,0(220"<"-, **K^B&*+* 8 0  R2E*4 AO,4$,-
M.-)0 X\\\M ##SSD(%MQK=5@PPTYY-!##SKL!V63/2PY0PLMK'?!APOTTT A
M#G3Y@$8/--!E! _HU<]>(2;""",%G!3339=DLDA6G709"BB@F9,*::+H\\J8
M'-%RI36Z?"#"E2HP*(PQCKIW30@#.N/@,]2<( *FUJ!&3#;:<+.999'5DTYI
M[&# 33R5E9,8/GCM\V= 9PUDYIADS6H6/ PYQ(P)*ES0YH@Z[911+!PQ<$!-
MD[RT[% F^602G"6%!,!-UEZK;"4([ 244'+B)!11%37"9IOEGLO444HEH$!6
M=F[%"4=D=A4606+^D87O __DRZ^^!KVE;S\3F+(*! 2S]8^L<L4E2BNO4# *
M8:14@!@^AS5F3SVC;BP.9Z-RAAG(W[2C<<6@#;R77@^K@P$'O#"C F^XN3;S
M;C/_)O-OP.V&,W'$%=A"$EI<D1P234B11!%,1%%=%$QPQT1R3"#!A'9)"Q&$
M# >J(,(&$&" : G F" ":L)4$\(%']3@0WA!Z,>?;#3'X$LS!P)GI0LR7%C#
M@@\ZF *%S8R= FPV)%A##*N5]T&'8X:XIB)ONC2) "VRR.**U;[(>8R5&/#F
M AI8F",-II>. Y!!YI"X<:W)8 ,..?"W'Y,[2"DE#L"Y@"7D$D30@+[^''48
M/ 2Q[ 60!/JJ<@A2;(*.2$EQ+DNNFP5<I57PJ)QRBCEVF0+Q*'].("@$A*I@
M:"X>A$#AHBG Q^DPO(2MBS&]/H._"<R<D'Y[\C,4#X\])AS>(PS%3D69;7C
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MMS"WQMO(9:N&+;&XR]2F14/ &0$T7-#.A3:'#IW:!@O4#C,V#-AJUU5C1X!
M.[;MV[ASZ\8ME5?3V;.EUD[&2S968,>1YYZZVRJPJ[UF^Z,-W"FSZ]BS[U3*
M3(*$ZSDQ;/!@\<2*%:%"Q8B1OKV+%R_<MU_O@GU]&.KGRV\/RI,,*U9HL846
M 0Y(8!-))(%$@DPT"$445F2Q11952"$%%%8P@801230111100"$%$TE P404
M69"HH!%(*'%$%4@4$4001,BH0PXYL#)C#C:L)T,02A@1A!!"!.&#$%4D6842
M/=A@0P\^[-B"##K^V"!))#%X,$$+/11AA(PVN%#00R4]%(),^## V0+1'("
M7=P,5H@B 2!BV"%W E G(0[ (,F?@-Z02B8]Y# ##)^ $D,-.)B2@PZ%[I"*
M)H3V,(,+GYB 00/F*$/,+\$,(P$PR'@*U0,+X-+F--=48]8A?$5V&38)G-,
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MB6''8>I&1?-R+CRE6O:R'?" #]31+_?&'$2#%<:P;UPQ)B&Q F'A*MIE
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M@6-&C!DS:MBW'T-#A1@V;/0P(D0-/HSW'1 UJ%""(RG< (00,^B A V6>?
M2@9PL]%!T\PC  'U?.B-  50L,)\,\AP7W\UV'!?=SV\&%\+*W!66'TVY(!C
M#SN\R*,/.N80@XPMF(#! ]8\D F2$_ DP2\22 !,)E=AQ<DO*26@4D((; 00
M-^V(DZ%%+C7 P ,-3.#3)Y]0\LD%G+BY%"9:_<*3!S.N8((BB;#E HW^*A2R
M"".",J)GH"*8D,*,B0XB2 J-%F+("26<,*@(?$7"2BR=;,KIFJ!0PM57?K%R
M%EJ@:'H))S1E0M4N$=")4S'$Q 1!5VNQI0@S%U0$DD #&' 2-@J,8\X]Z:33
M9;+QS(,.B!RN<X\[QL(S@#[&'KOA-M,,9-"6!QF )40&J!31 @I5M$"2#R"0
M0 $=?2L-- 9])&\".J&4TDKY2A34F#;]&U<P^%K34DPQ81.32441E5+#)KU$
M9@/ \-(F8*UP(,H%LPQS"R^M6I5)8*9X-8DE=%T2V%EIK=465#_Y$@PM%8>:
MBBM<J75K"%^Q4E9>@H5 6&6)14;998Y-9EG^TI@M=MAEC3T66I^*]=F"#J4U
M9\5JJFFAA16P27$<>U)4@=MZ[+&W6Q/#"2><<<4Q 85R2"CAG!+0)>'<<\X)
M81UXS5770Q!"Y"U>>8-+H1[83 #HHV63I<AB#2E,$,(-.F1'A [@&4&$$$#8
MT(*E(9A@ Q%$X B$"BU(+D&9OPP5DD';R+-. /78'B(\!6!0HPPHWK=B?S?<
MX.*+0+:@NF<VYJ"#\<WSR&,.,ZQ O0D7.. 2!)@H&64$#CP9Y9.7B"^!-5@B
MQ"Y"\Q:4CCP%R/X^0A&7"8Q/FL:2IL9HSH))!!)#P %'X:E0?/(3H Q5*64D
M0E"(<A0A4J"""#[^$%&'D)0R!+473&4*59S85 =# 4*[H&)GI.I*64#1J5G0
MXE53J<G$Y.*+6TS,&,A(QC)2L"N!".09U !6A815@'Z8 UK5*M:QJN6.#ZEC
M62"BECUHQRSVX>,<U?K5MF)WD(0\0UP.88A#)L+# S! 31!(R0$JTBV*?&1>
M'FG(%XW"$GU9 V(-@(!/:"*P@3FL* ]KB<+X.)2CY$0F2='>)4XUBDV\BA<3
M6^0NID26BY4* ZFJ %G*<C-3J24$)7"+FY($I:MH)10W&V&I;+66#([L+W9I
MQ2DXN8*F.0XQBHD!TGPG \O(1VF-@8%G7/""J7EFF* !#8VJIAXH(*'^":E)
M#1>XQC6S&4<*7M,"V(Y3F[<%APG"80)OCF,<Y#2G.7:S&^&<0QW!+4<(0<!.
MW0I7A'A"(3VN468[?8 #R? '!_:)''U,$ $2Z$ '-PJ"$>A6!"(82 6-, &$
MB& 8&X2 !#. P006@*0+0  EZ]M0AVI'#WC@;EF[>T$,?A<\%=E@>#@HG@[B
MXX+D%68^_2D>]'[@(QT<3T8GN!Y*'B 53MSB9>!#TI,X<14*E&]?"7D7^[KT
M)6[$[XP&.1+"ZN<FLAS2$I2P9%8U9LA?-" "'G"4"DR0)T44D#,K2,$"$T@H
M10BJ!(MR%&?^], 4G, 0>FJ$Z")1,S9Y<+#^;0HA*8XA*J>HXH2PZ$0M;)*+
M1;Y*+K#RQ62+@=AD*.,0UGM?-*2Q#8M@PTC:<,>79E?%(XZCBN!XQS>6%2UH
M.5%:3O0'/:1*D/:A@QK; .U429*0 2"D75VLZD1V*,;#PL5<OU7?#CWKD9'X
M42=QY-<<8\()#/R$&&9B@%"&HI(&3)=@"J/N40;F7>]6*"E4Z6 G %99N1!#
M%Q*P"2;1(ECW@JJ54"$%RSZ ,4O6@BZ'A0I7'K'*N]00L"KC;U<&XRBA*4V6
M,J!!#2Q, _KLTC*265IF)!.97U*M,Z&QFA6:8(0D6&$++'ZF%EAL-K%=@6MG
M8P]PMLG-T[CM.%+^X"9TF* $(.M-;W8CS^!FHYTBA =OSB%/>9!PFRQ4(0I)
M2&</&A.#'-R 15L&7F)"H &OV* (PCE">7H ND1XP 3_Z4$(.. "5/@R AA5
M4X44@(#X%8  &UIB$^>Q.Q?4IS[!NP$.<&#H0_, >C@(T@J2-Y\5Y6#1/7A>
MCUZD@R#Q% /X JHM)  77#@)2D;-"I64:B0LK21]\^KS;7$+/XL<K$QELA_^
MN&J).UK"DA3PGR\"&%-(J54$AT'>61%8J648JH%Y=6!>T9I60SGB$:8LF6/'
MDJJMDN)3-%OE*FP&BZ@(>,"L:I7'9$@GCJ5[D[<B%*)R^-EL[02CVF#^![7N
M8<0C5A$>WW@M$?T<4MH^\5KV^,BK=RO5:OT6 =X2%[@48A&&V,M<67R 629!
M@0=XL2).%0@;Y860\5[)BWQ\B7<;0 &OP(6[.2$OP0*YKST&DF$FT6-0# 9#
M^>9<8CFG["] QNMK=X*2]]V@6=CR9@R,6Q.(=,4&^#(JKYQB+XX8&7Y'X<H/
MB( 9LCPITBR#HBW?X,(TF$_2DC:9RF2FE[_<3+%IU*<<E*8*SH'"BUFSFA=;
M8<I1D((49JP%M(5-;3Z^VX][PX0>)X%NPPGRD*53."4HQ\EY:PX\B\ $>O88
M0-7) 6)N9!\<]<=$-<@!$6K0IQZ0.9[L1//^676&@O_4(.,J, 4,3%"A"%QR
M OAB"'*UY6=G<6,#B"'T\%::@T.W=-(]\!%W9&!LT40:!Y:^J75T"GWJ]30G
MGH;L4$?-$TR 6JE(?8FJ5>*M5G=)6@K7D)@D1C\T18629,FUQBHQ2D_ Q4P
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M8X(*:JH9#:[3%)/--A\$*^1PQNE#BC_IG%,!DTNN\M \P]DCCK/ZK$*!*1"
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MMJC_F&7J8$,,N(K&>+;T)CGE8 <Z0!$0[H0G'YD  ^]J@ 0L0($_">)/AI)
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ME'&,(V,-/(XD1MH8YS5L8P4\>+&-$?2"!$W^]$W9[&8<?+Q&!,EIW)N2)QW
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MHE _)'7A) H:$&0U<%<5B$H65PYD9$9M=(O^2W$!); "S"$XP+!K!#@XSV%
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MB57$A<*B7&6T*=ZBEX=@;Z4E*I8P6JG%":7 6DO(A$B41 7WA+?U6MYX,=)
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MI  0@(_.4019\!^D0V:4$U&CLSJ;PV:M%P574%(916>S$R!,$*1[MA]]U@3
M9R!!H&9=P 6P,QU,0&L/:B1A:0(QD"$:V0-?N9(/XC]4<FEA)9,/H@(<T!-T
M4D%T0B<2<"RGM@HH\!OSIP*&X0$^P 1+X)"CLP1'()2Q@3<Z@#O:QWTY8)6
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MVP/,(29/^7^UH:EQQ0*JQI*R$3V<[!T:-3D-%5/AC -!< 1(4 1$( 30JQI
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MGXHE?166%S!*6;S^ #WCBX;%%G/A+H/BQ"V!B&A+QKCN)Y\5XS7.0C6NH(S
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M'4!F>@M  2N@ U$@!57PDWU2!;YV0=E6!$8I!"0G!!RH*,HV6XE00HS !%1
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M\*E>50R@&9HZ,"X480(6\(=K8P"W)A39NGM \5][UW<G\Q+P84GSD: &0#U
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M+L+G<D$!#KX%X87**W\\8PND\.'$,DS< @0-0AAA\A1JZ)CN17()(]AAVXA
M^%)>^=B6<>ZI9VG^C/&X.Y-X/@EEE/PM5J785.+/HHLMEN\CV?6%,FJ#VWI^
MY";ZM6TN[5G2D^;D@ 8X(()_4E+[\*0D!+II/G3*H)YB!Y]#S:=]$&!4)'0@
M!(G50 ?20M@)1, !"^!%4RD83@<<]X$3S*L&11A5J4Y5B4L<@E6;:%4H7.4)
M)'K" R   :U2P!.>).41E<K-X'Z5"_U,!@10L (QS&&.93D#"<=@QA&B898:
MZ*,%1F "%7RAC9>4BUO,"E>XB&&%;#4A"MS85A6DT(,E1&$)0N"!$6#0@7TP
M) ='HTB^$G*#A]S 8 J1Y$6\(C""31(A G&!O!;6D:O$0",:(8D-1(7^#",@
M 8]\M 9+/A8%()PEBB_S20R 8*YS%6&626D*XFB!%&"];)@["V931A(0@ FM
M!V*15@]$EA82K*5&4&,@U2X#'<1(H&J3FP!F0/.UL='(00. 6FCB!J8Q+8!M
M\'&;ZT:3 ,@XR !W^Q5K5F,"4Q#SGI.21>"FR)N SL:*541B(AZ'JM MYW)Y
M:6C6!).Y"VQ 5L2!W.<NH)SI- <OI3.,1T]7GKZHS3WM:><[:8 "V[EB KIC
MTI$$5  /V )!:3F0"D1@F@=%:'D\G5  :D2!?H!H>C?!@("NI[WMD1-+_2O?
MC=(W  "TQ48WDI**=K0ER83036"#GTO/U"3^L-;/?U!]'Y6Z=S_&C*A[64T
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M$;0Y003TP-EF@]YTLPT#>#(0#C=\-F"!(@3^($+ H ,04$T""1Q @"<!!
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MHXO)M<B<;[\A!P-UGL- P^[<=3<=#CJP0!X($QS"R;@/)F^,MNWETB S&L
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MC>-U!;*T,8ML05L7ME@/+Y2%]&H-DI"T0!>ZUI6N-NFB%W4=5/<P[,CE<?C
M'+8%GHP1@0M\H 0K>%^!7, OTA;;<QBY0 E<X.*,<, #-_Z2"VQ@ AH95F/#
M/%+*-.@1+LWEA*_^3V&8/M\"&I3 JEBW!).;7"A6+$ "+=#*Z2SC R!<9B+J
MU+(YG\*.(.C@"&3QV11\A@2180UK3-,:V;X&MJM0H2K^E%J=B= #@3GE^DI
M0@P0U@P&*" !>JNB2@JP  XPYJ*AT3AM'\*!$,#H QPP6P^A D%P! 23 U#
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M3) EAR1@%PL' K$W%Z6%0BUD<B># 5\"@ [A4!RG)"7D6F&I0BO4B!]A8A:
M6^B@#&_R4+W5("Z'"S\4G_"Y)W>R#37GB:2B";_0"9#"<Z98,TL4=)?2BO-'
M1W0$8,OX"]@E*E=T=++R=+RX+)3B1%D$*]"B$N(2H?\A1S&AB^SV+D6'34#W
MC#4#2-2@+-6( -=XC=IH+[FP"]UH2754#0*V)[7@#'R'+EUE2>!B"KDX+N[(
M"WH2CRTJ2@CV !:W F@&:E4@!4A0'3J@!%FP!59@!(S3 C9P)/[0!/O^M 5:
ML 5@&@4/"24(L1 A$ ,],!%0X15"X0Y)<#F<MCED 04XD15,, 07L T=^@ ;
M] !]!(TKT0%(X 1!04Y&XP/E=Q0Z$#F7$0171C$MF39"L!45:!5<X9->9@4"
MY35QZF9G<050< 0)901IMI11X#06I0,A4P0Z$)(*T #HL  $4$4M 8T&T  K
MD -=>6D38S0)Y0/ BJA]F0,V4*P^H!5'(#HKQ6D,Z'U'&1HM\!L]H&JS$12V
M401[J0,X0 ,2J )!U1S*T9&VIFNVAICB4P,$X2$T@ .0"6_B6GM]R0(E\ $0
MD #@Q@IMIZ/-0$-J8A+*T!%J,@_5MEO9H@#^IH!UJ;"#"/"9K_ER#Y!',U$+
M#?L-#6()660 $N!Z(> A-]*<E34<Q#$[R#:'I8=Q&"<"P,0CF15[L/=Z+%1R
M9C)")X<.JB6SWHF=LC>>&;2=VUD?YTE#N"6QY=AR#_!;.<0-,^=#PA5$@N)?
M5Q2*2-0)/->?3%1V0$==G?(HV32A !(31Z2+R()?F3 HVL4('EHKO2@KH')V
M641V2]<)LU)>JA J"-NACR ,W)5?%5HS@.I?F/0+R8@H*ZJ-]7)(,:I(WZ*+
MS?9LW? ,>V=@@ <NW=4]H7AW0HH^/I2- V8_C)>D2RH%15D%3 ""-H $6: %
M4) #H>4".I ".@#^!5W*!;*[!;(KIC)" L!4I@I! CV@!)MS&EH0O/O4I6 *
MIL%[O&D!%DQP ?#U*WS* 0Q0HF377QR0K%N!3E6&J#W@@: 1DU9&94?#4T+
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M 1EP 1F  6,)9&)"<=^I6C]+0RT72XR\6R]GH\*5B:)4E8107,8E>%%(=XK
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MD3[/. ['-D;(1=@#$GPYQ^NE7%#C7PK5!'V\5\# 8&$#,+8 W_T)<SN]A?(
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MP6%[RZ&[H<';"YQ<,=S='>'] "$^_F!^CM[PT,"P;J[.SGXQ0$ _0$_^4%!
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M,U&P@:MF%1Q=E,#^!TJ 0NEP@YG;:&V?N;E"W&CD&G\&@0,:D( ##0G*@A2
M;SF(3F*PDP0CB"<(@XO"$Y!PN>RM+W$_<%P.;D #\:& />TQPG0XY[GL 8%P
MUSL=?P $((#.2$7905"">B"#TVS  A:00 )4J3"F  0E#FC!#1J4@^+=8 8Q
MJ$$/9M.9+CA/"DUHPN%P5)T8Q50_3/B.$8HT'R'PH :24P$L5*"#(/A@:4EX
M#A(.)P3:D14&[[L2_4K0"?G9]8=NBA+^\N>"48&I!N ;(/X*J#\ QFEX&U"
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MV7%0N,+IL$,=AP)H1E0X779\D" ;Q).G$W LQ^0U$.5D@ 4Q&![Q/G0>ILY
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M[%*0SSO@(<)AN'<$SW'',/%9@K13ZN@C,(&E5G I$SPJ EU@<[6?E0G(4NV
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MS%Q+?<*^L W<$"Q_*"PQMUW(,EW8$"SEA83^TJ)>-:I!/<>=?_)P9 U?=?0
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MS!PT;[Y NK1M"1+4XIX@(0(W"=TB1'@P7&LW!PX>.,BZ-2L#JUDM$)@4KOJ
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MIB5HIQ]OMQPNYAS.\0 RIHS",B53<6,-4C*&HW($Q"1.\IVXZ"3Q]#WIH3O
MV"+,68I/UA_6F!V )P![XW[I1#)]IUD5$E'^ 6*=V.,A*((EZ7D5+;85(:(D
M[Z%D+1)*"!H]R;,:N?>.F[A[GCAVQG-G[>4TZ\ATRI,V)S4YDUF9B[8@ '
M(K F"Q$FAN!4.<"0H;")#XF06%61<3)JAX!^^2,%(A! "" ."V(.Y'$ # "2
MJ- *1J $PY #,?"71I%8D0&3RF F*YJ D[$!), $#0$%\H8N&\&7BJ4H7NAQ
MH=!Q8,BESY !$Y"CA5,XO;(@3@F5S^(.UZ81,< "6+DL[\(#;E0$3/ $!0$%
M4> $.8DN_;8+ZY(#"*1O_":5QD #NQ5".B$#NK"6[R(OMU #*W$3A303C($8
M)+ S_M4"+O "GFK^A8(9 Z0* R:PHM @*J(P;8PIAO]21_LU:+'S)-SFH;9*
M#MHH2A/U.:/D,J]2$QVA2AZ  O_%<X*1FCWSA+2T8&4B"K&93%UG>R@CB5-W
M/'*6FZ+AB$X#&RL:-E[7B;<ABM#$-KMA/8RW ,DQ7FX''6Y'-ZM(G35F8S[E
M( /)4/-9KTL)9 023XW3K_-$=^TQ2E-BH'/C-L[13?X!4NYY'N(0C9FU=\@G
M%CSV4]:Q>;IS>/&19/'A>O\YAUB!9K^H'2 R9J07%P$Z>W+&H!>ZB1^F#2HC
M=GA&')^X%DRG&1=@LRFSCX[7?K<JL1 @ T; !%$P:5@@D5&0 ],E@5S^IP$H
ML"9+]7TP:C\S2J,T&@4 5*8-BU"7X*,:  2L0%Q"$ 0X<*25ND<K(#22@8BK
MZH6O$AN> 0(EX $YD 59D$),< 1!D ,ST!&'P7$==R: ^X5(P[:RV18(4#C#
M0@!8)@!/*96(JD2/2P.AY2Q:62Z2H@HCH0I%L 1 (%DVH!&>B@-1$ 5&L"FY
MY::2>Z0/XP)*]*@W\"@C45IQ:JF8JC"$J!B86A-3^ )6.(2".9CJ$K<7NH[-
M<+O MAB(@0+!ZE\E0',7 G@#$+$]JUX"8#MH]B+[*6698!<:L &MD5\KD6J!
MH0++RUPG8 (G<+[IB[Z#2(B,V6!>J$NRV4O^&="(EPAH9B-,V:JMJG&SN_2@
MS"2<HGAGOD&N9,<QC.=/+_9V=C.=REB>4P$.TFNO_G@XF<>PTY&+\ 1X\.0>
MU&@B*()2)VL<3^9X[4D7T%L=XR$A7S'!%NRPF%!/A_<?\H$ 8D:P &JN#1 !
M 8IFNBJRB8<EW3C"]N@T[MB]FRA53[,\%"IB<L86FB%5.)LCI>$ O]A.TPL6
M!A ".A!K?"H,WG<%4("T#K9]FE$".A"T"/E]5-O&;JPGA! %#H2U _1CU<&U
MOD!<0& #9-M!",.EHW"(;<LH'/ :\7,!?$@"2$!]5' H1H"6&Q%+)1"_75K)
MKR+($[@T&1 !ARO^.,/2'0Z  FX*<.,6J/]& U!9 SL0#R[H1E7T6R"!!)V;
ME@"W+BY  T\0!4,@+8'ZN>7V CH1 VKIIC@ N_26?XFD2'JI& DC2,KE$@[S
MER$$JALXF$,8 AW0O4<I&4(#-+V&7#PA8 3# )G0.-_S/16<Q2PW .@*)!J5
M.[ES(>DQ 3,9"GF4#!X0A39SK,BE2.EK8 6VFH6X<<XZO\M$F\043*4A3&.S
MOYZ$%Q#V89?HB2)&([V1%C(7'![[C3FU%>T:(_OAP/I:=]A)K[+XC !IG]7!
MKQR\KUTV>+UX3U<2(G9SLL^!L"*UL.A191,"5-E)GQ1;L1;+>3.<,?/^8;W,
MP<-:<78JEM- K(VDQ\!+K186D'M([+T0EAF^1'QI,;.VH8].LP&^Z;UA0\7<
M@'+MY,)MN  J4 ,]$+0%P039P@1DS RNP74A$ ,AV0E"BV\.D055D 4[.-B$
MO8-TNX-5( 52D 1H0@'9T].J<P .H $^H(2VY10QL (F,!EG AN:$0IL*U70
MR@$7P $ET )1H 6 ;1!%T ,XP$$^8P(C0,E'$[_.ZBJ!^X6N0::'.RPZMJ:C
MS$3"#;EORD1UZLJ_]:8QP$0V@+?U\&\HJ($NL 11D+<_V&\:L8&?2D&/:@]8
M*0OQH!(Z<1,.QQB.<6"V9!A[!)@OT-XIJ9+^*_DU>O$(>#$9(O"$SKQ<*0!)
M)^!?/F0 \41/"J7.;E@ P^-/)]51 %)X"A ![H@7>=0J^?QS@]'?_ZR^YPLT
M[;L8US70#78T2J-,G6&_";W0MK&_N>D97I,9$?9+D AVS&/ *],VYNHVZIH<
MEY/CT"'2Y8$=Y6EW+9S.IU-6#[4ZX*,X\)3!\O0DD!.94'U-5X%V./T?URAW
M!D*Q+!R+FP3#$67#DU/#(/6+V3B.]@$!16)V1%(D,A)*3OT>,]T? $7$Z?C@
M29S5L0&A3FP;.A+6A9Q,;ILC[]4  #+@TXL =R$"*7"5:6D/.> #.@!5BDC6
MS*"\!-?HI5(JEQ+^*4#@ Y;B YQ.$982MI[N SF@&66JN 65Z@.0  Q@ 4TQ
MF&PTMC@C% WT-=K@O:YALUC-2V?< ]0G+@81!)D" UK:0(/[MW\+R(#KK+:]
M 1FP -&;#J&,J#.@$<+-1$OTN)KB@OS6#K0T-"8@$KB51H#) IV +OQV#VFD
M+A/'NNYP VJ)E4% ;SI$<<G,E\JUFMA5$WX9F-6\0Q-(WQ$4<LS\,P]71\TU
M 1[,*UK.4 2^29H@(IC) "$E2OE47P_N 2) &"9P)H>![SYSX4*WX7C4S J&
M:TVZ6/_+B9Y$-H#FB<5$B4Z'&A8(-KTT811=8B=FG&0G<\Z3P-^X''7^\[%9
M\4VLF#>+ Q_BT&,- C@]!2'!LM+_BA["@N2+0R!-;D\8]3LC[&)NE[!5SA[6
M@2 .-;'IS$G?IC<R7(U&+>9K)L3$8>9G;N8;,X<@ZWEB=CNE%Z##0=4-BM5M
MJW42K3)]K^=4?3*X7M!YP314/!R3@\7J/  (D!8S*1D#. ,]T"H<9\91#(:]
MAD?,'("%R,S'*Q24^"(-, $7<-\@$$ 3<%(/8 $:0+Z?$I>LPMF *UT?T!EB
M+570(!LL7@),4+=6\ 1*8 2=.P.=4D@OE.P<%[_*7LGQ"W**P@#$TKA2R0O+
MO=R3.V[) H18V0/'C)4L$"LHHP$U(+;P3@/^,, "*X ,0*!OO(RHZN*[#P.Y
MCOLHJ'4#0^BI[.*'@(!B8E)26$)R:#BHTO+2V.+2TACIP>%Q&1*"F5F(6$+X
MF9+"DJ(B*JJB86!0L,H* "  .TM;:WN+FZL+>W"@\+L0+#RL(/PK@;&QX5$B
M*JAI(H@B:')2:&UH*)+-+>)]*$)"(I(9 F*N6<FAO(%Q\?Y. 4]1,6%O7U%?
M0<'?GU_QCH/ @>PVQ*-W[YX$"?86,IS@$(*$!Q0G4KS8H %%C1H?9&S H".#
M!QD($"A0X&3* 0,*].I58("L  !HPI)52Q9. 3H%L/S9,B5*E28'$&BILI6K
M TM?)@ 6+&3'BU3^'X1DL."7 @1,614-P-(G3[%C ]C<16L  +5 71EXZ2N!
M+P5/$]C56FQ!Q@<1($R  !A"A @3!@_&F)4N7&!Y%SQP0-$QU8<3WBFS)/#2
M0($;-+B[0"&AZ'L6+&_H\,%#:@\=UKVS$-K!@@,RT=K&]99!90W*/&/0  .(
M"4T@+GDX?5Q9APT$F:\KJ"P9ANG4JTO'P.'#)Q<U<@@Y$N1&#!<N7KP8[R*&
MC!HU6J0@)$*=AQ#O2XCX8/!"<V7Z,ZMN<0466%#!!!)$]&!##"M,0T@('V3R
M 0CG9%(<A!]<"$*$%#H8P@@>>H!   ZDP%X--,2 H@PTK+ABB>SA "/^#CST
M $0/.>3  PL6C%9!"T'D<(,--+C 0@LLD'##$3S<"&0-,\0 0PM1IL?>#5;>
M@..2.-0 PY222,*""J:D@,)[T:# S2<FI !)))*0%PD*K5DR7PB6D!.".(4,
M4D@I8I:2P@DGI+ "!ZL0X$H!.-W&:*.[O-4+7G@EEA<#QVB060EEDJF)FH/P
M*6@)V*1IGWW;G.J-.*F6DXEQQJV#00:? 03:0:,EU$\_\%2 '6;/18<!/__<
MZA!$$"WTP$3V)$O55(]YY!%(T8ZT408I'4  MDG!=8"B M!T%D[@!K#H3F/Y
M]%-2)R45U+HHI>366Y#VD@ "4.D%;544C13^D@(-+(  5S"M))-/Y'Y+;L(S
M,2H+6VNQA*A;BQUPEUV4YK678(+90]A@A45 E3%VO:2 +UD- YF^#]SS#F^;
MO;I9.^Z$=NL$]5!06C)T7GA):_SM.(%L"!3@J*,!&(# RA?\UMD%&L00Q' 4
M7L*.9G,Z=QET&OA&'3SP4,>!""J@2)XD*K 0II@OR+!>BS1$^9XH)7P@@@F2
MK'!?:O@MC?4%[&3&00D]!'A%%$R M\,,+CAC0GP2.IBAA!+6*6&$CT^(3H<2
M4K  "C2X>***+59Y0PU6QHA##C3^<&,/.BYDK#TH!(%#Z5&NT,(*(+1 Q XW
MPN@DBC 0R0(--ES^>0,..NC0Y)-=0O(EVF&>LB:9#'XZ2"EM0E]V"<L9ER$F
MYX3CR2=EDD+**:=\T(M;:A4-?_P R+L*7",GD-@"(_T"@<X>B+ I%(2@ Y_R
MU*@$-2IME,H;#&2@JKQ1CG.XBC,RFP=H_%$S?.1*'K1*ACI^-1U;)20"#'E(
MLHPUD<%8! (JBTQ'(/.1C7AD)!FP2[9ZL2VXQ 1A9LE)+'XXBY[P!"@Q&4I+
MCG@4E$#,*.\R2?VX52^HQ-!9(-O71RCU$E;$)"P%*PM/$G:3VYP+* .0F%/F
M(JEBW&LD@;D'83[6E\ XP %8L9?]GA*,8FAD 9!)V448@C.G.8=.,'O^C@9V
M59A;P29GE[G0:GQF$'X4QE(&>)_\=A&  VAD J79VG1B((3&I>,#/AM(!TKY
M' H6Y#=;VYK7WH&!#Z1@!C:PP9/@A$L7P" &-;!!ZVRPN.NM:05C@H_>5/.@
M=C!'9I=1C0A6P(0L# @*3"C"#\3C'C[=QT$8>I#E,)2Y<')H0A>R@ I,]#ET
MQB"=R4/=BV+4NA_\8$DY>%U#[D$"(&QI/%]*@0=\1,\<V%)XD2!/+VL SQS4
MSD0H0L\+W/0E,8T)4*4H$S7.]] O%;0%\3'.A331@0R%@(&* %3:J+<F$2C
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M"M9  DD'.><@.8AGAYDC4I8# B/  K[T.UB7=2Z2/.T$(PH5(UXG3_+$ A0
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MU4$K&-3F#.&.,SL1[:@RQ8BSE&S8&0KX&4#8=L%MKG5#,%$6SA4N>T77KR8
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M00\C*%$B4:)B"7X6,XJH2,&  0$" (@<2;*DR9,H4ZH4.4#!@I<-&BPX4*"
M1X\';A[8:># @PL:-'0(X8^?01, )9FH>.)$B:8G-CIU:G%CB8U629# %H)K
MI4J;$G+@<! #A@L5TJ:=L(QMA @3X+YE.Z$"A0D4*%S0>V$#V8. S9[^O4 X
M+UT);)TU6^SL ;,'#R1 GMQ@LH/+F&'*9,"@@0,&&1"(3G @@>F=!7:6/C
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M36\(6$"(X>DXQRC2DLY(9Y10ETKX+$Y!C8/<[00G/-KFTW(8RM"06+9(O52
MMASPA%@BN3P(U(LUU:11;';3GH^XDG6S$8E$FY:;?GF.<@NIV$'$]]%D_A-)
M24K!(ZJQ@A)LH%X.@-)W$M  ";14!3!P1S4B$8(2N",=W>M>*DC@3_'%)0(D
M0)_Z\"2$(B2""D?H05--0((10'5B4T64)S*J$!"<HH(7M$4$;3 I6FBJ%SD=
MH"\BR NSSJ)4:=6@!EL@@>O$X%8B)*$*&#VN:"1!""T4ASC( =ASW(*LO[YA
M.B(H0QG 8QX$J8<1JZ$":?$#!2I ]FT-DB'^;>4346.!M&<IH:ZK;,2*(?!
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M!$7@1A%:N*N^LJ"&A?4488E-K,0J%MG)ED<,JD%9R!)Q("H@ H_D< ,5;AR
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MG15%4"4QX38!%B:!.ID2%/A:=H@O < ;#4 8_U)G%_$\&I!;<B2"#=.4WL:
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M9YM3EG#1 CY CN7(GEE0!0U9/Y*P%3/ICI*&>*.0$-I :A44?3:TH;4 *CD
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MSDACC260T&".)%2V(V64%=@00PIUMD$&@%E4P3ONR+,.!.L \TZ2$W!D$D6
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MM\$IDRF"JXSA+!/^N,1M9@- A)PUKPF E:QD)ZR2'.6XM[US< X#'G 0Z#R
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MDW>)CH@,LP)1Z# 0F\=6A&5QS6(27.@.63(\%<$B(($OYF(E%  4YG!Y%W0
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M '6LYRKW\"K76Z_I;-(+P $E:P4Q'04]0!;7\J451LF5;" J@%O$81PC.6T
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M. YO'K#1Z5UO3;:K#9LF( B'BN\0WR.?9WAPOO19T3 ?H, !^"B !(1 "$7
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M6*(9RK,E08,[X!4GXD5/+!A*3 6#4 (U41,<O?$C+B)XBI(<]E4=N.0Z*M(
M^_4XVP%SW;$=!09UY;&$R50W.X=SRI0>[F$?^@%T=C%-.(( *_)/5J,:N-$X
MQ[!T[C$AQ 1BN44>\D%U@X-U6 <@;C@V_P1C7J=QIW%/8H=C. (@*7(F+]9C
MO$$E_G8D%.,RW07^=J&"&T+B=5IB)5E!9!P 1R+P"A/  #-U42(B/:Q3.UN&
M/1^5/8GG1N S/K^S >DP!$7@ @ G>1<  14UA0>P 3$0>CF@!)\'!5"@!-#
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M('H)]-<2AP(4+/$2)R K/--_7961E; O)4H)XE" 1G((&<EPB)!2Y+, *>F
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M!.^'15@D O=S=5<F'1-P 3Y@!5D@!#8P!$>@!.H",/@@ A=P)@@P =L5"Q/
M 47PG;3W*$UPKY_W>4H@04;0!$PP03:@ N66:1JDGKVG)"$P BP $O%@?!P*
M6FR% RQ%0K\"+/?2GPUQ6,["5M/RCM5B??/H Q?A+<+F T)P!*%G!"K^VRT
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M%9^9C9/T 1NPBJ%;FAS",3S6FL*Q)B 5',L*FZ@S4+NS))W! =**$1M*P"V
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M:@'.>$ "C6UX$E<>Z,@4!A5\X,,.0_CPPB&(M% "! PL(!D#(B#10PHA0*"
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M05]>Q'%X4WC[)18B$ 0Z4 0]8"?/DP+,=TK^BK48U=$ ![ ;Y8( OD08![
M*H .Z- *-3 #,; "F\A/ENAA-= "8.%##^1A<2<"&$AXVJ(C&B ;,  #!<4K
MG?!X*( "*4 ,J2(,.&8^R^ #0" $19 $25 $1,8#@L@#X8"(ZM *S^-D[A!W
M4J$\.:69S@)01K4"E;)W&(9 6P80;;8"Q6*,H)AXI'A!I'B:4/9X7^AWDC B
M#K*&<D5790$!LBB+9M1(23./ZJ6+N^@?WM$;944ARXD4IU07L*<M"J4GML=Z
M9-&,U4@7LC1\5"1J<D&-^9$?14-86'1*^I&-R==J^M8?2](QT_=)7],UV%$R
MJJ$=D4.?<61)>(3^,K'16>MX1_9G?]OA(@0H-O2!-HND&!_#&0 21Z!UD.DB
M$[FE63F3,@-8(^]9>J)TH'4A,'J!-@JZ2G#$'O?86+ZT<8LV0G.F@=N%@OL!
M?;"D'WCA.79C+)2'>3 )2TZQ C;@ T5@B!=P&4$#<8?T6-^(1I#1%Q8P7O;&
M 6,A D0&)4AX)]RB0M=(2F7Q157Y3IFD.8_6$5Z3 O\SEN6S993PFLTB$2K0
MI&8U+W_73V>"@=(9$@@P "%0F@H4/)M0""G@ERF@=8))/BV6 SUJ!-C@HXX9
MB)$9F4+& SLP/@1E=(XX0)NX/&@J$0"%9@64/9,B"VX2$)%W M$)(@_^@2:5
M6B^F6JE%!64DQD'*(V4@%&:X>6*O:&Z^N7F;8R"5,9SK)1^[6"7(:0 +@$TZ
M-!9L@11LI15< 7M;<9O*B&D&UXSGEE9G0WS[R%=EPZ'2VFD-8T7BB6I]<4KA
M"AV'!48>LV\^.7VU!I"W]EN\%CFG$1H$F8[\*7[UZI^@]3*24QS*5ANJ8:$/
MV'Z]9)[1D9WI!GI;E7V7!&SF@DF;]7^3LTEN,U_B9D;T$8)EX43$YQC^H9&\
MQC4[Z7XF:JS"E%V7QJ)1R1@?V  QJI(D6Z,BA&\7,QD/Q@$F$ ,UJ0U "K(4
M)S:/58#B=AB/=EVA4VE(<7,^( )"H .%  _^H4D^8^DKB8<*8H$!$?" J%<N
MO .':,(!FF$"KZ(J8%L#+A!E.=5FJ,A4!K<@M+0( %$M^!)4'Z *62&W(6 !
M ! !,Z ZA,!2 L:G*W I8!LIZ0,$AGH-V2 $B+H./* #1B:9CPDI?4@F4FI0
M@D>IP )":]9 GAF:&@4,L5"6GZI4IY!B8T85J)I!F]LLD:<K]V!WFQF7=B.[
M_**V$V"KFG< #&8="X  VV$ I>>-QJE.@":LS,F*%%(2'[!4H\ MN,26_1*,
M"\)$4N2,W+H7"I@76)JM T.]S@@8?E$81$-=:(.>4BE&C'62\2$RG9%5!S".
MM,%)MP&O3=,:QG;^1_V)1W140[%A?Y5C.=OW;:1':QZCCWL%KOIV1A#'5;R1
M)0S;)0FY;;9U$\ A@,XU6<#+)*+DG*2V@,H%>AWKL5RCBR7*.46S:-=%E/LB
M%N?E@1_(.<Z9>P$W>QRQ-QQX(1, >R+@E37I T *-COY'NB*P4$I 12@I!K0
MBK<D%A90 C[  0!VBI'0 HY;*MD0!#TP XXH>!\@:\U4,SYQ.U>C9YN1@T^J
M#:(BF3F  ZQ /H:"*Q:E S60 FZH%\1*2R%QC XQ1,G" 10P  A )LC#MY3+
M O<  V"+ SD0F8<K*M> QH_Y*.*C X^YJ)!+ R^@4I#:9!QDN77'F6[^F[K.
M$IJ<<$!=N)E*!1*%-SVF$ (C\)I#URRQS'BJZD^$P$%#)V4 H1&S2[NU:V>W
M>U7TE3321!08O#FO=H._"F@-T"&>@R_[M1$E0"G$TE1S97O+J+9FL1:\AVY7
M9*U-!$QF(6I+5&I%8\[']T7*9QB#L1\94ACEVGSZUB3!FQDBHQS8X4KONTHQ
MLR(-:K_WFK_D9T/QZ#, O#7)\4GYJ(_?_##=E1D(VY\&J1./$\$O81YT!&Q9
MXUS !9$%^L(<@A;?F5SE>48!*;\6"ETN_,(;5S>?<S<I=%XN*C95V+(GP9+,
M2\--,1TYM &58 (T)@X8$).>X6PK!Y3W*!_^0:ND<38])&&T)= #3QP$=U@0
M>C<#N%(^,D8K@L /HG<N$_TXC_, '.;)7B9E2W8+Q; "&% E9+72C_8OM&0X
M"+$\K#QI'= X S G^U F=G((?+LF/8H$1Y $A2H$0T!28((_QG!1.Z +CWEV
M:NQ0DCLFP8.$E6NYF\F)H'RZ1H5AA;("L"H0899?S!I[;37+0Q=0E@I3A^!W
M_R!XF;N*ES97%'(6!R>AP$P3N<M@JK0:I[5RB+0Y%?LQ0:H39*5#L%>J(K!?
MH[ ".A .:JD('- @85&=:LNBV.M7%DFM5W2]H,8AQ@58WNO=6)1\%<. TY5(
MZ8F^&,DD(/,UKJ3^P+BV2AJY??Y*D/_L&OB+O[AA;  H,^R$$W^D-;(!O_]:
M>M517."9&!26505N.T/!L.1125)C26'-D#+"T1#);P6LO7H5KI41(_Y+&P.H
MBP3\T6J%HMBEFTB!;@U>("DYLB@,5U*%I;^D%&W[TZ_2QSX;-)I1W*!$:XW1
M%W63FQRA 1A@ 2G0 QZ0#0CT=K;LB-!#$'%WRU;9'>6B$V#]. O 93D5$/Z4
M<^(0 @M P5RY9S<R2R?,%5"Q/%=1MT/D 0\P&@-P 5IFBDVY)CE@#4? !$S0
M!$VP!(6=N$&0N(\KB)$L/HY-R8P-4N;C/)GL"5+.R4('0CF5NO2"093^& _S
M@+8@1)>E+6:H;:F8KMJI6,NMBLL?ICP?0)VL=Q\'9P"Z[4('P!@.\"+ '6LJ
M6Z3&O1.V_BY/X0]-ZMQ!8 1(4 0Z$ ,G\&;]\JQ*A*5FDYTO?L[>#,Y2%.T"
M0[W;RA<>2G/*=UCFJ1@9HXT-J)XG.5Q]AG$)$''O&QI:<QNYIAKIJ-\##="Y
ML;^PT;\4+$-U?M "'#=-6)Y^Y8_JQKOMZQOE%^$\(:&YY30L\1,L4T,EKN%:
M98.8,1\??:7CW1:G]#$F_:[,QK.]%*XJ3K(IG$(4DE:#(7T5ZT7#:%?"5#TJ
M;&YJ58QG";@QX $HT>M$^AAD!/1,0C&/I@'^2)S"7X$4*: #3RP$[4!01[(K
M41]W):  6GXNYJ( QM.99=UXM+ .'&!HMHZ"#/ ;7 E+@4-O&_$!_1"*<.X!
M%L"5[CNV03=E*  #/>"CA7H->W\$2S#HAGCH]2,^%P7)DZS(C4K)XT ^RE"'
MD<Z734GIE0YB_D!4L!Q$_.2TLD K('001?14L>=3I0[FHMO:CZ?:$^&F)4#=
MU^WBI/06!T#K+92##!!ZN59ZKC/<YO2B2P*%ZI5#M/1#R]/<'^ "0H $2H#L
M<:QTA/?LRPDPVGLPW3VMT\_0@172WLEIR 6>WBV>7>3]7=3.WR^5_/%JT2?D
MZOJ0$Z?/<"0Y;:3^L'@T;/?^L/BZWP3N1^H%,S_#D23* $U8P@X#"! /#PT,
M"PL*" <'!@4% P," P "E)"5D@"3 )P  9V@FY": I*0 X^HCHNL"0J'APT-
M#Q$1$[<4$[D4%1.]$Q#!A L)"8VJCJL'BK"S@Q$0N1?3&!S6'![7&QC3N1 1
MA VP"\ZWOA47&!L;V!\?'MD<V]P4$A(7&R$E^R<F*RHA/&"88&@!@X*#&,@*
MY^ @H4&ZIFWH@ V>M7D76O3@(*1(#!<M6K@8&;)D2!4H5Z1(@7)EB0612LF<
M62IFS 0B2IA(L<_$OI\B<JJHT2,$@@(*/G!0$)-3@ $&#KQB #$=NP_^.?<%
M#>&NZP8$"C:D<%$#Q3H-&C:@"$*DB!$A/GP$ =*#AP\A<^GJR,&W+P\>?7?D
M$/PW!XT8B%G$4&S2)$B3*_Z=1*EBI0F?68/FU,PYA&:=(F7$B)Q"!+QW\-AE
M.^TNA&M].4^4D/T3:.S9)TZP5/&/IV>=EV5?%K%M6K<+O'3EFG  E//GT*-+
M!_4*0:,"4A<X<$!NP8-Q!F,53 "I0 ((U#AXSKJ-PX<60I @4?+6APT7)P(6
M-TZA/Z]>%01HS@2V$ A,@0@.: Z "YJS'"Z_W!*A@@9*4. $$MPBP0,;#D*+
MAQQZ"$Z'"25DR$$'C?,*(H@HX.*+"EQP0 '^!D0552K8U5CC*)J<XN./COPX
MB9!$%GF**3[B2  JJ!! 0#(VULC*,F#!0M4@WT@XH 3"/*#0 @@HLH@!/DIB
MBIFE=+()=$]MDJ:90B;C2%2+()  > HY X&#_?72GSG"C#?C(S36B%V==\;R
MS)Z^2'0--MI@0,\MWWPW#E6,!DB!1*JA9M$\?TY0S6W F2!""!P,Y"55#D5P
MY2#.+$1+1.JHMMI%T\2P@P<=S3#2KR*%Y )OD['4FV4,Q$1333,54!-.):1P
MF4^VN5;""CJT\,  !VS@@0)PEI=  \'@D\T'7"FE'KKRK%.1!^\X<$ %IYK0
MP@;=W%)"#S[PFX/^#3; @((''=# 0P\]_&M##C@ W'!?##,,< TQO#"28A>W
MH%(+*6RL4F2DK<22R-)>5EM0)7"FV7J?12O21SQ9 \^G,K.&[FM9S38;M;7]
M-&T_+&G,TV<[]21;"/LA%ZI_$RPPW=-02Q> BP<0$)5XL&ZGG0/BB&-0G@HD
MHP!Z^' @0F[2>K !NO#))U\10?1P0PPGF(;O<?XE-V"""MIRX84#ZNWGT@KJ
M32&%&2)8BX<;6O@A.-^06**)>7JMXB$N@OG*B@M<L(J.U\W)R %#<C(DD4'&
M:>3J12)99I(XBD[GE"]:>64P"_:2X3?@6"ZFCI=,LFQ-SJW9R2><#$_^/.R'
MU@E6HH>\BLMRNR@8C""8,Y)*(XTLDD"5K]*">P6;JE/S11C]6>EW*TJ/2SKF
MPXL:-NGS,BINTYI0=T 7" (B. F)U>1L00$,I.5\UY 4!F;0@P^X10:_(LEC
M2K("C;6$,B5[0  "@":9*&LF#YB  D10LN"D;"O6T@@&9@0!#%#E FJS"E:Z
M@A6N:&,;&#&.5=IQ 0,\ !L::($'S&$/";3 5RTP@6LZ< $,E2!B-JB!%"<V
M18 ![ 8U@"!*6,""+7*1!2HAV4ZFU;/:\.QD*%/95DZELIZL "0G4)NMXG&-
MF74%!*Y!V4]H4RIJ^20X*R%6$EMF,MR<X /^]% :]2[0BP=4(FJ0C)H %&&U
MS'U''-SACN5D80A9R((8V%F J-3Q@1-4D&-*<4T+@H $(QBA"'CQ@0YN,(,5
MV(T;BOS3?_IVBUJ8 W #FE#AE-,G81[NE[T$'  _1")P0 -$T/0056;AR:Y=
MKAF?_*2,<C0F'(&.3*?H49%2P;IRFA-(.%*%D[BGH^8=X'N<*\0S+L2@(OK/
M:V$:$SB'%"Z9] AJH_A@3= I.N?=B7,*$9^#E'..!P7J$(P@$XT(Q0H[P4)$
MT/!%^=Q5QW;1@P+! . X],0GJW@+7C.SA@)Y44 /A" W_?C9_E+EOWF6R#M>
M^A^MV%''>,R#*"+^<"5B/A+!D[1 !9.A3&4L$X%(<'!XSO*@J!P0K9WDIEIY
M=$$,+A "&>@ 8;+$SZG<<9JUR4.!DDH'-;JQ*9/*8P(/,$X)+L"A 7F@!!_H
M  8LL)P-92 &4LQB#:)8 QK00 :!E:(,7J#4QF(P?UHYE6<FBS,VLHQE;.S,
M93FSQY4@;1VV>E1%WG$SUXR LSI)+1_W>!F1_4,E)?A-J7(R' ^P]4&AVE8D
M=SL= 1B  (O@7$(<\!U+:5(\K"+&.QNPJ76$X(TG095KL 7+6,HRBC-H0=UB
MF#?#]?*8!,H2>+64"S^13Q<3>M!X(Y"A[Q+(F2#BDB"^(8QEYM1#LSC^2#7!
M(XXO;6<[GNSAG-J9BHC6R'3B1!TY69=@(34X$D1:$I-4H4XGT6AT[@Q3(F+A
MC%K80D!; J X$F&GB J)60/5!()#83Q,T$04Y9'3H33,.8/HB9Z[8!JE@E$0
M11P#*M=I13-$E"FW5N0B:47.@1[2@*E@:4_DV^AH4[H.2?G'/8;\H_YD(P*E
M]&]5DX.5F*E"0$=9)%+JL$$/5F $)(A&JT0%U@1YTUC+4 #" GBJ\DH!W!&2
MD38KXTH(:A $(R@!"; ,@@YD$,>9S0.TN-0A?Y1V 0M8@%/L\!8.D=8!/:[5
M A@"T4%4<-C"TH!BHEF,#!!+,:6: "5_!$[^&4_8Y:Z@%*7O>(UKT(6NE?EZ
MC6K,26D\RE/1SLQFE2TCM:[JQ_RAY"2Q)9H?9T,<'4\O%P\H &^W#9T+"Y<<
M#3CN?[F&-2\UN1@/*" [GGO*%:0R!":H@0[B@K!_S<!7*NDR=[U[3%_ZLM_@
MK9Z#A#FA]F)(0?;8TH86][]H.CRG^O4DN,FAWX<XW'.#*I0WVZGB<*+NG" 7
MYT!]M*1]%L!) G"2A:44Y'=2:47.H 4TVON@(@80$24&WB4\2+Q_KKAXE-BS
MD93QSC!=:A;0"(8N\Q9E2GGI$#[FWH6QDP"IP-Q#UZ-5_.AXUDE5RI.OB#FC
M^@._3LU/I?0856[^]-<3G>6FRQRX   ]#$W[%DC*,H/463<P;Q?(AV)#14P$
M29+4"TKK AO<L_(2 .^?17;7(4B!$)1P!+CIH 8KJ%NJ%(C#I*FUK9L"?5OA
M5RMOD=8UU,J)PCW$'3#]U;"'Y6)BM+KJ8:G@U;@O9,YHK3);>RJEQW;IS8 =
M[&!758XXU'M/C]V:RNY^UF1L[6Y"4IJMM+TG/@F!TB@596P;@-O@!X543I3-
M0UCJ$)KDI*A9E.Y:E3(%NBF!VN 1 A4@=F)OYEC=NKP.1H)X0(SR7M_%* '8
M( .G"^C%4'Z". RH<,B$(47D.![&.\\ (M14(BA230[Q(<+0)5CB.:O^D",;
MQP@!]6#,LV @!W)((F$3ID[( #HS4E$:AESB TQ$U"%?@@BLL",0AF<P%@I
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M'[KS?>;(;0;0/A=9$.9G*>$0/H+ 2>A1AU3&#9+B'M8"4RG#%?"0+^H%*,!
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MP2@F4" LDB[I/"0L<V-7VZ(7M.>6<58YV54B=KC35N9CC%>+2^KK(>=:5Q+
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M"0J O<3H&8H[&1K^H,$0Z0HY\?+%BK"M$$@[<\IAWMU%1-^0VR,IL599(PC
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M$DAWH-X$#!Y"F%@1(X:,&"E4V%?1(K_]%BI6[,_/WWT M@ =?OOAQ]\*R87
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M2<)D*(V$@I9S;8GS&KH@NOBAB<IZP#^3L @L @9P9&K9H*E2Q#GF !;@"Q2
M%VBBH!><.KS\EK7[+1(IM"L)*M="8-8C8! A21X2/*+R$+=\HNB$<!1G*M/@
M$CW\3_IY8/SJKSA<CPM1<3RM/1PGDSWJ%L_I%C-IQ I&'BN@1NI96<U*=G?)
M8T^;+'AR;T5Q'E51Q5FQU5H<Q5I];_K3<\OBQ73RQ7P*QPN O39AT@26/4&L
M4GI2E5SW0*85+W0X5&_[%6+1+VZL(CY;$X=I7,>'8_3 96RAQQ)LR"W^(;"
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MSA%Z (,2T(AS$Q!/UBS  >!\C3THV( "^ D  UA !"R(00Z<A@/')6ANK_D
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M-HZEQ=%I!6P14GQ*'<10R@,4NNSJI;2V-O !=Y!3A!RT8$8R\P &)/EB"6P
M!"G(Y+4I,"=9*& #)2A$#!RDB'73@$&X24$)XEF,5_WRE^)=[TT/PE;^>#$
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MHDE;$C<@"B(?0J(BHI$G*@(:4 X,A%,0B&\2:)+", %AJH,DUV&6="(8MZ]
MVAE,LE]#0@'U\3G;U&D:)YY&4A$;H )V$Z7:I0$DBW(H8 (NLC)P=*-?4R+X
MYZ50&96K(0(85[5GRH376"1J2AD/L5Q"AXIP<@!SVF)OJ@M]PC5]$QPAFH F
M6G(R$D_<XPSY@ QA.%'60)=HL@W;$"EH^'E[^0T.=3WL@&3DQ2K1V8>@Z@[S
M8X=X*(:HDBKK"@_?YRH)\*+NLF5?E$2S();^GN2J]B*)CAA!D'A!3354%.06
M)L&(G0E5FJF)U/(6U1*LKJEGLBF,@X$ MMDGI9";A-:L8L4+I.B:9D8  E
M,(%ZOM +141WX;H17;$LQ3NL>*(P[> PDZ4ZGT8!_.";]\:N#'-JP?<9^QH9
MK>9*G:"-("59ZSE\/V)&\#F?_QJ5:HN#]GFP!4:>%H$1\.B?XJ=0,J9LW_<
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M*.02![Y0-8(1)3#(J3C)CG1<TGW3Z!K>""0@5KT/;QX0@0D@T0&-F&0 (#G
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M@<VD.%?R#O-5<)_@<4@9E#>0E"Z8E#NZHQO7DSM@E$$:I#KPDS+( T+Z@CC
M T%0!%;9!$P !5# !%G9 PJX7Y8@=,[TE588HF6Y#Y^SI03W(QAR*NA@*LD3
MEW59("5"E_"S1\PP(B6H !U!  K  -WQAH#Y*V%Q,Z\@76:F=L4P74/^L4 L
M])!*H3(5,$%1YIC8\BR ])ZML&75*!*O@!_G@A6]QA>7B$* )'B'9U5\P5I6
M,0&VT'"J=4$BQ)>_MAAY]AAF!0!@\1AJ!6BT>AFMT43@ E>:53$/HQFL43.O
M6)R5)A/> AR^IYS(UQU:=FE&!EME@R#5613-03CG\3+)]QK3T1G?*1NSB&K
MX3.;U5G<J!LA6330UT[?,'WR\47#8(Y=Y9HFM(=S(57UF:9\Q!R&R2#VB T1
M<I?/Y@R:)'\#82&_)7\(FJ $83=LV@P54@*VL A<TB4YB DWN6 Z&8,\L*%
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M\QQJY!8(,DQGXS!Y1 ZX=#4C=P]_8R$99CFF4P)M=@OS-!XOQE\Q=BDZIF*
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M462$Q)0@*^*JWW/./H!ZKD<1^DH).ZU[)M%CE4A3YE/=-!D8IH2Z .\.IR(
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M7$N+95T$$X)PS:PN@(/]:KA7H;C\(O5(+,&RGVTY X<=6S9VF[>AFNZ;5X"
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MJC/]T<8W#%>W HG"! GRTOD8A*$(U2UO>AL=WP22BELJI(VQ.67T9EFW$J2
MDS&8P=?J<ZG*]4 (1D "$HC@@QRX8'Y_.^6)_->(_?"G 1/YRW@H*8  A%,\
M!8  !TS N$K(1TLJD%SZ,' J_=$*01*"D)T@1(*VK7(4:U-E/U6IRG<42 7H
MX%K;5*!/?ZKR!/[DY^3^"="(HH!()D!!1/<I-U6$(T##2QS\/CHD^26$ A%8
MP '$P\ $3, X[-% FC[D+%:@B7XFC8K]BLC G.JC3!/YB /"\E.2")7^@M6
M2TJPT4&;.&LFS?)@4\>QKAPV:8R\68K/?N&Q7RSE:J@15UBH@J]GK"4]72G7
M#=4BEAV6!2KSDA=;YAA#:EC BA$KXNJJ)A@J,M$H$P-D(+N50K_>Y1"5]%<1
MG=.+8KR%6BMK%W-\!EB@^<(7)0P69H1C-.-H5CLTXV.U2G*21; ";7];!4P,
ME<V5A>0T/>OI,![XE,4"QQ7_HUEPJ-4R78 'G(5%1%BJL=+]A> $Q'S!"DX
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M2<-2/,9BK>1C[>!C[5,*D_,0': *?80 C9$1 K!D%^!2>])9V7!!*I,2!X0
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MA9RA 57'@QZT FUD,B30 6@7"@+@ !@  BI016Q6,Z8W'G$G'C9C>J/&,R_
M'(0$(GS7&'W(9X)W1H+7&(#G'B_P H"%>)-%>ZN&:J;F>>AQ>9LG=Y1(B74X
M=W,7'I-H>FYEAW"7>E8T:J+8::<&5S1@5;4G64V#-8UA C[" 40A'9SD>YV
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M/*<VW<1V6AY0/.%S>U88WF9"2]16]%F7)EJU!^*(EEF15>)0'=4_,QR2$1I
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ML^X:,J#VW@P<> P9+&I@OHP\1N7++I@W'SL9,N3%+18G5I'0A,&U0HG^8@!
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M("MRN/.=Y6-)/.?)S $H=@,?* %)J[,"?CET!",P5OUB(+'<3$5_^;,*;7
M0Z":!2WO$TH3UU+1<M7%@8"AL$8URE$(KTM=$PVIO;"34GRE5&5S&3$+M)49
MJL@T83@ #6QL$$,?7B: /!7.3W]ZXL=LYL0$Z[$ ?U@=LB 5,F=I7['^V,(=
MMT145:K"'E$N8 ',84YFL<7J>D+AR%1L8VAV7-N5/G&-LIJR([9@K5L3]*"G
ME63-$DIC&H&!G[SR-HM]#55??WNBK[&(;*O3QC2\.8U1"9H5GG@1[S"K2'H\
MKE!WJ^V0G#NX2I:6D5J&[IT41UQ).@Z3HYJ<-:1KBU3FXK4(RNHF"D$ 61I7
M&;FM$NER:9$LH>Y$87/2X8@[S%6SFG:0!5*4'KL.(/W.49 27JHD:LT3,*18
M06G5IT2T)'"6ZE3_:#*K7*4]]+:3O=SN-CM=I#Y\#3FIB6&@"ER0XOW5ABH"
M5K?%Q%(6LSP4(DQVBP+C,JX-4UB"&N7+NMK^)2^U"#RD(F6?0D9\'7SAJ\0E
M/HNYKN.4$]O4,U?)06R@5=/,;.;&'/<I2W\,\J(VAX01+_F/BXK4?2FU,.^*
M:%29;+UK6W74-)>R54F-U:/\D1.(\ZO/QHIGKY;U/O<I=EK7&J SV[5!4&MC
M?M@8M:P]/:]S]"TWAO%-%0%W;%Y=SY[E=$?4?M.P;@JTDRBPCD\FUW:2U=NB
M:K;<R )NTI".M&DQJ65MO(Y(D&94WCT4"XL$K[6C[I)Y@X%IS>JZ2-'09.!+
M=;8XD6CG\C$L,/<DD\4?ET:U-02B!?5V5:1'/]/MQ4<0Z) 3M.Q=0#GG!+B+
MIT%&ER/]P06K)'+^/8JL!Q'SA"]\DP&3WP??>S=3!P&4PH%YK8 L'G=!8.1R
M%G33@#95R4U"81.5_G7F8\Y'"UJ@"C^!(!#" 1^7!2]JP0VG7U[JOXM>/J "
M^&O'FNR[+KV6*F)\H> OA>&_]_]/%]T"@'_!4IR10V/A<27S' D(5$#E&$[Q
M@&-Q;A-(%N?F?!=(@4)4,A[$<DEF;5)U;>1%%%;U9%+F#ZA255?U>K/@'K$@
M-!\2(H D5EU4-$77(&F43OR!5E.S@Q+@('+E9B5!(745-15"=2QX(5WV2DY2
M6-/@#=206(#U"J0C6"4""@U 6(JC./; A*'B)A 0.'4'64@B67B3-V_^MUS*
M)(9IUPR39BAL @X\AV68-TE'4CCS, QVYB$6L0];$BF8XPO\L5=D\B.JIFNU
M1&B?%F<6P8>!!7:PHC@Z(DR:AUL!< Q3 DETB"B)P"B$-@MBE$K3Y 'B<A#8
M]3Y/5!%8^%FO0'O4(RD@Z!W9=@S -SM&,CN!TU[RI"O"QU['9P&CF (M<&..
MX5 /UU)5P151$2V=D1O;MW$B)"\P$U7CYU_EIQ;H\D 6IGX9M2Y+Q!8/@4'6
M)([W1U(BIC(*AX[]]W\"V"U]41?7P7Q M1A"1(#G%G&/(4#<AQPF,QD*:#("
M4X'=)Y 9^( =-&3[XG!VT6SC]0^M(H)5E8+^*(B"$$F1,P<F_%$1<P2#UX Z
MZ4%(KJ!S6(0?11@UZ20U9P0,#K(@%)(?:^8@>66$<C1TNR0?H8 /OP0]3@B%
ML,*38S-K:/-'0:, 6,@V3O)-D',X;J():#<C 8!H-=)H.T((E15WB+8H9,AW
MSW!WG?0.5N25.I*5;NAW=B8T<^:'J11EAG=XGA /E*!Y.2-ZK*@?+*D?+K@>
M7E>%\>$F^& /G>,YE(A;-!)*;W<[?L.)/.)XI,<E%, J$B4"JH=-#]%ZNM=-
MFB"7==4/YB15Z%02"C"+K$8^1;*++.%[?3)\HUD3-V$ #G !]!.,"XAB,_!#
M#O=_S=$;T8*,S:C^C#<@,5&Q<1+H< T6?N(7+L5BC0 '+Q5T%A96?H/1%]>X
M0..H0?EGCOBG<-9)%]D)< 37<(DQD A',&115,0!@651,@IH@65!@1684A<X
MD,X7,-,AGRG3@<,Y7B'HD ZI 1H@$OQYG_?Y$1&Y2A>Y@AH978XR:UOFD52(
M2[3'DOP@5U5#(%=3A"JI'Q62'U$'1D=XH$-W(1IB9WWI.F976&GS-GWTDT*Y
M(7QY.#HI6H-T (:D=I]W-V4X#VQ"*)F6.S5R69"D3)%6"9, E3WR659$)J\#
M2LZ%AO>P9>RA):V%"U$:B'!F)[<#.X>H6[ F=142"QMA.@C:D9[ E_;^D&F&
M")AU5S-[4UF%22CO0&C0U%JB6#S7M6QKT7K>$6O?H "/MV:N.$W6YGH0X#P'
M,(OJ=3/E 9K.<(N+2IJAJ5[(8  -T)HB\)JP"53746(:F&(PIHS5IYNXX8S0
MD9!J\7*J@D )]"Y+E*K)Z4 .]"YX44$!QQ;O%X B97_ULE38F8[V8B[=XJN^
MFIV]VIT(EQAF453;XE,R4) C%Y !"8\(UZP6V$'2D3+6H1TBX$1,AGO6LZVW
M]Y_C!8(.V9 S!V6!6!$QZ4=G<W4SZ#-$4S3A](,W**%9$Z]S>:%WY:!"F%=&
MXZ'N 4B9A)1MPI=&65CLJ@\?4CHFVB0#NX7^3^*P[V!(I#  3MEW;-=(F8"C
MA5FCXF"C./(W83AI93B5E7:D5DH3F5<XBP*']N!S?.H?M1!ENJ""&6DG97(,
M $ >B]<(FI0E9_62'.&EL=9':@-:ER<.9JIKQH259O@.C)()>J,);SJ2D2*G
MT=D^FJ)-S&,1L+*GTF4@PB(2@ H0Z!0!JOB7.(,F.2L):KN+--&H+D$^Y &I
M#S"IE=I\[<DQGM$_VF=]ROAN&]=]P:D\P]E$X?)1UMB-[M>J%D00K1I_]R:K
MX\(^\S>Y']9_N\H^Z *LO4J;M#FL ]B>Z4DR&W-B B2>CT&/[$FLT#J! Q1D
M*L=_FE*J,$>[N/?^@6$;<][ZK3)7@N8:1^MA(F#U92#I*$:#KR29H78U(1NJ
MK[\K1UW*@NU!=#_393QW#]"#E&/7-JV#)]T;A7E):W4B2&,*6@$K6H.P6&MX
M"J;5L5/Y(QI[(QU+)9*X2$&Z67=X.Y15I(3(L9EG"IF5H_60AQLY5ZCT6J/&
M2AEY90A@I;:U:K7$)*7DLVS$$=602Q>1H#=)IIEVIFZ+2$C2E2$,#UT)6IT0
M>&1$70(!8?3G,MSQ1 UR#:$2>'4U3@T)<YV"3J#">YJGMHHJ.Z9 'ND +/=$
MJ8V1'/R(MP9#&[*QFQ7#&QT3N"V\9*9J;]4H< 7T;Q2F;\YYG 4$?P3^X6'3
M*<:56R]S$9V_VE3C\HX.U;GJXIWJ&8%.09[^J%*JN[IW_!=.@3+Z@AW:X8'9
M:KO;>CV##*Z["Z X/+,:ZJ7J6I,*"B*E](GQFJ%/$V<12I='"'D57%8'2VM8
M-@Q/TI=BQX3X@">W)(6#I9>QAUJ?Q84CG J+)24ABXF>1R5.2Y50R6@B/ A"
M8EMVU[Y$"K![!SY2DJ-/"SV'!6:E B"BMDI5IL!5*AY(&SL0+&VDIR#Z&GCA
MI*ZML,I@:8MG6C['9,R1>,R_9,Q%FEBQ4)(>45VDN'KO,Q&<>3:D8BHOBRK<
M>FV<^0##T$Z.:J@TT0P]7 Y O+;H4- "$*G^$T!?]C5NY-;&S'>;LM&WGPH5
MO?F;4=P0]*:MQ&.X5HRX&I:<Z>>JQ0)_W;B<&42Y5WNKO,K2[ZC&=%$0P9H7
M#%=N=]R//@2!T8>!%(C'/<T8>VRM)D"JX3><@'I[4A6NAYR?_QF17U)FLK 1
MO-3('W(4=50J:;0?8117),D1,?F\C[<1UR"]ZC$BG1P*6-:5W]2$HT(G;Y.N
M/WE+7+0).IF';NK*$R X3]E96ZF_D\5H?G?.\>!);EF'?*TWQGRDP;1,Y##+
M3\O692,+ &+ F(-S5*I5Q*!XQB4 T7!+?:@T*=F\N60Z&1Q[4G2EE,AK2**R
M\# -V$L(6_A9>3C^.JL%BE$J$JA7$//W4)PR$LVC#Y"R)=63NS@<B-R5V$VK
MIF4ZL08-T)H]  J /OB47_CX&.V);@8CT<BX&[QYFX ;N PFC0)1;PD$8:IZ
MQ<4"J\MITK'J?NC=J@5WJRO=,DQ5%^T3K-[W<)[;TX(1??;8WR,7<43EGO6H
M4CYMX#]]%@HANX"\T4VV*MT:$IK)G^*EF;@+D857:L\<PUN41ZX "S58='.9
MU7@E(9@\1[.PR!^.P23R-33)5\?MVJL<:)$S#2^8-BFJ(8=56"R;2:WMVJD@
MHY]7-[CL(^X;3,FTRUU)SJ[3P&Z9UX9M  S<B:[#)D<+?/.4*(Q"=GG^AJ\&
M+*6!J*^@0*;%]<"B@Z!#V$KI1(10[:6C32)S_;"$R@B'BMK(E1-^!TRN7*2N
M+#ER*5?&ULX+9&2GN$U9%5T"4@OW?,,7_B6^T+ST"GGSC&GM8"83N]Q![">;
MK1'"XIH_?3+2<18 ^1PT!*H5DQN:,4._L2T.)9E%S=$=_520:]+<^*JLFDWQ
MIW[62<9B+-^ZS9V<R[G%V,8-][G$ZI[1H5+TV-\'SNSGF!8,[N!AF]2&/%7X
M6>$ (: $"F<;L:##:^,-&N+)JZ]>O8@<D<U9$M:G\Z4_A^/K&LPAK-9)2>,(
MP  U_KU2V.U%:UCEK"=="<M2\N2QS+%,*P_^B,F5<!C"MJ8G<QZ& ;]H/9+G
MJ7"5NF.+R%7,D&-8(,*(Q78+O "(CFYJA)#9M]5X4NN'MJ#F0HCNZ/[FH."$
MNRPDTCQ+M&CGSP4.6AC"SS/"A$9L*"S<E%(I\\=ZVN4IY@4G24.U&_VM%]XE
M36]X8"Z$9\/DQ? (Z&#U:9(2!K  $' !S*)\YZ8O2;5@HFX9O:F;VATQ%?W$
M4+Q@:1$"TTC%$$'>_D7WU]A^)LT7\,*-%B;?2(2YO$IP,PT8[XC&"0FZ",??
M*E,6Q+CL^QT8B2%!CQ_YU?D7"HZMT-[@N"M5_AGAA@R+Y*5*OJNANU1G8(5+
M\'I7)DGNS\N(08O^%&?S^NVN(=R0DS".F-@+R@Q+[_=^RAKB-C/>RA$/L0%?
M]9Q'RY1ES(>P-S@:A]*@\%//.%J9Y7_]M, T\8LM-XW@=ZGEI%X[V:J4P)9=
MOJ,@\VFR"+^$2W\^ 16 \OSPLU!='^O.#8$F\9.(VJ')>3>_\]=[\UUHPO@!
M"!,3%!<8&!L>'B$B(B6.)8PA(1\<&Q@7@@\-#0\2$H,4A!L<B8F5AY4<E1N6
MAA>OA; 7H;,3$+<0# P+" @'!@3! P'$ 0, R,G( 0("!0<-$Q<<'R4I*2HN
M+=O;VBTL+BPL*N Q,33H->HW-3;J[_ RZC+T,2XN*BJ/(A\?IJJE^GW^D$10
MQ**"!D7D.YA014&'*A1^6!@QGPD5)BZ:2)&Q8T:,'CN6,/&HI"-])?2I1'D2
M9;Z4*_.I5,A(H<R;-^_APY<M'T^9-G'>#%HQ'U$2-S5:E)FQ1(A_JJ)&'45U
M%5566+-JW:K5T*57H01-D/"@[*X%:-$J6)!@@8*U;N&BW=3 0=D'$<I"N%LV
M+]^_G!XP:#"XP0+#<],J=KMX[=NW!Q H.'!@\J]?!BAKKGP@@2\$"4*[1<!V
ML6)=C4WW4@"ZEZ_-FC,;D#UA@&T QVSKWLU[MF_9E(''/O ,=F37R'MI+E#@
M=FYDN747^&T @>_7L&?O1M8,N@#;TV%[3B#^%RU?")] @;4@B&S9M,&;WU9&
MOWZRXI(7,, +01 %L8+<$H%?=]%U5EJLA489<\UU9]^#]@D 0#/?.6>;;Y=1
M]IEQ'&J8WWYX^4?(!:-X,% C)#D2B3\<7$+!7IN$& HA&)!B8C]6C2)55E[U
M*,LL8>&B"P.N'1#,D;Q)QQP!F2' "048>"#"-?EP8Z5.X.CD@CDSI //EV#2
M(X\YX0QE4"E1!41000=),I%"DAAD5 @1,;*0G#;12:=#'7&T$38?A6114RF:
MI&(C)B'J$DR/K)02HT)%&NE/DN)$4YU#F1D14DA=VA%(()$TB0<M'L)**E>I
M<BI7K&ZU2HY>P1+^UB<2#'C7+H[%]5AYA^VBBP-V_26LL/OI0MBQ^J&U"V*I
MJ>78LV])9EF'&7;&66>A*> 9::7Q:II:X+K5EF2M]>)99,'!-AT%T%EH3)(#
M:"<OAL$)MZ!Q"W 6+7*Q&2#??-#AIN1TLV$V6W&;$:S;=]PQ/ !S]&);WI!W
M 1B*!1=88,%_F;SG5G $-,>,A/0%4-]W"+=U6%F?5!!*!6+U-Z!?,:+66+3+
MR4<RA#PK$QV\SZ3L(6S3PN;:6IQ$D!Z4J)BX"*(J0L+B!K7LU=<@L-1XHR2D
M8J6JJE=AY54KL0#YWRUFH9:<<L:Q1AH##D@@RB(;K="""E9V<P\XXMS^8PXZ
M-(#Y3N#OT /X##+8P].AHY):2B(#K9E0336UB:F>!NE)D21&.6131G[Z^6E(
M)#5EZ.DG/5H1U*JKSE*EL,<.%%!V=KYZYT$MXCE$$3V28D>1D*J!!H>8NNJK
M5;6JO%:K^&CV6)[X9;.SNS+F;%J#"3;L \&:%1A=A*%VX+<(YKHK9.2"IJ!Q
MLF6V60+H@E89>=QR2WZS:)&VJ_J<G;N9^\0Y0&VV Z]X&2!> PC&;X;SOVJU
M;34>8MN"_E6?Z#0'8@<S&,+^=\ !4(AA[;H0ALA3&>OIYR^>$ 18P,(QOHR&
M,B'3#7TD1(QC= <\E"'/RAZ 'E#\AV,3F)G^K<JRB>F5SW\,\B"$=M:S9$C(
M0@=+&?QZ41UJ:>@X;]O/@/SS"JV="$6.((E!*&&)%[FG+%A[18F<U@\/,$]'
M7VM5C[[R/%Q8C8=# M%Y(# @N:E1$2/!AMU:H*5[$#)+]N!2E[PDN!K00![R
M<*28%"<31[C)'X\3")LRQQ X&<63E*M3)#JGNZ1LY",82:5'0E4ZU)6D=Y"(
MY>L8E;J8O 02M[-4[&Q"%#S-B7)R>EKEA G,IT&"$249(ZDXH %+.--K5<F1
MCK#2S#<>+VRM< 58Q.()OMAL+>2IGK<*PXG ;$][FBC,D,B7J[A(2U?G<UN"
MU@>_@F$F7=:*#/S^(O,8'9+&?B;\5CM5]I9M;0@[FAE   O KN<4L#<&I YP
M?A.>S?AB,D=SFW*P<T'<>#2$N\$@!C.(,)':!H0?E8X]X:>MB>G1%F*A!9#$
MXD*U:'!AW#FIPZ;#)(GML#\^G%',^$C$=(ZO?*R98(.:R%3<2.@[%7H8<S@$
M0/<!$)^O60N((@ !F38M3F&TA@G.= I,2& O>TFC(6PDD*FY2FQS]%&L9#6C
ML #Q12_RSR"".J)"D.(#(MB("@99R,)NR1R&(UPCTQ%)P\V 3.,P"B3<!+D;
M12Y.E",FYB#2$#K5SK.]W%,(+L)*/['2(R,)JRM/PCI%P1(FE8PM3"[^53O9
MW<2SGH,3)SWW-&+61)3 #&Y-CLDUX1'/$&^UBC2AF95J9D6:Q:.C4(-HM>GU
M\S&,X96O='&78 &K0'DTC!$5$\_RGD]:^_+%/O?9+ZLZT%KD"6>T\A<N=@KT
M?*%!J+HN8P (R/"_!3P@DR2*3_<:+8*?65O.YG,,^B@IB@;S%\*LJAT/4B@Z
MN!DI +&;EK\ -8T9F^Y=G!4; NSFB5#UH&Y\DZW#-("K*9S1\VQ!5,&LD[S4
MD]]TY/,@)C:QP2<&#X.FRD'J,,B> )0,=R,@(A*5Z(MA%..H6#&+L^Y%:5A#
MQ5_;2$:Q\6B.78R%-G^TPEF8F85]_=%7+G'^B$30#1N$)&0AR:03<\1 !NE0
MK",#EV=(H@//-#!'9%^R(H%8]K*1F%QP-<>Y2/36T0[17)[Z!"B-!(IT(HE:
M,EGRJ$XWJG6N<UVF;)NI2S%Z=9F-"&B'*=Q6%Q.3E6CFV(SWW%;%^JW*&_-,
M!3%$CR$H+MD-J+(&P]VR>!=8QB+VS70%S_)*BUSZRJ'\UM? =%WU,^>Z*+E*
M<S_3P(4US^J?@CAZ (5>9ET"<VB2<'/ =DNTJ@6KXM VFAR-]HLY $L&D(?\
M;@-F2*(8UO<QW)WDXYQF 7R)*5W#,H&:XDRB1S*QB5>\8050[!8^Q$!=.7;6
MM!WU9M/R38,%8#+^97R0.TY$.84F%-7=+'"BLQGPNX7S(2VJYU1.0^9(4L2U
M2EP 9NZ)L1K7:&BP>3F;8BX$FY>N]*2'F<U*GS6MO080*042;W[;4M:U?EC$
MTJ.1ZGAD#<2$YWJ0Z27Z*#27^X$08?HV3\?,+", 2Q%34T0%HK.T8#$MDD(A
MBG5A;<JB.JV2EMP2[9\<"FPC15M1XE*XL:1)<'/[6U<C,W.F&)ZLC\Y<Z"Z/
M5=&%^L^'>D?K.@:][3Q-'KW'B74:AEEJ.9JYIGB<^&D&.?*\5CX9^(MGV.OV
M^B1A2\'I+6_CV+R323[[(DP!"_'F7R)L=T3A3>%JO2;!]+9]?)KS49_^/9\Z
MTV>@R!L<L)\]S-]8!"C<*O8 L0!IU]%+)X**S"0%"CAD]GR+LO0"5!E/MYO:
M,S[MI'_2LASS03)/-2%.E( IMX 5\D0N1QW\]1O3%V^W)QF!P60W!Q" A2@I
M< *6-#6C=T:?0 M-\SBF 'IQM8(L:"JTE@JODB:D8",!<2+6@#=RIG6*DTA=
M=V=DUUA^)DEC-X1X=F>0=4N.UE::U$F813F3]5MT<A)/HVIKLA"BI1"CPQ$8
M(3H<P1%19CI0 WB& C4807BTA!,I012DIBDJT"F'T@C 1%R6YW9-Z&I/L4S.
MQ2K+U17+ UW.0P$N$S,$<F/4 RWZ@S2JET?^Q/9QYY5?RL%>5[1[5B0_EJ%\
M]7)/F>%['")?SP(NJ<=.WP9/E%&)''2)_:5N!'0AJOAN!F.*]H1]R9%^&(49
M/&8?SU>!!-9>'?0<%00>]E09O7!P"9<>&X-F-#5BL<=>&")S_#:*;W%Q'R93
MA !$9W1\P:8K"7,;S& RW9& )+=R/O94W0A1+U<O,4=P"W09P4@8:*0>)/)7
MQO2!(#@J/F=65J,T)L@**+A,N?9,4S=-</0U4E%UIK"/2KB$@05G<W98?F-G
M7O=UD%0X\_"#9=<EBC-H*D(0:R<YB@9Y>=)J@#41M[-9? (Z?Y)WH:(/A)),
MEZ=IKU01*4%:H8;^=JUC.VK(>+.#*9A" I*'*<#4*8L&3'422RS)"&C2>9_'
M>:SPCUPQ5V8#,[; 569A8TCU&.B%8\K2*RYF1&N1/IWA&M2F&0JR05:40]0R
M49IH8)KQ&/J$>G(1BMW6;/$TBMD1;P;0?.GF40%6@:TH@?92)/06B_\#?>07
M, )S0>B8F!/802F%82IU;<&X?]Q3,5RT,80 (&>$&@553XL985>E52\E(FG&
M<:57E>05;N9(#-_HC0NH<@J(@,U@?M&'(78)# @D<_CTE?JQ55T5"C@'9=<
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M4;<PB$I4"@ 2,O1E BE0DBOT8,RF J?G;"^S,Y%0 SG0 S[0 S79 SJ@ SF
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MQ-!34ZA$$Z5"Z\G^;%\(ABX$DV6( SD@!$9P!$=@!$9 !/<9!$#0 VB8 XK
M0Z1'>@$JH'G8>CLB:U*5-A(61!E6AZ(*;$9)K!-&;K5'-#Q5A<:'H6?S5%SI
ME4H3E@[90,Q7B>=@B0BW8]'')?/ </6P#STV+A"WA(8#/Z*#=K!5%1-!ER41
M27;7:7-WJ'L)I( A*T.*<@=$<7\6G(BUBR['23&W9;=R@#TA.\98<LN(2V/:
M%P*T%5E:L,^X9\V#2I=5&KACC==(L<YA)T2V +IE)F4R+A:@F]6R&:@3=.^$
M&&\!$9W1=<35#V$GCWVZ. &4%;AXBAJA7*.VETB;C?_3@XWZ@Y *CN/^U9 Q
M1F/KL!X%%6B(1UST4:#($$)#]%,=-B/ZI5$KU(6J^E\]HX:O*I-&P 1OFP1)
M@ 1'8)]%$ 0UJ0-KV"'_"315)(=#U;70:FXP!J'2:D0?^HA^"*V32%5Z2&(?
M^0M$\K?;RD4JX(A)I:WB=F'+2FY38E6M1QZA2ZZ7B)9VXR5?U:Z$-U9M>8K6
M\5VD8X'?5YBU$ECFUXHW^*_J5SQX1CY#&IA99J3!B:^.E4>+Z5BCA!6#91<B
M80!@ :09"QQ_X2J;];P*N)F=DXQV96?&N"JU:!>Y!"OU1"J9MK+?6!!>ESWD
M6!!/ 5V'T1R)45@*$5[&1&C:-)')%;1F<13^%7<5;_F,2/N*QSERBKHGC\2H
MSGD<-Z%W"=EW_=1K@4AK:KF"?M,=#5Q<E/JI9!LU4PEB# I"R7:2!9)YJDI@
MD% #-W"&. D$2= $+?RV3) $M6H$14"30)"W-)-MVA:4 $6BS7J'2P.(,\6Y
M0^-B $6X$A:5S#J55KBAQ^?$12PT 2<E0>1KGHM&E5B6.<:)IZNN+9J1,5L0
M>_090+$HT&$K%O<0G^%-7%JH!YR[QOF^5 :DHX%+@"E+H4.8ER(_WC<_QAM*
MI/1S=G$J:':EB;%<[ >!"OB[ ,.E1Z>]JS*R?4D2TB$7=R$L)Q<P@#I,UV)-
MQD2_K1%UF"&/HA3^5]<%OPCD:!<9:6#G@?<[J'=)/OFHBZ%3I:0!<G)W+.^D
M5W-'P,S9@XZ:&![Q+K$%&7@J'ASP1*QWJ>68$.'%FOU$'PX)#!FEA<7VB!4Z
MML+&7ZBJDIO7D@MRPCC  SR@ T+ !%$0!5#0PDW !+1:J[JJJWKKGZ27>I,K
M<(%;-$0%E20:H47YN+''(B&*Q,NGQ#O24T BE)@K"TSU5 W];\FZSP%%8V<T
MKFC4?..AQ5K,B5WR):<;5M02QH7I3:/A5W4A%VC,&X.Z=@)Y2!_WQJZ(*JP8
M&/749PE(,-P8G'*2*0N;I#)8K\AKM(>C@%&:=,H8& *82U7&L9O)9JO^Q6>S
M<UK4&(S3\7.L]'Z9/+076!":\<F2MH(S6Q4KS2VOM!2/T=4Q.P';,Y&=4<E5
MYCK,8A5M!1W1)5UMUYS/N1(CVVDRS3P#F6H*3"N!5LR<>LQ%R'I6(C$34!!I
MHD^#[< ,Y%"8< (99;8FZ9$^ E15&'DI0\TAC*I?"* E7 ,X@ ,ZP ,]8 1-
M@,[IW 10T,[OO*NZNI,TPY(IF53W3(?-6I3QAL24Z&Y"_*$3ZL-5$\3%2H=)
M_,^WAX@.ND66&U7.#8D1S3">&U 6;=U9O$;2AP]=LMT9V:YNRC=M@F@B$5?0
MDQ%XU%CCY$T>RW:,]-+HA\O:4G+!DF<C4;+^3VJDD#6*TN.+^+>D%:'?H_28
MA[,3D0G)R+.,!"C?6&J]3)W4(&=GQ=B]P?B8C/R][_=:#B%HGPS*V ,09L*^
M;^4O1V%!Y]/57BU':9)]09>QRS68P@3@\AJ"]W-(=S=W5!:0+\B*.U> LI(5
MP^P8T#*=#-1!HU"UM789L!E>/,M0L"#9DRW"E; RX_EAF UY),,+6LC-)/R%
M)DS:.M #1\ $3P %9?ZV2& $^)F3\LD#\LQ#8%C/_L:X]J'/O'UAO^W;!#VM
MR1Q[QWK$<W[<O+>@8LMM2D(T7.EBF[NL0R.Z5FS1'.1\*8JN7\5P7NS%7ZR;
M91+>IPA7.+%D2W?^HX7Y.G<!/^W-2"[]WM.U*RLAQ[I#WP+(O,WH+@8P)]QG
M.MJ!TF%V5IH$U+%TX2)!U(3<XLI#=%+=X [^3;93/*8ULD!Z9Y-<X?5=*B<'
MZNQE@N"83<?T@18QL H<3M5T@O2;@O]  6+'UG)1RX"M9197M)H)R_\8'/Q:
M@ZLXI>UW:64!3,J;*0S1A)"F> L#E5@%1^A"1ZLQ:- ,V2%0 I0=Y990(+N0
M;B9F8L1V,F5KMNR)M@OB"&6(VDFP!"\,PT<0!#Y DZ\*!+TZ4J;W7T%9;S!&
ME(?[AU#IVR-J1L@-\X^;?(7KVP2WZ(XKJAYF;T0%Q?D<8^?AD'0XW17^?=T8
M?8E;A25:PJ[</0\-%R8_=B8,@&@>JRBB0W\21Y??BQ.=]CB4D^I.^V0%#)KT
MS<@IEX_ZMWVIHUB[&$KC%'X06XLF,;%I3T]6NN"A64E,?6K+3IK%.)FI0BKX
M;<E6=N$&Z$>+M1GG:STHOKXA;K3M\A:?(;_5(^[9CEL&41N5G$OS&H/^_2U?
M/QB=EO;_&!8R+=.K]EF@Y2Y'\1G#I$^/=DW_7ITM0G"7"M('@S 0H% 7D/"E
M@'DI66P(;9Z@6I(GZ=D-/\+,IO&1H -$8 1(8/W6G^8VJ?TH[Y, V@(LD'KF
MA=O%*F+C@.<3G><V#W ZDE,R/Y;G[VU$7.7^A/Y!P3?T2WF@1N@)8LD)\=5
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M27+"HF)'(#%8BX.LK"DG;F[&%%-[[>7UGF=8%17 4XHNRBA4E%%6F0"6738
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ML.O]IV&WQ,U"SAD+%B7(@&73F!BM\8&<(>*!$RH9$5$F-(QA$(/PR!$GF)3
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MHA$4X$%W@@Z<2<B\3K#;X,D95NO#/C/U?8&[KIOKD.!A)$8WQ1"@3,6J:'3
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M\!"E^DG)*.<1INGB::E(A>7LT;C6%8ID$)  ?4R4"4\LJDA^DH=)3@*J!TQ
M:#Q\'>V$YLA::BA#*(O0928S&00JJWEJJ5__B$=,NAA/  6X#6"6)QCFZ4J
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MM:==7)(")> ![.)*QU$<UK9J^W-/K>8_YC4<IMA[_Q1NR0=3SF=N\J5K^?5
MTK=0^H49YJ&("F)P-Z,J]$$3%P4R&;4Q^.%](--O*404_U9A%?9^LH(>#))
M>Z@\SZ$P!.9^.$-3&Q(J%@(4&F12&?=_1(0B RB 1%6.<&)4,+<U5@:!;<5T
M==1R3]415T,D7E157F.%A?17(GB//]=7&#@2BN5T3;56*F<G7B9U4=A$?S1F
M9,:/5G@.$&D./9C^#HP#$)[4B["#$::$A?0P"@J1)QN823X2-7$G=9[C1*'@
M"R-89!(I)O:@ :L#$#=A$X\#>%]8*) F'_Q1AO^14ZQE'M32.PMW%K?"3']Q
M+T@I:KR"%[ZR:M<6:FBQ+(<!6X"X3(/1/* ',+G6(-_!:^*1&:P' 1_@ N$3
M7>74 Y.8 Y7(1I?83N_S -X%3[,Q6^(E3]W&3]6F3WK9>_ST%P#D7JLX3<05
M4.<6';3":8*@B[2X2ZQG?0,S8+IX,>XQ$QLS?OL&'Q<U?O=1,E8A(<GH,T11
M(,G8C-=S4,G1<-G1%34U8I:"2QF'8NM!4^]A*!I1FQ4Q5W.G-"5G24G^:&4%
MN51-EV5ETG)6PV-!HH%"-DCY:&:$Q&>9A"?YB$@NN%@]\A!ILE@[89#[ &A^
M5!$&*&,1J%E+HH/DV9*(YA">\CY#$TNK\FB-8#J,A718-V1[TF=&HDIK$E=B
M-E<"P8"D0)Z(UBDQ>1)^-P$7<:""LB(CE&"&0A.N9$*<R3,CE2#NYE+%U6%H
M\8:Q%FJMADQL@18!('DA*GGU$J+X WR?!YCC1I2P)6NT=AB#"8L.LEQB$1:*
MN(@/L $G( ,ZT /B0XEJF5WE4@.FP4[N!)=W&6KP@AOXE$_=MD]XV3^=N)?*
MH:*,P1SU15^!Z1Q9*C 0)"NRR%_68WT.Q$O^D6F-)(*9&M5]:[I@@A9"HM,4
MRBBGRMA^$6(>P_5Y7"IO Q)G&N*%A75+%\(>_=<AE[)Q160)D* 1N"F#5'>;
M4O,C>I8Z2[5E2B><._8CDMICQ^EU-:=F:;:<SGF?0:80*/=RUUFI6\9TK+I4
M4.<I)9F;5'>2@5,0XKF2YI!D2:9U*ZEFZ-E)(S,TEN5(% &?:3</23B1?%9E
M^*E',2A7_!FI'MDU$,F<;_<0@$:3[WD1I6,1E'59C^9]DT"9B#<4(Z)+W#%#
M9'$8OB5KM98\>Y@_:3&B>[$;>M@OQP*CT;.N"W>A@=A;T$.8^,5 P!8SBD@K
M,;, $^ !*H -:CG^+D3*1C/ 1C)P+NGB 6\Y ?PR%_@2>4^:EWDIE_U"BLJQ
MI848HP<$,--3&6$J".RF.S4*?35C,^K!BR43 1\WC DFKJ%S4W/ZLT#;:_5U
ME,>R0 1F0]>(?R>C0[;3?_Z'J$L48X'#-X^*">!Y5#.7<L$ID'K3JECV<CP6
MCPT(#%[DCTDBJA.Y19WZ6$ 2D%W;5"R8JE"GG[AYFTDS$!'HD0[)DKI:GM7*
M9G^R2N_#<23T48Q@.I43CSM6CZ"J@4^C<H(%2- *:(!4G3*'2+6P 3 I@S1Y
M"5O(K?'AH(4G"2 C6BMA6!6"AFF(<-9Q*T-9%L_R:J''HD7IHOAZN\S^DRL&
MH*_T-5"] UO-]&GNQ;N&.(T4PW@ -C%A$18-0 $?< (N\ Q/(C;1&[U%N@(G
MP $8, '-^UV\YWOT4VWF)1OD:QSBJU[H*[)5FGQ9VHI=2DWRQ4 M]:4V1'TU
MFJ[4@GUGBF('UF ;99F9J5'#^!ZD0F% F[HI56'M5C!'F3_4!& %YG]6P4,[
M0U$YY2I$Z!Z9676*6DJ"(S4RF(!_9$KIZ( ^\K; B4>)TH(N5X&=VC1"AA!F
M>U4A6&.--8\]5DE,)8%Q6ZESVSBQJFBW&1!TDF,JN9)]ZX$_U[?FN45@EQ'"
M2IOP.9P=B;6(DSBET"<4B:U=1B> -"=?+#C^[OB.H; Z$D%WE5"L!CH)BO"@
M,^$?I!7'VFABMR,K%5.:#6( '/:&CC>[H/9I1.G'R+$\MLL\@SA_ :-\NPN\
M@N@\T-.^,DH>U-)I+?48S;L!(@ :)[#)F]P:)Y "H1$.KK&]KH0_V>:4>0A\
M27I>QB>EMTM_SK*EQ97(TZA\+!46!N>RK&49Z<9X ;:(\F:-DA0ZOAB,"::3
M$1:H=0:TR]C,@P QO1-,Q2)-]S4>#W)#$DS!^:<A/A0T44%1HY)1!FA$?;20
M.4)%3YB -D@CJ+-%;IO"/)QC;(6L%)@UC[5F:@:2,EQ(__@HF_0H;3N=*S<U
MV;D3SAK$<M>=5MO^#S<(13KH@;HJ=+O*DGR5"S\(Q9 3P%,HSWHCJ8,T1T02
MD%1+)]!*TOOY1-AY#\_J.1<!>&P,.:RBS98BT[!I.ZK+LN(Q006S&-7,86<Q
ME FW<,WAAXPQNRW*HKA"E;]47*AW4$G=6\M$&,VR<(<A/;KF;M:DO/FU !"
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M*6CAQ#Q-Y3]$-> 8+?*%X&IB#):]9!8>DT4L$C4RF"S#0U8!$4]BDH!9T*F
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M*3)$0PAQ;""I4:2:GLMF0X\RAO65DE("A?^5-5D3:Q5%8N 9*;@P(CJ)J=?
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ML<J0!;$1ZSP4RV9Z?1[J6_!6MSX N_")_.\7KJ]V):?#&&BU&["MNT>MM2Q
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MR.;-0:[6<GX0D-25&Z]8=3)U(]9/V>ZK&A;912SPS'[,8_)\R_9?33%ATUE
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M?]D9O*(*P^@<[I*8QIB,R-B8S*B ^9.8V>1-LA6-[+)H%+AHQP@_X00P!3
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M=[$W(<357\2M&M88<Q*L&18B98MBE?=C^PN1I^+6O'QYOBS T ;,1]2'TG;
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MB=[&]@ZRG8;WO7C^X&<<S7_&GJ3Y,&M_\8RN ( P(0! *#!(B)BHN'@((#
M,-!H.*G8. "9&6GHV-E)Z3@X><C)6=A8B%A)*<HJ^8@9:U!@4&M[8%N+JUMP
MX/NKD+ PO,"P\' \C(Q,C*" \.N;:W!08+V[._U[+4V-[1T=#CRNH'!@'IR0
M@%Y>[MSN_JQ /#Q?3X^?/]Q W\!/_._?,&/&]@TLZ."8@P<,(3B$,"$BA8D4
M+E2TB-%BQ8L7-&ZD"#+DQXX;.YH\V1$#2@PL6UYH"=.ERIDH*42\&4&"A D/
M(NJ<\%." PD0'!1U@+19@F@$JA$@8*T 5%K3<F7+!=4 IED$P"T]I^S^P4X*
M%EYNV,#!PX</(=JV%0$WKML0:SUXX,!A TN2-B,R_-M@8;%[\-(=6&K.ESQS
MB-LML#=X&8/)?\7J['D3)\Z=0'UF_@S:<VB)(2?TC0@Q0H2_#AH0+*@O]N/9
MY1Z_LU<;H#%_#!ZX_DOY=X,'O7\3K\R ]V1_KOTA$V@0-KUY\&ZW0_ 5VM*O
MA\5Y;^KK:?@$XL%YY_Y+'8+UMR=X6@0_OB)(I0;1/_4I$G[X]5FU(A5*?XF(
M(I\JI7SBWRNQ+%C  %1IDPTNN/0"S#K"$-/;,7\ET\QZT5!CBS6SB&B5+B'V
M\J TV/B"HG?A0'..8N6H<U@P\:Q7V#.TX0/^66RXY2:;;- 9U,\"2"%5F4.9
MV2021B5Y-!&4(DUD&D466!#EDQRAE-),*KT$$Y@QA?F225=>"1I$0.G$9IM"
M.3#!D0D]MMTO3TDUU0!/;555GP8\-956?UHE8U@_E77!67BIQ=9;(<0EPJ-P
MT16"77CI]265:[+F@#',S%;/C.O$"(TYI18&:CZ>5B869J/=)%8$H'$FZZNR
M[D2KK+4N"9)I$>D*066N!7D/L<,@0 QUJ>;#W'#)^0;8<<L-1^URT/;F&W,%
M[5:0/_K@]AAU,UYWF'9U^@*C=^:!=YAX3Y&W(CC>P,C8=@G<MH $ !;(KR7_
M$<A**@"_APE^ /O^UXK "0L\8,/OY8>P))C  D"#6@TP8HK8]#)+-=&HXU@Q
M#&F(;3,+>/C+-"1&Y>>)(E[EYX0>J^B==KY\A<Y2[&%W+XXWYJ/LLJ$&O0_1
MRO8XG;'/+?27DC<Q29%))5T4I49\:2H2EF6!Q-=)6W(III=AC]UE1U>2-9JK
M;:XI5-M''MNSG5#I"2@!& O:LC9WTO*4+L#4AB1G96&@:%IK-2JI7)/2]8&E
M>6GP)98^L?8 TW,.:1M[.>98K&XB#_?7:J&=9@%G.^7T4V<W<;:Z:*Y/(*NK
M3)YM 6BL=IK<0$ G6Q!D2(M+=+CX[/9;;]@^Z]IRQAOO;+:3*4,/,]+^#38=
MLL!CY\QA-)K:G8OB4,CBG>$WU=4WYOVB'78'G-J.>Y;T"W^ _H7BR'VF'"()
M(?0A7)_\ ?<W,/JA8C_WXY\A%K25N[$L1 RD1HNZLXY@T*,XN</'SE*6BZAH
M$&^VN%O&'I2W:[1(7A+RGC@2\Q7UK$>%/G.,N,+U.QBZ$(:AHF'(9".=933D
M 0^!2%^:-+4L@>1LO6(2::8T-9* K6Q@&IM,R@1%LUFD=A.@8F9,USJ=%.4H
M21D&>IQB#;MAHBMW\^ MXE6+J8 P'"%CR*',@A:[',XMDXI4I.;2.$N=92\6
MT4QE$O*V9,V&/3*L#9#H <AGL4HU.1D-VJ[^Z!E<G>XSN\H,9CCC*EY1Z326
MA-UJD/(\'X'+D#PBS(^$AX_D468RQVM><)R7/.7D+D,<0L8L90,/&/(L@M"
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M=3V[INJA /\@)W_AGEB+D-=W1=2[FT_CF_6ULL*9):C*>#=A10_!2#2&+ Q
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M;U)2E&*1GM]57]2Q7G0XG;ZZHWQWW1-$P4T0@AF <("@<$"HH( @B'C R$C
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MRDB%F"2FFCA#'^)S$#\B%+0*SB1",\F&OL@THGC( QWM4@ B1)$ -H$" 0S
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MPIBV8R,W=0DXV"HXVNIL]P6N,^I?\FJNPEIKM1*.<4<Y.3IIV!A';?.8FX0
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4,*QR]$0ML:7,8';*6?A]FQ ( #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2516624d12hqlreporti002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2516624d12hqlreporti002.gif
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<TPNW7+.-32[!L=>RUIG476;OC&S2U5+Z0 $ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2516624d12hqlreporti003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2516624d12hqlreporti003.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M,C(R,C(R,O_  !$( .\!8@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M $*7B+_OQ%_\=KI(88K:!(((DBBC4*D:*%50.@ '04^@#F/^$ON/^A2\1?\
M?B+_ ..T?\)?<?\ 0I>(O^_$7_QVNGHH YC_ (2^X_Z%+Q%_WXB_^.T?\)?<
M?]"EXB_[\1?_ !VNGHH YC_A+[C_ *%+Q%_WXB_^.T?\)?<?]"EXB_[\1?\
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M) _X1/Q$,]S!#_\ ':M?\)#<?]"YK/\ WQ%_\<K<HH P_P#A(;C_ *%S6?\
MOB+_ ..4?\)#<?\ 0N:S_P!\1?\ QRMRB@##_P"$AN/^A<UG_OB+_P".4?\
M"0W'_0N:S_WQ%_\ '*W** ,/_A(;C_H7-9_[XB_^.4?\)#<?]"YK/_?$7_QR
MMRB@##_X2&X_Z%S6?^^(O_CE'_"0W'_0N:S_ -\1?_'*W** ,/\ X2&X_P"A
M<UG_ +XB_P#CE7-/U.6^D=7TN^LPHSNN50!O8;6-:%% !1110 4444 %%%%
M!1110 4444 %%<Y>^-=,L?$HT25;@RJ@::9(R4A)&5#'W&>>G3UXKR?$+0XO
M#$OB _:OL<=PUMM\G$CNIYPI/H"><< T =717/ZMXRTO1KFV@NA<$SQK,6CC
MW+$C.J*SG/ +,!QGO5!?B/HDC,D<=\\A9%@C$'S7.Z1HP8^>1N1NN.F: .OH
MJEI&JVNMZ3:ZG9,S6UR@>,L,''N/6KM !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 <5J?AK6KOXAV&LVSV=O9P ;YXV99GC ^:)UQAP3R"
M3QSWQG*OOAOJ-[X7N[$:A##>F\N[B#:<Q,)LC#ED)!VDC*C(R<&O2J* /-]8
M\&Z_KTY68V<4/DQ6+O)*=[11S12B4!5()8JXVG;C(^E5+?X<:W;7UI>K/I[R
MZ:8EM4,K@3JMQ)*2YV?(<2 <!N17J=% '+:-X1DL? VG>'YM2NK>6V0;[BPE
M,;%LDD D=,GTIO\ P@W_ %-/B?\ \&'_ -C75T4 <I_P@W_4T^)__!A_]C1_
MP@W_ %-/B?\ \&'_ -C75T4 <I_P@W_4T^)__!A_]C1_P@W_ %-/B?\ \&'_
M -C75T4 <I_P@W_4T^)__!A_]C1_P@W_ %-/B?\ \&'_ -C75T4 <I_P@W_4
MT^)__!A_]C1_P@W_ %-/B?\ \&'_ -C75T4 <I_P@W_4T^)__!A_]C1_P@W_
M %-/B?\ \&'_ -C75T4 <I_P@W_4T^)__!A_]C1_P@W_ %-/B?\ \&'_ -C7
M5T4 <I_P@W_4T^)__!A_]C1_P@W_ %-/B?\ \&'_ -C75T4 <I_P@W_4T^)_
M_!A_]C1_P@W_ %-/B?\ \&'_ -C75T4 <I_P@W_4T^)__!A_]C4<7@V&<,8?
M%WB.0*2I*:D#@^G"]:N>.?$T/A/PG>:B[?OBIBMU[M*P.W\NI]@:\DT>7X@>
M!-'M-?D1]0TF\47%U;G+/"#T+<97C!XX'0XH ]37P/M8'_A*?$QP<X.H?_8U
M>_X1C_J.:U_X%_\ UJ/"_B_1_%VGBZTRY5G4#S8&XDB/H1_7H:W: ,+_ (1C
M_J.:U_X%_P#UJ/\ A&/^HYK7_@7_ /6K=HH PO\ A&/^HYK7_@7_ /6H_P"$
M8_ZCFM?^!?\ ]:MVB@#"_P"$8_ZCFM?^!?\ ]:JU_I%II=E+>7WB35K>VB&Y
MY)+W  _*G>+O'&C^#;(2W\I>Y<?N;6+!DD/T[#W/Z]*X2Q\*^(OB7?1:OXQ9
M['14.^UTN,E2P[%NX^I^8]MHQ0!F-X]GN;N>;1].\6:EH\+;&O([I@<^N!&0
M!]2#TSCI5RR^(_A69_+OM9\4Z=*#AEG?<!_WP"?TKUBV&EZ19PV=N;6TMXOW
M<<2LJ@$=A[TZ\TS3M4C O;&UNT(P!-$L@Q^(- '':=J/A?5<"S\=7CL>B-J(
M1C_P%@#75Z9I8L6:5=1OKM9%&/M$_F*/<<5S>H?"7P7J')T=;=_[UM(T?Z X
M_2F^%_AE8^$M<%_INK:D8-C*;260%#GUP!G'T]* .='BSQ5!8>*FFO[--0L8
MVN%MI(,B-!T>(CAU(QU/!Y/7!Z"ZUO6[/6/#,CW8-EJCQ1-&;<",9B9FR_7>
M6 V@8& :J62_#>V@\0".XA6W*&*]\R>3:(VZK&2<[2V?N=_PJ_/9>"9M=MHO
M.$>IRQ1"#9/*,'RV$38)V;PF[:6&Z@#/\6^,]3LO&UGHNDWME   DR7 #&1W
MC=EXSNPNU>F,EP,U%'X@\0W?A3PKJ4&K*E]JDT5NT/V>,JY+$NYXR $4]/:M
M?5;KP5I=S9V>JS?Z3I$2LC.LK-&I0J&=E&#E0>M%K>>"+&/1#%*L*66]-/$G
MG#RMQ",2&]2P7<WKP>: .THHHH **** "BBB@ HKS77-0O;?XI6D1UJ6.VE"
MV\,=N0P@D9?NRQG&0W!#>H'I62VKZHW@YT?7K]]6?5;NTLTCD"/<2 E4+-_"
MB?>(&!V]* /8**\M\:ZYJEC?QI:ZM(9;&PMYBMNX"RS-<Q1MN Z@JW0]-V:P
MK/Q#KEQJFFV<FL7WDZH8'N6$N#&6NYD*H?X 515P/2@#V^BN-\+>([O_ (5M
MI&KW]M?ZC<R1A76UB\R5^2 Q''8#)J?_ (3G_J5O$_\ X+__ +*@#JZ*Y3_A
M.?\ J5O$_P#X+_\ [*C_ (3G_J5O$_\ X+__ +*@#JZ*Y3_A.?\ J5O$_P#X
M+_\ [*C_ (3G_J5O$_\ X+__ +*@#JZ*Y3_A.?\ J5O$_P#X+_\ [*C_ (3G
M_J5O$_\ X+__ +*@#JZ*Y3_A.?\ J5O$_P#X+_\ [*C_ (3G_J5O$_\ X+__
M +*@#JZ*Y3_A.?\ J5O$_P#X+_\ [*C_ (3G_J5O$_\ X+__ +*@#JZ*Y3_A
M.?\ J5O$_P#X+_\ [*C_ (3G_J5O$_\ X+__ +*@#JZ*Y3_A.?\ J5O$_P#X
M+_\ [*C_ (3G_J5O$_\ X+__ +*@#JZ*Y3_A.?\ J5O$_P#X+_\ [*N?\8_%
M$Z3X>N/(T76;*^N%,5K)>6HC4.>^=QR0.>G7% &1K!7XE?%B#1E_>:'H67N2
M#\LLF1D?B<+] Q%=AX;^(^D^(=;NM%:VNK"_A+;8;I-OF(O<>AQS@_K7DXEN
MO#W@!_"MMIVH1>(M:EW3/) 09HSU5#G<W''3^)O6NUE32[SP;#X?N_"GBEME
MHEL;M-/Q+A<'AB>FX9V]/:@9/XJ^%[17K>(?!=PVEZS'E_)B.(Y3W '12?3[
MI]!UI?"?Q62>\&B>+;?^R=77"^9(-L4I_'[I/Y'U[5@:3XJ\1> =+$-SI&NZ
MKI4<I+3WMJT+6T.   <L/7@D 8 '7C8\02^'/B181%=-U1KE(E9)([8-)&C<
MC(#9 [CM]: /5.M(SJBEG8*HZDG %>#6OA3QE!&NGKXBU^VTZ/(AC@@DWA.P
MQN&/SP*DA^'-E=,SZP?$]^ZC(P1@GWRI('7O0(]<O?&'AO3@?M>O:=$P_A-R
MA;_OD'-<7X@^*JW<\>C^!X#J^JS@@2JA\N'WYQG'K]T=SVJA8>"O!]I&7?P;
MJ,\BGAI9)'7\>0/TK<CE&E6GE^&?"KZ<[C$LL5E\Q';D#G\: *?AOP)8Z%J"
M:WXNU!-2\0W!#+YK;EC;_9!ZD=,]!VQ74QW.KZ\;B'[.^G694J)6!\S.>W3W
M_P :S;6:V6Y2]O-#UNYO=J[I'M/EW =0,UL_\)/_ -0/6O\ P$_^O0 0^$=+
M2Q%M+&\ISN,C.0V?PJ.?PS(B0KINIW-H(EVA=Q8'DDGJ/6I/^$G_ .H'K7_@
M)_\ 7J"\\9VNGVDEW>Z7JMO;QC+RRVX55'3DEJ )9#XEMKU%C6VNK;Y5)/RM
MC R3SUZGO4]CKDEUJ364VFW-NPSAW&5('O\ _KKB[OXLMJ=A*?!V@:AJUU'(
M$<M ?+CR#@G:23T/''U]=#PF/%.JZM:ZIKUS=V3PVS)-IRVQ2WD8L<,&+')P
M1D8ZCKB@#G[;PGKLNG^*[(:&EM;7%O(+2VDDC?%PW>%\Y"$'/S$ $X'0UKR:
M?K2^)-+EN_#]Q)I>E6T;HUM+"3+<"/!=QNW'8"RJ "<Y([5E#Q9XJ@L/%337
M]FFH6,;7"VTD&1&@Z/$1PZD8ZG@\GK@] =<UQO$^@6D%[#,MY#'//:+ /D@\
ML^9*[?PDN5"@<'F@9C^*_#NK:]<M=6FA:DAOX[=KP)J21(\2QONA9"1\X+
ME6&><CG-1O"_C+^TQ?P)J$<DC-';-+J"N]K%]I5PLQ\PF1?+WC +]A[UM^-O
M%>K>&]<C-K=V\T0B\YK+RA\L05@7DD/W<R%%7H.N:R;?Q=XC/A2SUDZO!<A+
M_P"QSM#;(8F/V@+O=@?D38>,<Y9><&@#UBBBB@04444 %%%% %&31=+EU:/5
M9-/MFU"-2B7)B'F*#_M=?\,GU-0W'AK0;M%2YT339D5WD59+1& 9R"S#(ZG
MR>^*U** ,F+POH4+JZ:19%TE,T;/"&,;D 94G.WA5Z8Q@>E2'P[HC)<H=&T\
MI=,'N%-JF)F!R"_'S'//-:5% #(88K:!(((DBBC4*D:*%50.@ '04^BB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *\2W/\3_BJ9XY%.B:&0(R6P'(
M/+#UR1^06NM^+7BIM!\,?V=9L3J>JDV\*KU53P[?D<#W;VKE$\KX<?#2W>S@
M6\U35V%LL4J$ DYW_=.2.,#D'E: -WPO%I_CGX@7GC*.:=[?33]CM898QLW
M??5L]/F)QC(W UZ=6+X4T"V\-^'+33K:W$&U=\J!R_[P\MR>O/'T K:H *XG
M6OAS:7OB>+Q-IE[<:=JB.'D\IODGP -K>F0 #C@CL:[:B@#SK1?B#J]C/=VO
MCG1CI0M4WF_B1S;OE@H ^]R<]B>AX&*[K3M3L=7LDO-.NX;JW?I)$X8?3V/M
M3[ZQM-2LY;.^MXKBVE&'BE4,K#Z5P6J?#N]TBP4^ =2;2)EG:>2!Y&:.<D
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M=([_ -H7]UO&,7,V\#Z<4 :-%%% !1110 4444 %%%% !1110 4444 %%%%
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M8?B(9[G2IO\ "K7_  E%O_T#=9_\%TO_ ,36Y10!A_\ "46__0-UG_P72_\
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M7'_0QZS_ -]Q?_&Z/^$>N/\ H8]9_P"^XO\ XW6Y10!A_P#"/7'_ $,>L_\
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M7S$9]NT?*5^4_-R0<$X[T ='X0^QQ65Q;V.BV^F0I(&86LL<D,CD8)4H<Y
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M::WBE:*2%G0,8Y,;D)'0X)&1TX)%2444 %%%% !1110 4444 %%%% !1110
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M21QE=V6S*Q.6W 8&!\HH ZNN:\;NJZ+!&=,L[]IKJ.)!>!O+B9L@.2JEAZ9
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M,JVES=2-."K *PE<KC)#9P3E10!Z!6+XMGCMO"U_-+80WZ(@)MYT+1M\PY8
M$X'WN 3Q6U69XATVXU?0+RPM;G[-/,FU9,L .0<':0<$#!P<X- '":,FNV/B
MC2K::$Z9:7<LBK#:7LLZ.L:;F?9(A5(VX48*MEA7IU>?^&_ VHZ1X@MM0?\
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M 'V@!ARH)/!P#W9JO@C6[SQE<WL-MML[W452Z?S$^>TQ Q.,Y^]"5QUYZ8H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2516624d12hqlreporti004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2516624d12hqlreporti004.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M,C(R,C(R,O_  !$( '$ L0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MILH_>1?\NTN/^/AAU\SC_([9H ^K:***!!1110 4444 %%%% !1110 4444
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M\C:-.J121F0G48#@"9G_ +O. 0?\>@ /H2BBB@04444 %%%% !1110 4444
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MI UT',Y.06\G"KN^N<_49J+PM\49O"NAP:;I_A!<*H,DWFL&F?'+GY>_Z=*
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M3_\ "J]4?Q3*6NGLYC$LB8E6/RSCS#W/Z^O/3FOV>_\ D'Z]_P!=8?Y/7LY
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?.BB@1Y3X6_Y+:G_7T?Z5]*T44#84444""BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
